M [ADDRESS_208183] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1/ [ADDRESS_208184] u d y of t he Safet y , T olera bilit y , a n d 
P har mac o ki netic/ P har mac o d y na mic Pr ofile of M4 3 4 4 (f or merl y 
V X -8 0 3) as a Si n gle A ge nt a n d i n C o m bi nati o n wit h C y t ot o xic 
Che m ot hera p y i n Partici pa nt s wit h A d va nce d S oli d T u m ors 
P h ase I
I N D N u m ber 
E u dr a C T N u m ber 2 0 1 4- 0 0 3 8 3 8- 8 6 
C o or di n ati n g 
I n vesti g at or 
Tele p h o ne: 
S p o ns or I n t he U K , S pai n, a n d the Net herla n ds: 
Merc k K Ga A 
Fra n kf urter Strasse 2 5 0 
Dar msta dt, Ger ma n y
I n t he U S A a n d Ca na da : 
E M D Ser o n o Researc h & De vel o p me nt I nstit ute, I nc. , 
A n affiliate of Merc k K Ga A, Dar msta dt, Ger ma n y
4 5 A Mi d dlese x T ur n pi [INVESTIGATOR_177586], M A, U S A
Me dical Res p o nsi ble: 
Merc k K Ga A, Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 Dar msta dt, 
Ger ma n y
Tele p h o ne: 
Fa x: 
Cli nic al St u d y Pr ot oc ol 
Versi o n [ADDRESS_208185] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2/ [ADDRESS_208186] or y 
V er si o n N u m b er T y p e V er si o n D at e 
1. 0 Ori gi n al Pr ot o c ol 1 9 -S e p -2 0 1 4 
2. 0 Gl o b al A m e n d m e nt 1 1 4 -N o v -2 0 1 4 
3. 0 Gl o b al A m e n d m e nt 2 3 1 -A u g -2 0 1 5 
4. 0 Gl o b al A m e n d m e nt 3 0 3 -J u n -2 0 1 6 
5. 0 Gl o b al A m e n d m e nt 4 1 6 -A u g -2 0 1 7 
6. 0 Gl o b al A m e n d m e nt 5 0 2 -F e b -2 0 1 8 
7. 0 Gl o b al A m e n d m e nt 6 2 8 -A pr -2 0 1 9 
8. 0 Gl o b al A m e n d m e nt 7 2 9- J a n -2 0 2 0 
Pr ot oc ol Versi o n [ 8. 0 ] ( 2 9 J a n u ar y 2 0 2 0 )
T his a me n d me nt is s u bsta ntial base d o n t he criteria i n Article 1 0(a) of Directi ve 2 0 0 1/ 2 0/ E C of 
t he E ur o pea n Parlia me nt a n d t he C o u ncil of t he E ur o pea n U ni o n. 
O ver all R ati o n ale f or t he A me n d me nt 
T his a me n d me nt ser ves mai nl y  t o clarif y  t hat e val uati o n of a dr u g h oli da y  s c he d ule m a y  b e 
c o n d ucte d i n parallel t o ot her parts of t he st u d y . T o facilitate t hat, dr u g h oli da y  s c he d ules are 
defi ne d a n d arra n ge d i n a ne w Part A 3. 
Furt her m ore , t his a me n d me nt i nc or p orates clarificati o ns a n d c ha n ges t o all o w i n vesti gati ve sites 
a d diti o nal ease i n e nr olli n g a n d a d heri n g t o t he pr ot oc ol. 
S e cti o n # a n d N a m e D e s cri pti o n of C h a n g e Bri ef R ati o n al e 
T hr o u g h o ut w h er e a p pli c a bl e R e or g a ni z ati o n of dr u g h oli d a y 
s c h e d ul e e v al u ati o n i n s e p ar at e 
Part A 3 , wit h m et h o d ol o g y, 
o bj e cti v e s / e n d p oi nt s , S o A s, et c. 
s p e cifi e d. T o cl arif y t h at t h e e v al u ati o n of a dr u g 
h oli d a y s c h e d ul e m a y b e p erf or m e d 
i n d e p e n d e nt fr o m c o n d u ct of P art s C 
T hr o u g h o ut w h er e a p pli c a bl e A d diti o n al P art s C 4, C 5, C 6 
a d d e d a s o pti o n al e x p a n si o n 
c o h ort s f or P art A 3 si mil ar t o P art 
A 2 wit h P art s C 1, C 2, a n d C 3, 
t h e s e ar e c oll e cti v el y r ef err e d t o 
a s “ P art s C ”. T o a d d t h at a d o s e a n d/ or s c h e d ul e 
t h at h a s b e e n e x pl or e d i n o pti o n al 
e x p a n si o n P art A [ADDRESS_208187] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3/ 1 5 9 S e cti o n # a n d N a m e D e s cri pti o n of C h a n g e Bri ef R ati o n al e 
T a bl e 2 S c h e d ul e of A s s e s s m e nt s: 
S cr e e ni n g ( P art s C ) 5. 2. 8 
S cr e e ni n g 
5. 3. 1 I n cl u si o n Crit eri a # [ADDRESS_208188] eri sti c s 
7. 7. 5 A s s e s s m e nt of bi o m ar k er s f or 
P art s C: Eli gi bilit y Crit eri a 
S y n o p si s: Pl a n n e d n u m b er of 
p arti ci p a nt s U p d at e d t h e n u m b er of 
p arti ci p a nt s f or P art s A [ADDRESS_208189] a c c or di n g t o n e w p art s C 4 - 6 
T a bl e 7 Tr e at m e nt a n d F oll o w- u p 
P eri o d ( M 4 3 4 4 si n gl e a g e nt 
t h er a p y i n e x p a n si o n P art s C1, C 2, 
a n d C 3 )R e m o v e d e v al u ati o n s o n Da y [ADDRESS_208190] or e d i n P art A 2 a n d 
d e cl ar e d s af e, t h e s e ar e n ot n e e d e d 
S e cti o n 3. 1 S ci e ntifi c R ati o n al e A d d e d i nf or m ati o n r e g ar di n g 
pr e v al e n c e of m ut ati o n s. T o e n h a n c e r ati o n al e cl arit y. 
S e cti o n 3. 2 T o xi c ol o g y a n d 
C o m p o u n d S af et y U p d at e d M 6 6 2 0 e x p o s ur e 
i nf or m ati o n. F or a c c ur a c y of d at a. 
S e cti o n s 5. 1. 2 P art A 2, 5. 1. 3 P art 
A 3 A d d e d t h at “ C a n di d at e 
p arti ci p a nt s wit h a d v a n c e d s oli d 
t u m or s c arr yi n g alt er ati o n s t h at 
ar e s u s p e ct e d t o s e n siti z e f or 
tr e at m e nt wit h a n A T R i n hi bit or 
( e s p e ci all y t h o s e d efi n e d f or t h e 
P art s C) m a y b e pr ef er e nti all y 
e nr oll e d.” T o i n cr e a s e t h e p ot e nti al f or b e n efit of 
p arti ci p ati n g p ati e nt s 
S e cti o n 5. 1. [ADDRESS_208191] e si z e 
8. 5. 7. 2 S af et y i n P art s A 2 a n d A 3 A d d e d B a y e si a n o pti m al i nt er v al 
m o d el ( B OI N) f or d o s e e s c al ati o n 
i n P art A [ADDRESS_208192] eri sti c s c o m p ar e d t o 
3 + [ADDRESS_208193] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4/ 1 5 9 S e cti o n # a n d N a m e D e s cri pti o n of C h a n g e Bri ef R ati o n al e 
S e cti o n 5. 1. [ADDRESS_208194] of P art s C 
S e cti o n 5. 1. 5 All P art s C; Fi g ur e [ADDRESS_208195] at e c a n c er 
S e cti o n 7. 6. 1. 3 P h ar m a c o ki n eti c 
S a m pli n g: P art A [ADDRESS_208196] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5/ 1 5 9 S e cti o n # a n d N a m e D e s cri pti o n of C h a n g e Bri ef R ati o n al e 
S e cti o n 7. 5. 3 Cli ni c al L a b or at or y 
A s s e s s m e nt s;  T a bl e [ADDRESS_208197] u d y, t h at 
p arti ci p a nt will r e c ei v e a n e w 
u ni q u e i d e ntifi c ati o n n u m b er. F or cl arit y. 
T hr o u g h o ut Mi n or e dit ori al a n d d o c u m e nt 
f or m atti n g r e vi si o n s .Mi n or, t h er ef or e, h a v e n ot b e e n 
i n di vi d u all y s u m m ari z e d. 
- C o nfi de ntial – 
T his d oc u me nt is t he pr o pert y of Merc k K Ga A, Dar msta dt, Ger ma n y, or o ne of its s u bsi diaries. It  
is i nte n de d f or restricte d use o nl y  a n d m a y  n ot –i n f ull or part –be passe d o n, re pr o d uce d, 
p u blis he d or use d wit h o ut e x press per missi o n of Merc k K G a A, Dar msta dt, Ger ma n y,  o r its 
s u bsi diar y . C o p y ri g ht © [ADDRESS_208198] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6/ [ADDRESS_208199] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7/ [ADDRESS_208200] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8/ [ADDRESS_208201] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9/ [ADDRESS_208202] a n d D ose L i miti n g T o xicities ............................. 1 0 6 
7. 5. 1. 5 Safet y  Re p orti n g t o Healt h A ut h orities, I n de pe n de nt Et hics 
C o m mittees/ I nstit uti o nal Re vie w B oar ds a n d I n vesti gat ors ............ [ADDRESS_208203] u g E x p os ure ........................................... 1 0 7 
7. 5. 2. 1 Pre g na nc y ................................ ......................................................... 1 0 7 
7. 5. 2. 2 C o ntrace pti o n ................................ .................................................... 1 0 8 
7. 5. 3 Cli nical L a b orat or y  Assess me nts ..................................................... 1 1 0 
7. 5. 4 Vital Si g ns, P h y sical E xa mi nati o ns, a n d Ot her Assess me nts ........... 1 1 2 
7. 5. 4. 1 P h y sical E xa mi nati o n a n d Vital Si g ns .............................................. 1 1 2 
7. 5. 4. 2 Electr ocar di o gra m ................................ ............................................. 1 1 2 
7. 6 P har mac o ki netics ................................ .............................................. 1 1 3 
7. 6. 1 Bl o o d Sa m pli n g ................................ ................................................ 1 1 3 
7. 6. 1. 1 P har mac o ki netic Sa m pli n g: Part A ................................................... 1 1 4 
7. 6. 1. 2 P har mac o ki netic Sa m pli n g: Part A 2 ................................................. 1 1 4 
7. 6. 1. 3 P har mac o ki netic Sa m pli n g: Part A 3 ................................................. 1 1 4 
7. 6. 1. 4 P har mac o ki netic Sa m pli n g: Part B 1 ................................................. 1 1 6 
7. 6. 1. 5 P har mac o ki netic Sa m pli n g: Parts C ................................................. [ADDRESS_208204] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 / [ADDRESS_208205] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 / [ADDRESS_208206] u g E x p os ure C o m plia nce ................................................... 1 3 0 
8. 5. 4 Efficac y  A nal ys is i n Parts A, A 2, A 3 a n d B 1 ................................... 1 3 1 
8. 5. 4. 1 A nal y sis of Pri mar y  Varia bles .......................................................... 1 3 1 
8. 5. 4. 2 A nal y sis of Sec o n dar y  Efficac y  Varia bles ....................................... 1 3 1 
8. 5. 5 Efficac y  A nal ys is i n Parts C ............................................................. 1 3 1 
8. 5. 6 Cli nical P har mac ol o g y  A nal y sis ....................................................... 1 3 2 
8. 5. 6. 1 P har mac o ki netic A nal y sis ................................ ................................ 1 3 2 
8. 5. 6. 3 E x p os ure -Q Tc A nal ys es ................................ ................................. 1 3 3 
8. 5. 6. 4 P har mac o ki netic/  A nal ys es ................................. [ADDRESS_208207] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 / [ADDRESS_208208] u d y  Re p ort ................................ ....................................... 1 4 2 
1 0. 6. 2 P u blicati o n ................................ ........................................................ 1 4 2 
1 1 Refere nces Cite d i n t he Te xt ............................................................. 1 4 4 
1 2 A p pe n dices ................................ ....................................................... 1 4 7 
A p pe n di x I : Si g nat ure Pa ges a n d Res p o nsi ble Pers o ns f or t he St u d y .................. 1 4 8 
Si g nat ure Pa ge –Pr ot oc ol L ea d ................................ ....................................................... 1 4 9 
Si g nat ure Pa ge – C o or di nati n g I n vesti gat or..................................................................... 1 5 0 
Si g nat ure Pa ge –Pri nci pal I n vesti gat or ................................ ........................................... 1 5 1 
A p pe n di x II: Pr ot oc ol A me n d me nt Hist or y ........................................................... [ADDRESS_208209] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 / 1 5 9 T a ble of I n -Te xt T a b les 
Ta ble 1 Sc he d ule of Assess me nts: Scree ni n g ( Parts A, A 2, A 3 a n d B 1) ........ 2 9 
Ta bl e2 Sc he d ule of Assess me nts: Scree ni n g ( Parts C) .................................. 3 0 
Ta ble 3 Treat me nt a n d F oll o w -U p Peri o d ( M 4 3 4 4 si n gle A ge nt T hera p y , 
Part A) ................................ ................................ ................................. 3 2 
Ta ble 4 Treat me nt a n d F oll o w -U p Peri o d ( M 4 3 4 4 Si n gle A ge nt T hera p y , 
Part A 2, a n d 1 4 d +/ 7 d -sc he d ule of Part A 3) ...................................... 3 5 
Ta ble 5 Treat me nt a n d F oll o w -U p Peri o d -M 4 3 4 4 Si n gle A ge nt T hera p y , 
Part A 3 ( dr u g h oli da y  wit h eit her 3 d +/ 4 d -, 5 d +/ 2 d -, or 7 d +/ 7 d -
sc he d ule) ................................ ............................................................. 3 8 
Ta ble 6 Treat me nt a n d F oll o w -U p Peri o d ( M 4 3 4 4 a n d Car b o plati n 
C o m bi nati o n T hera p y , Part B 1) .......................................................... 4 1 
Ta ble 7 Treat me nt a n d F oll o w -u p Peri o d ( M 4 3 4 4 si n gle a ge nt t hera p y  i n 
Parts C 1, C 2, a n d C 3 a n d t he 1 4 d +/ 7 d - sc he d ule descri be d i n Parts 
C 4, C 5, a n d C 6) ................................ .................................................. 4 4 
Ta ble 9 Treat me nt a n d F oll o w -u p Peri o d ( M 4 3 4 4 si n gle a ge nt t hera p y  i n 
Parts C 4, C 5 a n d C 6, e xce pt f or t he 1 4 d +/ 7 d -sc he d ule) .................... [ADDRESS_208210] u d y  Desi g n ................................ ................................ .6 1 
Fi g ure 2 Part A: D ose Escalati o n Sc he matic f or M [ADDRESS_208211] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 / 1 5 9 Fi g ure 3 Part A 2: D ose Escalati o n Sc he matic f or M 4 3 4 4 wit h De nse 
M o n ot hera p y Sc he d ule ................................ ....................................... 6 6 
Fi g ure 4 D ose Escalati o n Sc he matic f or M 4 3 4 4 i n C o m bi nati o n Wit h 
Car b o plati n ( Part B 1) ................................ .......................................... [ADDRESS_208212] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 / [ADDRESS_208213] of A b bre vi ati o ns 
A E A d verse E ve nt 
A L P Al kali ne p h os p hatase 
A L T Ala ni ne a mi n otra nsferase 
A T M Ata xia tela n giectasia m utate d 
A T R Ata xia tela n giectasia m utate d a n d Ra d 3 -relate d pr otei n 
A S T As partate a mi n otra nsferase 
A U C Area u n der t he c o nce ntrati o n vers us ti me c ur ve 
β- h C G β- h u ma n c h ori o nic g o na d otr o pi n 
BI D T wice dail y
BI W T wice wee kl y
B OI N Ba yesia n o pti mal i nter val 
B R C A -1/ [ADDRESS_208214] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 6 / [ADDRESS_208215] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 7 / [ADDRESS_208216] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 8 / [ADDRESS_208217] u d y  o f t he Safet y, T olera bilit y , 
a n d P har mac o ki netic/ P har mac o d y n a mic Pr ofile 
of M 4 3 4 4 (f or merl y V X - 8 0 3) as a Si n gle A ge nt 
a n d i n C o m bi nati o n wit h C y t ot o xic 
C he m ot hera p y i n Partici pa nt s wit h A d va nce d 
S oli d T u m ors 
St u d y P h ase I
I N D N u m ber 
E u dr a C T N u m ber [ADDRESS_208218] u d y sites/c o u ntries T he st u d y  w ill be c o n d ucte d at a p pr o xi matel y 
[ADDRESS_208219] u d y peri o d 
(first p artici p a nt i n -l ast p artici p a nt 
o ut) Ja n uar y  2 0 1 5 t o Dece m ber 2 0 2 1 
Tri al Re gistr y Cli nical Trials. g o v a n d E u dra C T 
O bjecti ves: 
Pri m ar y o bjecti ves: 
Part A :
T o e val uate t he safet y a n d t olera bilit y  o f m ulti ple asce n di n g d oses of si n gle a ge nt 
M 4 3 4 4 ( he ncef ort h referre d t o as M 4 3 4 4) a d mi nistere d t wice wee kl y  ( BI W) i n 
partici pa nt s wit h a d va nce d s oli d t u m ors 
T o deter mi ne t he ma xi m u m t olerate d d ose ( M T D) a n d/ or rec o m me n de d P hase II d ose 
(R P 2 D ) of si n gle a ge nt M 4 3 4 4 a d mi nistere d BI W i n partici pa nt s wit h a d va nce d s oli d 
t u m ors. 
Part A 2: 
T o e val uate t he safet y a n d t olera bilit y  o f m ulti ple asce n di n g d oses of si n gle a ge nt 
M 4 3 4 4 a d mi nistere d i n a t wice dail y or o nce dail y  d ose sc he d ule i n partici pa nt s wit h 
a d va nce d s oli d t u m ors 
T o deter mi ne t he M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d i n a t wice 
dail y  or o nce dail y d ose sc he d ule i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
Part A 3: 
T o e val uate t he safet y a n d t olera bilit y  o f m ulti ple asce n di n g d oses of si n gle a ge nt 
M [ADDRESS_208220] u g h oli da y  d ose sc he d ule ( 3 da y s of d osi n g f oll o we d 
b y  4 d a y s of pa usi n g [3 d +/ 4 d -] or [ADDRESS_208221] in Human Study
MS201922- 0001
C O N F I D E N T I A L
I N F O R M A T I O N19/159[5d+/2d -] or 7 days of dosing followed by 7 days of pausing [7d+/ 7d-]) or 14days of 
dosing followed by 7
 days of pausing [14d+/ 7d-])in participant s with advanced solid 
tumors
To determine the MTD and/or RP2D of single agent M4344 administered in a drug 
holiday  dose schedule in participants with advanced solid tumors.
Part B1 :
To ev aluatethe safety an d tolerability of M4344 when a dmin isteredin combinati o n
with carbop latin inparticipant s with advanced s o lidtumors
To determine th e MTD an d/orRP2D ofM4344 a dmin isteredincombin ation with
carbop latin inparticipant s with advanced s o lidtumor s.
Parts C
:
To evaluate the safet y, tolerability , and efficacy  in terms of confirmed objective 
response of M4344 administered at dosesand schedule sdetermined as RP2D in Parts
A, A2, or A3in participants with solid tumor harboring loss -of-function mutations in 
the genes ARID1A (Parts C1, C4), ATRX and/or DAXX (Parts C2, C5), or ataxia 
telangiectasia mutated (ATM )(Parts C3, C6) .
Secondary objectives:
Part A :
To evaluate pharmacokinetics (PK) of single agent M4344 when administered BIW in 
participant s with advanced solid tumors
To assess potential antitumor activity  of single agent M4344 when administered BIW  
in participant s with advanced solid tumors.
Part A2:
To evaluate PKof single agent M4344 (and metabolites as appropriate )when 
administered in a twice daily  (BID) or once daily  dose schedule in participant s with
advanced solid tumors.
To assess potential antitumor activity  of single agent M4344 when administered in a 
BID or once daily  dose schedule in participant s with advanced solid tumors.
Part A3
To evaluate the PK of single agent M4344 (and metabolites as appropriate) when 
administered in a drug holiday  dose schedule in participant s with advanced solid 
tumors.
To assess preliminary  antitumor activity  of single agent M4344 when administered in 
a drug holiday  dose schedule in participant s with advanced solid tumors.
Part B 1:
To ev aluatethe PK profileofM4344 w hen a dminis teredin combin ation wi th 
carbop latin in participants with advanced solid tumors
Document No. 0900babe812f8f49v1.[ADDRESS_208222] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 0 / 1 5 9 T o e v al uate p o te ntial a n ti t u m or acti vit y af ter ad mi nis te ri n g M 4 3 4 4 i n c o m bi n ati on wit h 
ca r b o p lati n i n partici pa nt s wit h a d va n ce d soli d t u m or s. 
Parts C: 
T o f urt her e val uate efficac y i n ter ms of c o nfir me d best o verall res p o nse, d urati o n of 
res p o nse, pr o gressi o n -free s ur vi val ,a n d o verall s ur vi val ti me of M 4 3 4 4 w he n 
a d mi nistere d i n partici pa nts wit h l oss - of- f u ncti o n m utati o ns i n t he ge nes A RI D 1 A, 
A T R X a n d/ or D A X X, or A T M 
T o e val uate t he P K of M 4 3 4 4 (a n d meta b olites as a p pr o priate) i n i n di vi d ual partici pa nts 
wit h l oss - of- f u ncti o n m utati o ns .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208223] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 1 / 1 5 9 Met h o d ol o g y: T his is a P hase I, first -i n -h u ma n cli nical st u d y  usi n g M [ADDRESS_208224] u d y w ill be 
co n d uc te d i n m ulti ple parts (P arts A,A 2, A 3, B 1, C 1, C 2, C 3 a n d p ote ntiall y f urt her Parts C 4, 
C 5, a n d C 6 ). E li gi ble partici pa nt s i n Parts A, A 2 a n d A 3 will ha ve a d va nce d s oli d t u m ors f or 
w hic h n o sta n dar d t hera p y  i s a vaila ble w hic h m a y  c o n ve y c li nical be nefit. Eli gi ble partici pa nt s 
i n Part B 1 will ha ve a d va nce d s oli d t u m ors f or w hic h n o sta n dar d t hera p y is a vaila ble w hic h 
ma y  c o n ve y  c li nical be nefit, a n d/ or partici pa nt s m ust ha ve disease pr o gressi o n after at least 
1pri or c he m ot hera p y re gi me n i n t he metastatic setti n g, a n d f or w hic h car b o plati n w o ul d be 
c o nsi dere d sta n dar d of care. Eli gi ble partici pa nts i n Part sC will ha ve a d va nce d s oli d t u m ors 
f or w hic h n o rec o m me n de d sta n dar d t hera p y is a vaila ble a n d w h o carr y certai n l oss - of- f u ncti o n 
m utati o ns (see bel o w f or details) .
I n Part A, d oses of M 4 3 4 4 will be escalate d t o deter mi ne M T D a n d/ or R P 2 D w he n 
a d mi nistere d BI W as a si n gle -a ge nt. 
Part A 2 will esta blis h t he M T D/ R P 2 D of M 4 3 4 4 as a si n gle a ge nt a d mi nistere d BI D or o nce 
dail y .
Part A 3 will esta blis h t he M T D/ R P [ADDRESS_208225] u g 
h oli da y  sc he d ule ( 3 da y s of d osi n g f oll o we d b y 4 da ys of pa usi n g [3 d +/ 4 d -] or 5 da y s of 
d osi n g f oll o we d b y 2 da ys of pa usi n g [ 5 d +/ 2 d -] or 7 da y s of d osi n g f oll o we d b y  7 da y s of 
pa usi n g [ 7 d +/ 7 d- ]) or 1 4 da y s of d osi n g f ol l o we d b y  7 da y s of pa usi n g [ 1 4 d +/ 7 d- ]) .
I n  P art B1, d oses of M 4 3 4 4 will be escalate d i n c o m bi nati o n wit h car b o plati n t o deter mi ne a 
c o m bi nati o n t hera p y M T D a n d/ or R P [ADDRESS_208226] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 2 / [ADDRESS_208227] u d y  Parts C t he safet y , t olera bilit y a n d efficac y of M 4 3 4 4 a d mi nistere d as a si n gle a ge nt 
at d ose sa n d sc he d ule sdeter mi ne d as R P 2 D i n Part sA, A 2 , or A 3 will be e val uate d i n t hree 
differe nt  selecte d p o p ulati o ns (l oss - of- f u ncti o n m utati o ns i n t he ge n es A RI D 1 A i n 
C 1 a n d C 4, i n A T R X a n d/ or D A X X i n C 2 a n d C 5 , a n d A T M i n C 3 a n d C 6 ). Parts C 1, C 2, a n d 
C 3 will use a d ose a n d sc he d ule esta blis he d i n Parts A or A 2 . Parts C 4, C 5, a n dC 6 are o pti o nal 
a n d will use a d ose a n d sc he d ule esta blis he d i n Part A 3. Prese nce of eli gi ble  will 
be assesse d d uri n g Scree ni n g i n a ma n dat or y fres h t u m or bi o ps y  (a bi o ps y o btai ne d after t he 
e n d of t he pre vi o us treat me nt re gi me n is als o acce pta ble) or, if n ot p ossi ble f or me dical reas o ns, 
a n arc hi val t u m or tiss ue sa m ple c o ul d be use d . T he   f or par ti ci pa nt selecti o n will be 
assesse d b y  a  ce ntral trial assa y  or b y  a n assa y  wit h a p pr o priate re g ulat or y  s tat us .Details of 
t his pr ocess are pr o vi de d i n s u p p orti ve d oc u me nts. 
E nr ol lme nt is restricte d t o partici pa nts w h o ha ve e x ha uste d all sta n dar d of care o pti o ns 
acc or di n g t o N C C N G ui da nce. 
 
 
 
 
Pl a n ne d n u m ber of p artici p a nt s: A p pr o xi matel y  3 0 0 partici pa nt s (a p pr o xi matel y 
2 5 partici pa nt s i n Part A, 3 1 partici pa nt s i n Part A 2, 4 0 partici pa nts i n Part A 3, 2 5 partici pa nt s 
i n Part B 1 a n d 1 9 0 i n Parts C .
Pri m ar y e n d p oi nts: 
Part A :
Safet y  p ara meters, i ncl u di n g A Es, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d electr ocar di o gra m ( E C G )assess me nts 
M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d BI W. 
Part A 2: 
Safet y  p ara meters, i ncl u di n g A Es, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d wit h a t wice dail y or o nce 
dail y  d ose sc he d ule .
Part A 3: 
Safet y  p ara meters, i ncl u di n g A Es, cli nical la b orat or y  v al ues (s er u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P [ADDRESS_208228] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 3 / 1 5 9 Part B 1:
Safet y  p ara meters, i ncl u di n g A Es, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P 2 D of M 4 3 4 4 a d mi nistere d i n c o m bi nati o n wit h car b o plati n. 
Parts C: 
Occ urre nce of :
oTreat me nt -e mer ge nt a d verse e ve nt (T E A Es )a n d treat me nt -relate d A Es 
gra de d acc or di n g t o Nati o nal Ca ncer I nstit ute C o m m o n Ter mi n ol o g y 
Criteria f or A d verse E ve nts La b orat or y a b n or malities 
oCli nicall y  si g nifica nt a b n or mal vital si g n 
oCli nicall y  si g nifica nt a b n or mal E C G 
O bjecti ve res p o nse (i . e. c o nfir me d c o m plete res p o nse [C R ]or partial res p o nse [P R ]) 
acc or di n g t o Res p o nse E val uati o n Criteria i n S oli d T u m ors (R E CI S T ) v 1. 1 assesse d 
b y  t he In vesti gat or .
Sec o n d ar y e n d p oi nts :
Part A :
P K para meter esti mates of si n gle a ge nt M 4 3 4 4 a d mi nistere d BI W, deri ve d fr o m 
plas ma c o nce ntrati o n -ti me data 
O bjecti ve t u m or res p o nse O R a n d disease sta bilizati o n as e val uate d b y  R E CI S T 1. 1. 
Part A 2 :
P K para meter esti mates of si n gle a ge nt M 4 3 4 4 (a n d meta b olites as a p pr o priate) 
a d mi nistere d wit h a t wice dail y  o r o nce dail y  d ose sc he d ule , deri ve d fr o m plas ma 
c o nce ntrati o n -ti me data 
O R a n d disease sta bilizati o n as e val uate d b y R E CI S T 1. 1. 
Part A 3: 
P K para meter esti mates of si n gle a ge nt M 4 3 4 4 (a n d meta b olites as a p pr o priate) 
a d mi nistere d wit h a dr u g h oli da y  d ose sc he d ule , deri ve d fr o m plas ma 
c o nce ntrati o n -ti me data 
O R a n d disease sta bilizati o n as e val uate d b y R E CI S T 1. 1. 
Part B 1 :
P K para meter esti mates of M 4 3 4 4 a d mi nistere d i n c o m bi nati o n wit h car b o plati n 
deri ve d fr o m plas ma c o nce ntrati o n -ti me data 
O R as e val uate d b y R E CI S T 1. 1. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208229] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 4 / 1 5 9 Parts C: 
C o nfir me d Best O verall Res p o nse (res p o nse assess me nt acc or di n g t o R E CI S T 1. 1 
as assesse d b y t he In vesti gat or will be use d) 
Durati o n of res p o nse assesse d fr o m C R or P R u ntil pr o gressi o n of disease, deat h, or 
last t u m or assess me nt 
Pr o gressi o n -free s ur vi val 
O verall s ur vi val 
P K para meter esti mates of M 4 3 4 4 (a n d meta b olites as a p pr o priate) i n i n di vi d ual 
partici pa nts wit h l oss - of- f u ncti o n m utati o ns .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208230] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 5 / 1 5 9 P h ar m ac o ki netics: 
Bl o o d sa m pli n g f or plas ma P K a nal ysis will be c o n d ucte d i n all st u d y  parts. Ric h sa m pli n g is 
i m ple me nte d i n Parts A, A 2, A 3 a n d B 1. S parse sa m pli n g is i m ple me nte d i n Parts C. Detaile d 
sa m pli n g ti mes are liste d i n t he S o A a n d Secti o n  7. 6. 
Effic ac y assess me nts: 
I ma gi n g sca ns (e. g., C T, M RI ) will be perf or m e d at Scree ni n g a n d at t he e n d of e ver y 2 c y cles 
(i.e . 6 wee ks) u p t o 6c y cles of treat me nt, a n d e ver y  3 c y cles (i.e. , 9 wee ks) t hereafter u ntil 
disease pr o gressi o n occ urs . I n Parts C, partici pa nt s w h o disc o nti n ue t he st u d y  treat me nt f or 
reas o ns ot her t ha n disease pr o gressi o n or wit h dra wal of c o nse nt will c o nti n ue t u m or 
assess me nts acc or di n g t o t he sa me sc he d ule as partici pa nt s recei vi n g trial treat me nt .B o ne sca n 
(if p ositi ve at Scree ni n g) will be perf or me d at t he e n d of C y cle 4 a n d e ver y  4 t o 6 c y cles 
t he reafter f or t h ose partici pa nt s c o nti n ui n g b e y o n d 6 c y cles or as cli nicall y  i n dicate d. F or 
partici pa nt s wit h pr ostate ca ncer, or ot her ca ncers t hat ha ve b o ne metastases, b o ne sca ns will 
als o be use d f or e val uati o n of disease. I n a d diti o n, f or partici pa nt s w it h ser o us o varia n ca ncer, 
c ol o n ca ncer, pr ostate ca ncer, or ot her t u m ors w here a p pr o priate ser ol o gic t u m or mar kers are 
a vaila ble, t hese will als o be use d t o m o nit or a ntit u m or effects. 
I n Parts C, p er R E CI S T 1. 1 o bjecti ve res p o nses nee d t o be c o nfir me d. C o nfir mati o n s h o ul d be 
deter mi ne d at a sca n n o less t ha n 4 wee ks after t he ori gi nal assess me nt of o bjecti ve res p o nse is 
ma de; c o nfir mati o n of res p o nse at t he ne xt sc he d ule d t u m or assess me nt is acce pta ble. 
S afet y assess me nts: 
A d verse e ve nts; cli nical la b o rat or y  v al ues (ser u m c he mistr y , c oa g ulati o n, a n d he mat ol o g y 
st u dies); sta n dar d 1 2 -lea d E C Gs; vital si g ns; a n d p h y sical e xa mi nati o ns. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
C CI 
M [ADDRESS_208231] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 6 / 1 5 9 Di a g n osis a n d ke y i ncl usi o n a n d e xcl usi o n criteri a: Male a n d fe male partici pa nt s at least 
1 8 ye ars of a ge, wit h t u m ors meas ura ble b y  R E CI S T 1. 1. I n a d diti o n, partici pa nt s will ha ve t h e 
f oll o wi n g c haracteristics: 
Parts A, A 2, A 3, a n d B 1 : A d va nce d s oli d t u m ors f or w hic h n o sta n dar d t hera p y is 
a vaila ble a n d t hat m a y  c o n ve y  cli nical be nefit 
All Parts C: A d va nce d s oli d t u m ors f or w hic h n o rec o m me n de d sta n dar d t hera p y  is 
a vaila ble a n d t hat har b or l oss - of- f u ncti o n m utati o ns i n o ne or m ore of t he f oll o wi n g 
ge nes A RI D 1 A ( C 1 , C 4 ), A T R X a n d/ or D A X X ( C 2 , C 5 ), A T M ( C 3 , C 6 ). Prese nce 
of eli gi ble bi o mar kers will be assesse d d uri n g Scree ni n g i n a ma n dat or y  f res h t u m or 
bi o ps y  (a bi o ps y o btai ne d after the e n d of t he pre vi o us treat me nt re gi me n is als o 
acce pta ble) or, if n ot p ossi ble f or me dical reas o ns, a n arc hi val t u m or tiss ue sa m ple 
c o ul d be use d . T he bi o mar kers f or par ti ci pa nt selecti o n will be assesse d b y  a  ce ntral 
trial assa y  or b y a n assa y wit h a p pr o priate re g ulat or y  stat us. 
I n vesti g ati o n al Me dici n al Pr o d uct: d ose/ m o de of a d mi nistr ati o n/ d osi n g sc he d ule: 
M 4 3 4 4: A n A T R pr otei n ki nase i n hi bit or; 5 0 m g ta blets a d mi nistere d orall y. 
Car b o plati n: A D N A -al k y lati n g a ge nt a d mi nistere d u p t o t he A U C = 6 m g mi n/ m L  v i a 
i ntra ve n o us i nf usi o n. 
T he S p o ns or will n ot s u p pl y  c ar b o plati n f or t his st u d y . Sites will use car b o plati n as s u p plie d 
b y  t heir p har mac y .
Refere nce t her a p y: d ose/ m o de of a d mi nistr ati o n/ d osi n g sc he d ule: N ot a p plica ble .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208232] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 7 / [ADDRESS_208233] u d y a n d tre at me nt d ur ati o n per p artici p a nt : 
Partici pa nts i n Parts A, A 2, A [ADDRESS_208234] u ntil disease pr o gressi o n. F oll o w u p will i ncl u de: 
Up t o 1 4 d a y s ( ± 7d a y s) f or Safet y F oll o w -u p ( Parts A, A 2, A 3, a n d B 1 )a n d u p t o 
3 0 da y s ( ± 7d a y s) f or all Parts C; 
Ra di ol o gic F oll o w - u p e ver y  [ADDRESS_208235] c y cle of c he m ot hera p y 
f or t h ose partici pa nt s i n Parts B 1, a n d all Parts C wit h o ut pr o gressi ve disease ;
A d diti o nall y , partici pa nt s ma y  b e f oll o we d f or o verall s ur vi val or pr o gressi o n -free 
s ur vi val f or u p t o [ADDRESS_208236] atistic al met h o ds: A nal y sis of all data will be perf or me d b y  t he S p o ns or or desi g nee. 
E val uati o n of efficac y , safet y  a n d t olera bilit y  of M 4 3 4 4 as a si n gle a ge nt ( Parts A, A 2 , A 3 a n d 
all Parts C ) a n d i n c o m bi nati o n wit h car b o plati n ( Part B 1) will be pr o vi de d se paratel y. T he 
o verall safet y  pr ofile of M 4 3 4 4 will be assesse d i n ter ms of t he f oll o wi n g safet y e n d p oi nts: 
I n ci de nce of d ose li miti n g t o xicit ies (D L Ts )f or Part sA, A 2, A 3, a n d B 1 o nl y 
I n ci de nce of T E A Es, i ncl u di n g A Es lea di n g t o d ose mo dificati o ns or 
disc o nti n uati o ns 
Cli nical la b orat or y  val ues 
E C G o utc o mes 
Vital si g ns .
Safet y  data will be s u m marize d b y  treat me nt gr o u p a n d b y  st u d y  part, a n d o verall. I n ge neral, 
safet y a nal ys es will be base d o n t he Safet y  S et, defi ne d as all partici pa nt sw h o recei ve d at least 
1d ose of st u d y  dr u g. 
T he s u m mar y  of D L Ts will be base d o n t he D L T E val ua ble Set. 
Efficac y  data will be s u m marize d b y  treat me nt gr o u p a n d b y  st u d y  part, a n d o verall. Efficac y  
data m a y  a ls o be s u m marize d b y  t y p e of ca ncer, t u m or sta ge at baseli ne, W H O perf or ma nce 
stat us at baseli ne, ti me ela pse d si nce ca ncer dia g n osis, pri or c he m ot hera p y a n d ra diati o n 
t hera p y, ti me ela pse d si nce m ost rece nt t hera p y , d urati o n of m ost rece nt ca ncer t hera p y , a n d 
me dical hist or y .
M [ADDRESS_208237] u d y  parts 
wil l be a nal yz e d a n d re p orte d i n acc or da nce wit h t he i nte grate d a nal ys is pla n (I A P). 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208238] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 8 / 1 5 9 All P arts C: 
F or eac h of t he Parts C a [ADDRESS_208239] u d y  p art will c o nti n ue t o e nr oll 
a d diti o nal 5 3 partici pa nt s i nt o Sta ge 3. 
Pri m ar y a n al ysis: 
T he pri mar y  a n al y sis will be perf or me d se paratel y f or all Parts Cafter Sta ge 3is c o m plete d f or 
t hat part , or w he n t he st u d y  part is st o p pe d after Sta ge 1 or 2 , if a p plica ble . 
The 9 5 % Cl o p per -Pears o n c o nfi de nce i nter val f or o verall res p o nse rate (O R R )will be 
calc ulate d . W he n 1 4 res p o n ders are o bser ve d o ut of 7 3 partici pa nts, t he c orres p o n di n g 2 -si de d 
9 5 % Cl o p per -Pears o n c o nfi de nce i nter vals f or O R R is [ 1 1 %, 3 0 %] a n d e x cl u des a n O R R of 
1 0 %. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208240] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 2 9 / 1 5 9 T a ble 1 Sc he d ule of Assess me nts: Scree ni n g ( P arts A, A 2, A 3 a n d B 1 )
A s s e s s m e nt S cr e e ni n g Vi sit s 
( D a y -2 1 t o D a y - 1) a
I nf or m e d c o n s e nt X
D e m o gr a p hi c s X
M e di c al hi st or y X
I m a gi n g s c a n di s e a s e a s s e s s m e nt bX
B o n e s c a n cX
Tr a n st h or a ci c e c h o c ar di o gr a m dX
Pri or a n d c o n c o mit a nt m e di c ati o n s X
H ei g ht X
W e i g ht a n d vit al si g n s X
P h y si c al e x a mi n ati o n X
Cli ni c al di s e a s e a s s e s s m e nt X
W H O p erf or m a n c e st at u s X
St a n d ar d 1 2 -l e a d E C G X
S er u m F S H ( P o st m e n o p a u s al f e m al e p arti ci p a nt s 
<6 0 y e ar s ol d o nl y) X
S er u m β- h C G (f e m al e p arti ci p a nt s of c hil d b e ari n g 
p ot e nti al o nl y) X
H e m at ol o g y X
C o a g ul ati o n X
S er u m c h e mi str y X
Uri n al y si s X
T h yr oi d sti m ul ati n g h or m o n e gX
S er u m t ot al t e st o st er o n e ( m al e p arti ci p a nt s o nl y [ P art A 
a n d P art B 1]) X
Ar c hi v al t u m or ti s s u e bl o c k e
O pti o n al fr e s h t u m or bi o p s y ( P art sA 2 a n d A 3 o nl y) fX
X
A E s C o nti n u o u s fr o m si g ni n g of I C F t hr o u g h S af et y 
F oll o w -u p vi sit 
A E =A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, C T =C o m p ut eri z e d t o m o gr a p h y, 
E C G =el e ctr o c ar di o gr a m, F F P E = f or m ali n fi x e d p ar affi n e m b e d d e d ti s s u e, F S H =F olli cl e sti m ul ati n g h or m o n e, 
M RI = M a g n eti c r e s o n a n c e i m a gi n g, W H O = W o rl d H e alt h Or g a ni z ati o n .
aP arti ci p a nt s will h a v e a S cr e e ni n g p eri o d of u p t o 2 1 d a y s ( D a y -2 1 t o D a y - 1) b ef or e t h e fir st d o s e of t h e st u d y 
dr u g. 
bP arti ci p a nt s will h a v e a c h e st a n d a b d o mi n al i m a gi n g s c a n ( e . g., C T, M RI) a s a p pr o pri at e a n d, if cli ni c all y 
i n di c at e d, i m a gi n g s c a n s of ot h er b o d y ar e a s ( e. g., p el vi s). I m a gi n g s c a n s p erf or m e d wit hi n 2 w e e k s of S cr e e ni n g 
m a y s u b stit ut e f or a s s e s s m e nt of eli gi bilit y. F or e a c h p arti ci p a nt, t h e s a m e i m a gi n g t e c h ni q u e s h o ul d b e u s e d t o 
f oll o w t h e di s e a s e (if p o s si bl e). 
c F or all p arti ci p a nt s wit h pr o st at e c a n c er or f or p arti ci p a nt s wit h ot h er m ali g n a n ci e s wit h k n o w n or s u s p e ct e d b o n e 
m et a st a s e s or a s cli ni c all y i n di c at e d. If a b o n e s c a n h a s b e e n p erf or m e d i n t h e [ADDRESS_208241] h or a ci c e c h o c ar di o gr a m h a s b e e n p erf or m e d wit hi n 3 m o nt h s of 
S cr e e ni n g p eri o d of 2 1 d a y s ( D a y -2 1 t o D a y -1), r e s ult s fr o m t hi s m a y b e u s e d i n st e a d. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208242] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 0 / [ADDRESS_208243] u g (if 
a v ail a bl e). If i n s uffi ci e nt ti s s u e i s a v ail a bl e fr o m a n ar c hi v e d s p e ci m e n, or if t h e bi o p s y w a s o bt ai n e d m or e t h a n 
[ADDRESS_208244] e d t o u n d er g o a 
pr etr e at m e nt bi o p s y d uri n g S cr e e ni n g. 
f P art sA 2 a n d A 3 o nl y: a n o pti o n al fr e s h F F P E bi o p s y c a n b e c oll e ct e d f or p h ar m a c o d y n a mi c a n al y s e s d uri n g 
S cr e e ni n g a s pr e d o s e bi o p s y. T h e p o st d o s e bi o p s y c a n b e c oll e ct e d o n C y cl e [ADDRESS_208245] e d d uri n g 
Scr e e ni n g. 
gN ot r e q uir e d f or P art A 3. 
T a ble 2 Sc he d ule of Assess me nts: Scree ni n g ( P arts C) 
A s s e s s m e nt S cr e e ni n g Vi sit s 
( D a y -4 2 t o D a y -1) a, b 
I nf or m e d c o n s e nt X
D e m o gr a p hi c s X
L o c al b i o m ar k er d at a f or p arti ci p a nt s el e cti o n cX
M a n d at or y fr e s h t u m or bi o p s y dX
M e di c al hi st or y X
I m a gi n g s c a n di s e a s e a s s e s s m e nt eX
B o n e s c a n fX
Pri or a n d c o n c o mit a nt m e di c ati o n s X
H ei g ht X
W e i g ht a n d vit al si g n s X
P h y si c al e x a mi n ati o n X
Cli ni c al di s e a s e a s s e s s m e nt X
W H O p erf or m a n c e st at u s X
St a n d ar d 1 2 -l e a d E C G X
S er u m F S H ( P o st m e n o p a u s al f e m al e p arti ci p a nt s < 6 0 y e ar s ol d o nl y) X
S er u m β- h C G (f e m al e p arti ci p a nt s of c hil d b e ari n g p ot e nti al o nl y) X
H e m at ol o g y X
C o a g ul ati o n X
S er u m c h e mi str y X
Uri n al y si s X
A E s C o nti n u o u s fr o m si g ni n g of I C F 
t hr o u g h S af et y F oll o w -u p Vi sit 
A E =A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, C T =C o m p ut eri z e d t o m o gr a p h y, 
EC G =el e ctr o c ar di o gr a m, F S H =F olli cl e sti m ul ati n g h or m o n e, M RI = M a g n eti c r e s o n a n c e i m a gi n g , W H O =W o rl d 
H e alt h Or g a ni z ati o n , F F P E = f or m ali n fi x e d p ar affi n e m b e d d e d ti s s u e. 
a P arti ci p a nt s will h a v e a m a xi m u m S cr e e ni n g p eri o d of u p t o 4 2 d a y s ( D a y -4 2 t o D a y -1) b ef or e t h e fir st d o s e of 
t h e st u d y dr u g. 
bP arti ci p a nt s will u n d er g o c o nfir m ati o n/ a s s e s s m e nt of s el e cti o n bi o m ar k er s /l o s s- of -f u n cti o n m ut ati o n s i n t h e g e n e s 
A RI D 1 A f or P art sC 1 a n d C 4, i n A T R X a n d/ or D A X X i n P art s C 2 a n d C 5 , a n d A T M i n P art sC 3 a n d C 6 (r e s ult s 
e x p e ct e d t o b e a v ail a bl e wit hi n 2 1 d a y s) .F or p a rti ci p a nt s wit h u n k n o w n bi o m ar k er st at u s at t h e ti m e of c o n s e nt, 
bi o p s y bi o m ar k er re s ult s m u st b e a v ail a bl e b ef or e c o m pl eti n g all ot h er S cr e e ni n g a s s e s s m e nt s. P arti ci p a nt s wit h 
k n o w n p o siti v e bi o m ar k er s st at u s c a n u n d er g o all S cr e e ni n g as s e s s m e nt s c o n c urr e ntl y . 
D oc u me nt N o. 
O bject N o. C CI 
C CI C CI 
M [ADDRESS_208246] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 1 / [ADDRESS_208247] a n d a b d o mi n al i m a gi n g s c a n ( e. g., C T, M RI) a s a p pr o pri at e a n d, if cli ni c all y 
i n di c at e d, i m a gi n g s c a n s of ot h er b o d y ar e a s ( e. g., p el vi s). I m a gi n g s c a n s p erf or m e d wit hi n 2 w e e k s of S cr e e ni n g 
m a y s u b stit ut e f or a s s e s s m e nt of eli gi bilit y. F or e a c h p arti ci p a nt, t h e s a m e i m a gi n g t e c h ni q u e s h o ul d b e u s e d t o 
f oll o w t h e di s e a s e (if p o s si bl e). 
fF or all p arti ci p a nt s wit h pr o st at e c a n c er or f or p arti ci p a nt s wit h ot h er m ali g n a n ci e s wit h k n o w n or s u s p e ct e d b o n e 
m et a st a s e s or a s cli ni c all y i n di c at e d. If a b o n e s c a n h a s b e e n p erf or m e d i n t h e [ADDRESS_208248] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 2 / 1 5 9 T a ble 3 Tre at me nt a n d F oll o w -U p Peri o d ( M 4 3 4 4 si n gle A ge nt T her a p y, P art A) 
E v e nt/ A s s e s s m e nt C y cl e ( 2 1 d a y s) S af et y  F oll o w -u p 1 4 d a y s 
( ± 7 d a y s) aft er t h e l a st d o s e of 
st u d y  dr u g a D a y [ADDRESS_208249] er o n e 
( m al e p arti ci p a nt s o nl y) X
C o n c o mit a nt m e di c ati o n s C o nti n u o u s fr o m si g ni n g of I C F t hr o u g h S af et y F oll o w -u p Vi sit 
A E s 
St u d y  Dr u g A d mi ni str ati o n 
M 4 3 4 4 d o si n g X X X X X X 
P h ar m a c o ki n eti c A s s e s s m e nt s 
M 4 3 4 4 ( Pl a s m a P K 
c oll e cti o n) oX X X X X
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208250] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 3 / 1 5 9 E v e nt/ A s s e s s m e nt C y cl e ( 2 1 d a y s) S af et y  F oll o w -u p 1 4 d a y s 
( ± 7 d a y s) aft er t h e l a st d o s e of 
st u d y  dr u g a D a y 1 D a y 2 D a y 4 D a y 8 D a y 9 D a y 1 1 D a y 1 5 D a y 1 8 
A E = A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, , C A- 1 2 5 = C a n c er a nti g e n 1 2 5, 
C A 1 9 - 9 = C a n c er a nti g e n 1 9 -9, C E A = C a n c er e m br y o ni c a nti g e n, C T = c o m p ut eri z e d t o m o gr a p h y, E C G = El e ctr o c ar di o gr a m, I C F = I nf or m e d c o n s e nt f or m, 
P K =P h ar m a c o ki n eti c, P S A =Pr o st at e s p e cifi c a nti g e n, W H O = W orl d H e alt h Or g a ni z ati o n .
aP arti ci p a nt s w h o d o n ot h a v e d o c u m e nt e d di s e a s e pr o gr e s si o n u p o n c o m pl eti n g t h e S af et y F oll o w -u p Vi sit s h o ul d b e f oll o w e d, if p o s si bl e, f or u p t o [ADDRESS_208251], o n a n a p pr o xi m at el y 3 -m o nt hl y b a si s u ntil di s e a s e pr o gr e s si o n, i niti ati o n of n e w t h er a p y, or 
d e at h. 
bR e q uir e d f or C y cl e 1 o nl y; h o w e v er, a s s e s s m e nt s m a y b e p erf or m e d at ot h er u n s c h e d ul e d ti m e p oi nt s at t h e I n v e sti g at or ’ s di s cr eti o n. 
cS y m pt o m - dir e ct e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or ’ s j u d g m e nt. 
dC T s c a n of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d, i n a d diti o n t o C T s c a n of ot h er b o d y ar e a s ( e. g., p el vi s), a s cli ni c all y i n di c at e d. 
eC T s c a n s will b e p erf or m e d e v er y [ADDRESS_208252] a gi n g (I t o I V) a n d T u m or -N o d e- M et a st a si s. 
hF or all p arti ci p a nt s wit h pr o st at e c a n c er, or f or p arti ci p a nt s wit h ot h er s oli d t u m or s wit h k n o w n or s u s p e ct e d b o n e m et a st a s e s. 
iC A -[ADDRESS_208253] e d at t h e s e ti m e p oi nt s a s d e e m e d a p pr o pri at e d e p e n di n g o n t h e p arti ci p a nt ' s pri m ar y m ali g n a n c y ( e. g., C A 1 9 -9 f or p arti ci p a nt s wit h p a n cr e ati c 
c a n c er or C E A f or p arti ci p a nt s wit h c ol o n c a n c er). 
jVit al si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1, 8, a n d 1 5, a n d at 4 ( ± 1) h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 of C y cl e 1. F or all s u b s e q u e nt c y cl e s, vit al 
si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1 a n d 1 5. 
k1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 1 of e v er y c y cl e. I n a d diti o n, 1 2- l e a d E C G will b e m e a s ur e d 1, 2, a n d 
3h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 ( ± 1 0 mi n ut e s) d uri n g C y cl e [ADDRESS_208254] of a n al yt e s a n d f urt h er d et ail s r e g ar di n g l a b or at or y t e sti n g 
s c h e d ul e. 
mS er u m c h e mi str y a n d h e m at ol o g y will b e p erf or m e d o n D a y s 1, 8, a n d 1 5 of C y cl e 1. F or all s u b s e q u e nt c y cl e s, s er u m c h e mi str y a n d h e m at ol o g y will b e 
p erf or m e d o n D a y s 1 a n d 1 5 o nl y. I n a d diti o n, s er u m c h e mi str y will b e p erf or m e d o n D a y s 2 a n d 9 of C y cl e 1. 
nF e m al e p arti ci p a nt s of c hil d b e ari n g p ot e nti al o nl y. 
oM 4 3 4 4 ( a n d it s m et a b olit e s a s a p pr o pri at e) pl a s m a P K s a m pl e s will b e c oll e ct e d d uri n g C y cl e 1 o n D a y s 1 a n d 8 at 0 ( b ef or e d o si n g) a n d 0. 5, 1, 1. 5, 2, 3, 4, 8, 
a n d 2 4 h o ur s ( D a y s 2 a n d 9) aft er d o si n g, a n d o n D a y 1 5 at 0 h o ur s ( b ef or e d o si n g). 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
C CI 
M [ADDRESS_208255] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 4 / [ADDRESS_208256] e d fr o m all p arti ci p a nt s o n D a y 1 of e a c h c y cl e a n d at S af et y F oll o w- u p Vi sit or at di s e a s e pr o gr e s si o n if t h e p arti ci p a nt ' s di s e a s e 
pr o gr e s s e s b ef or e t h e S af et y F oll o w -u p Vi sit. 
D oc u me nt N o. 
O bject N o. C CI C CI 
C CI 
C CI C CI C CI 
M [ADDRESS_208257] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 5 / 1 5 9 T a ble 4 Tre at me nt a n d F oll o w -U p Peri o d ( M 4 3 4 4 Si n gle A ge nt T her a p y, P art A 2 , a n d 1 4 d +/ 7 d -sc he d ule of P art 
A 3 )
E v e nt/ A s s e s s m e nt E a c h C y cl e ( 2 1 d a y s) S af et y  F oll o w -u p 1 4 d a y s 
( ± 7 d a y s) aft er t h e l a st d o s e of 
st u d y  dr u g b D a y [ADDRESS_208258] u g A d mi ni str ati o n 
M 4 3 4 4 d o si n g pX X X X X XyXy
P h ar m a c o ki n eti c A s s e s s m e nt s 
M 4 3 4 4 ( Pl a s m a P K 
c oll e cti o n) qX X X X
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208259] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 6 / 1 5 9 E v e nt/ A s s e s s m e nt E a c h C y cl e ( 2 1 d a y s) S af et y  F oll o w -u p 1 4 d a y s 
( ± 7 d a y s) aft er t h e l a st d o s e of 
st u d y  dr u g b D a y 1 D a y 2aD a y s  3 - 7 D a y 8 D a y s 9- 1 4 D a y 1 5 D a y s  
1 6 -2 1 
A E = A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, C A - 1 2 5 = C a n c er a nti g e n 1 2 5, C A 1 9- 9 = C a n c er a nti g e n 1 9 -9, C E A = C a n c er e m br y o ni c a nti g e n, 
C T = c o m p ut eri z e d t o m o gr a p h y, E C G = El e ctr o c ar di o gr a m, I C F = I nf or m e d c o n s e nt f or m, ,P K =P h ar m a c o ki n eti c, 
P S A =Pr o st at e s p e cifi c a nti g e n, W H O = W orl d H e alt h Or g a ni z ati o n. 
aC y cl e [ADDRESS_208260], o n a n a p pr o xi m at el y 3 -m o nt hl y b a si s u ntil di s e a s e pr o gr e s si o n, i niti ati o n of n e w t h er a p y, or 
d e at h. 
cR e q uir e d f or C y cl e 1 o nl y; h o w e v er, a s s e s s m e nt s m a y b e p erf or m e d at ot h er u n s c h e d ul e d ti m e p oi nt s at t h e I n v e sti g at or’ s di s cr eti o n. 
dS y m pt o m - dir e ct e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or’ s j u d g m e nt. 
eC T s c a n of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d, i n a d diti o n t o C T s c a n of ot h er b o d y ar e a s ( e . g., p el vi s), a s cl i ni c all y i n di c at e d. 
fC T s c a n s will b e p erf or m e d e v er y [ADDRESS_208261] a gi n g (I t o I V) a n d T u m or -N o d e -M et a st a si s. 
iF or all p arti ci p a nt s wit h pr o st at e c a n c er, or f or p arti ci p a nt s wit h ot h er s oli d t u m or s wit h k n o w n or s u s p e ct e d b o n e m et a st a s e s. 
jC A -[ADDRESS_208262] e d at t h e s e ti m e p oi nt s a s d e e m e d a p pr o pri at e d e p e n di n g o n t h e p arti ci p a nt ' s pri m ar y m ali g n a n c y ( e . g., C A 1 9 -9 f or p arti ci p a nt s wit h p a n cr e ati c 
c a n c er or C E A f or p arti ci p a nt s wit h c ol o n c a n c er). 
kVit al si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1, 8, a n d 1 5, a n d at 4( ± 1) h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 of C y cl e 1. F or all s u b s e q u e nt c y cl e s, vit al 
si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1 a n d 1 5. 
l1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 1 of e v er y c y cl e. I n a d diti o n, 1 2- l e a d E C G will b e m e a s ur e d 1, 2, a n d 
3h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 ( ± 1 0 mi n ut e s) d uri n g C y cl e [ADDRESS_208263] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 7 / [ADDRESS_208264] er e d M 4 3 4 4 a s a si n gl e a g e nt u n d er f a sti n g c o n diti o n s a s d e s cri b e d i n S e cti o n 6. 2. 1 . 
qM 4 3 4 4 ( a n d m et a b olit e s a s a p pr o pri at e) pl a s m a P K s a m pl e s will b e c oll e ct e d d uri n g C y cl e 1 o n D a y s 1 0 h o ur s ( b ef or e 1st d o s e ) a n d 0. 5, 1, 1. 5, 2, 3, 4, a n d 8
h o ur s aft er d o si n g ( b ef or e 2 n d d o s e , if a p pli c a bl e) a n d D a y 2 at 0 h o ur s ( at ti m e of P B M C s a m pl e b ef or e 1 st Da y 2 d o s e), D a y 8 at 0 h o ur s ( b ef or e 1 st d o s e) 
a n d 0. 5, 1, 1. 5, 2, 3, 4, a n d 8 h o ur s aft er d o si n g ( b ef or e 2 n d d o s e, if a p pli c a bl e) a n d o n D a y 1 5 at 0 h o ur s ( b ef or e 1 st d o s e )a n d 2 h o ur s .S u b s e q u e nt c y cl e s, 
D a y 1: 0 h o ur s ( b ef or e 1 st d o s e) a n d [ADDRESS_208265] e d fr o m all p arti ci p a nt s o n D a y 1 of e a c h c y cl e a n d at S af et y F oll o w -u p Vi sit or at di s e a s e pr o gr e s si o n if t h e p arti ci p a nt ' s di s e a s e 
pr o gr e s s e s b ef or e t h e S af et y F oll o w -u p Vi sit. 
yN o t a p pli c a bl e t o p ar ti ci p a nt s i n P art A 3 f o ll o wi n g t h e 1 4 d +/ [ADDRESS_208266] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 8 / 1 5 9 T a ble 5 Tre at me nt a n d F oll o w -U p Peri o d -M 4 3 4 4 Si n gle A ge nt T her a p y, P art A 3 ( dr u g h oli d a y wit h eit her 3 d +/ 4 d -, 
5 d +/ 2 d-, or 7 d +/ 7 d -sc he d ule) 
N O T E: Part A 3 1 4 d +/ 7 d - sc he d ule will use t he sc he d ule of assess me nts fr o m Part A 2 (see Ta ble 4).
C y cl e 1 ( 2 8 d a y s) C y cl e 2 o n w ar d E n d of tr e at m e nt 
E v e nt/ A s s e s s m e nt D a y 1 D a y 8 D a y 1 5 D a y 2 2 D a y 1D a y 1 5 S af et y  F oll o w -u p 1 4 d a y s  
( ± 7d a y s) aft er t h e l a st 
d o s e of st u d y  dr u g a
Cli ni c al vi sit s X X bXbXbX X X
S af et y  A s s e s s m e nt s 
P h y si c al e x a mi n ati o n cX X
W e i g ht X X X
Vit al Si g n s Xb, d Xb, d XdXdXdXdX
St a n d ar d [ADDRESS_208267] u g A d mi ni str ati o n 
M 4 3 4 4 d o si n g o3 d a y s o n/ 4 d a y s off ( D a y 1 -3, 8 -1 0, 1 5 -1 7, 2 2 -2 4) 
5 d a y s o n/ 2 d a y s off ( D a y 1 -5, 8 -1 2, 1 5 -1 9, 2 2 -2 6) 
7 d a y s o n/ 7 d a y s off (D a y s 1 -7, 1 5 -2 1) 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208268] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 3 9 / 1 5 9 C y cl e 1 ( 2 8 d a y s) C y cl e 2 o n w ar d E n d of tr e at m e nt 
E v e nt/ A s s e s s m e nt D a y 1 D a y 8 D a y 1 5 D a y 2 2 D a y 1D a y 1 5 S af et y  F oll o w -u p 1 4 d a y s  
( ± 7d a y s) aft er t h e l a st 
d o s e of st u d y  dr u g a
P h ar m a c o ki n eti c A s s e s s m e nt 
M 4 3 4 4 ( Pl a s m a P K c oll e cti o n) pX X 
( 3 d +/ 4 d -
a n d 
5 d +/ 2 d -
o nl y) X X
A E = A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, C A - 1 2 5 = C a n c er a nti g e n 1 2 5, C A 1 9- 9 = C a n c er a nti g e n 1 9 -9, C E A = C a n c er e m br y o ni c a nti g e n, 
C T = c o m p ut eri z e d t o m o gr a p h y, E C G = El e ctr o c ar di o gr a m, I C F = I nf or m e d c o n s e nt f or m, ,P K =P h ar m a c o ki n eti c, 
P S A =Pr o st at e s p e cifi c a nti g e n, W H O = W orl d H e alt h Or g a ni z ati o n. 
aP arti ci p a nt s w h o d o n ot h a v e d o c u m e nt e d di s e a s e pr o gr e s si o n u p o n c o m pl eti n g t h e S af et y F oll o w -u p Vi sit s h o ul d b e f oll o w e d, if p o s si bl e, f or u p t o [ADDRESS_208269], o n a n a p pr o x i m at el y 3 -m o nt hl y b a si s u ntil di s e a s e pr o gr e s si o n, i niti ati o n of n e w t h er a p y, or 
d e at h. 
bR e q uir e d f or C y cl e 1 o nl y; h o w e v er, a s s e s s m e nt s m a y b e p erf or m e d at ot h er u n s c h e d ul e d ti m e p oi nt s at t h e I n v e sti g at or’ s di s cr eti o n. 
cS y m pt o m -dir e ct e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or’ s j u d g m e nt. 
dVit al si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1, 8, a n d 1 5, a n d at 4 ( ± 1) h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 of C y cl e 1. F or all s u b s e q u e nt c y cl e s, vit al 
si g n s will b e m e a s ur e d at 0 h o ur s o n D a y s 1 a n d 1 5 
e1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 1 of e v er y c y cl e. I n a d diti o n, 1 2- l e a d E C G will b e m e a s ur e d 1, 2, a n d 
3h o ur s aft er M 4 3 4 4 d o si n g o n D a y 1 ( ± 1 0 mi n ut e s) d uri n g C y cl e [ADDRESS_208270] a gi n g (I t o I V) a n d T u m or -N o d e - M et a st a si s. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI C CI 
C CI 
M [ADDRESS_208271] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 0 / [ADDRESS_208272] e d at t h e s e ti m e p oi nt s a s d e e m e d a p pr o pri at e d e p e n di n g o n t h e p arti ci p a nt' s pri m ar y m ali g n a n c y ( e. g., C A 1 9 -9 f or p arti ci p a nt s wit h p a n cr e ati c 
c a n c er or C E A f or p arti ci p a n t s wit h c ol o n c a n c er). 
kC T s c a n of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d, i n a d diti o n t o C T s c a n of ot h er b o d y ar e a s ( e. g., p el vi s), a s cli ni c all y i n di c at e d. 
l  C T s c a n s will b e p erf or m e d e v er y [ADDRESS_208273] e d f or P art A 3 ( e. g. “ 3 d a y s o n f oll o w e d b y 4 d a y s off” or “ 7 d a y s o n f oll o w e d b y 7 d a y s off” will b e s el e ct e d b a s e d o n t h e R P 2 D aft er P art A 2). 
pM 4 3 4 4 ( a n d m et a b olit e s a s a p pr o pri at e ) pl a s m a P K s a m pl e s will b e c oll e ct e d a s d e s cri b e d i n S e cti o n 7. 6. 1. [ADDRESS_208274] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 1 / 1 5 9 T a ble 6 Tre at me nt a n d F oll o w - U p Peri o d ( M [ADDRESS_208275] ati n C o m bi n ati o n T her a p y, P art B 1) 
E v e nt/ A s s e s s m e nt bE a c h C y cl e ( 2 1 d a y s) F oll o w -u p a
D a y 1D a y 2D a y 3D a y 5D a y 8D a y 9D a y 1 2 D a y 1 5 All p arti ci p a nt s: 
S af et y  F oll o w -u p 
1 4 d a y s ( ± 7 d a y s ) P arti ci p a nt s wit h o ut 
P D o nl y :R a di ol o gi c 
F oll o w -u p: e v er y  
6- [ADDRESS_208276] er o n e 
( m al e p arti ci p a nt s o nl y) X
C o n c o mit a nt m e di c ati o n s C o nti n u o u s fr o m si g ni n g of I C F t hr o u g h S af et y F oll o w -u p Vi sit 
A E s 
St u d y  Dr u g A d mi ni str ati o n 
M [ADDRESS_208277] ati n d o si n g X
P h ar m a c o ki n eti c A s s e s s m e nt 
M 4 3 4 4 ( Pl a s m a P K c oll e cti o n) XtXtXu
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208278] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 2 / 1 5 9 E v e nt/ A s s e s s m e nt bE a c h C y cl e ( 2 1 d a y s) F oll o w -u p a
D a y 1D a y 2D a y 3D a y 5D a y 8D a y 9D a y 1 2 D a y 1 5 All p arti ci p a nt s: 
S af et y  F oll o w -u p 
1 4 d a y s ( ± 7 d a y s ) P arti ci p a nt s wit h o ut 
P D o nl y :R a di ol o gi c 
F oll o w -u p: e v er y  
6- 9 w e e k s c
A E = A d v er s e e v e nt, β -h C G = β- h u m a n c h ori o ni c g o n a d otr o pi n, B R C A = Br e a st c a n c er e arl y o n s et g e n e s 1 a n d 2, C A -1 2 5 = C a n c er a nti g e n 1 2 5 , C A 1 9 -9 = 
C a n c er a nti g e n 1 9 - 9, C E A = C a n c er e m br y o ni c a nti g e n, C T = C o m p ut eri z e d t o m o gr a p h y, , E C G = el e ctr o c ar di o gr a m, M R I = 
M a g n eti c r e s o n a n c e i m a gi n g, M T D = M a xi m u m t ol er at e d d o s e, P D = P h ar m a c o d y n a mi c, P K = P h ar m a c o ki n eti c s, P S A = Pr o st at e s p e cifi c a nti g e n, R P 2 D = 
R e c o m m e n d e d P h a s e II D o s e ,W H O = W o rl d H e alt h Or g a ni z ati o n .
aF oll o w -u p will i n cl u d e a S af et y F oll o w -u p Vi sit 1 4 ( ± 7) d a y s f oll o wi n g t h e l a st d o s e of st u d y dr u g a n d R a di ol o gi c F oll o w -u p e v er y [ADDRESS_208279], o n a n a p pr o xi m at el y 3 -m o nt hl y b a si s u ntil di s e a s e pr o gr e s si o n, i niti ati o n of n e w t h er a p y, or d e at h 
( s e e S e cti o n 5. 2. 1 1 ).
bPl e a s e s e e S e cti o n 6. 2. [ADDRESS_208280] e q uir e d f or C y cl e s 1 a n d 2 o nl y. 
eR e q uir e d f or C y cl e 1 o nl y; h o w e v er, a s s e s s m e nt s m a y b e p erf or m e d at ot h er u n s c h e d ul e d ti m e p oi nt s at t h e I n v e sti g at o r’ s di s cr eti o n. 
fR e q uir e d f or C y cl e 1 at M T D/ R P [ADDRESS_208281] e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or’ s j u d g m e nt. 
hA h e ari n g a s s e s s m e nt will b e p erf or m e d o n D a y 1 of e a c h c y cl e a n d at t h e S af et y F oll o w -u p Vi sit a s p art of t h e p h y si c al e x a mi n ati o n. 
iI m a gi n g s c a n ( e . g., C T, M RI) of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d, i n a d diti o n t o i m a gi n g s c a n of ot h er b o d y ar e a s ( e. g., p el vi s), a s cli ni c all y i n di c at e d. 
I m a gi n g s c a n s m a y b e p erf or m e d ± 5 d a y s b ef or e t h e e n d of i n di c at e d c y cl e s; h o w e v er, t h e i m a gi n g s c a n m u st b e p erf or m e d b ef or e D a y 1 d o si n g of t h e 
s u b s e q u e nt c y cl e. F or e a c h p arti ci p a nt , t h e s a m e i m a gi n g t e c h ni q u e s h o ul d b e u s e d t o f oll o w t h e di s e a s e (if p o s si bl e). 
jIf a p arti ci p a nt di s c o nti n u e s t h e st u d y pr e m at ur el y wit h o ut e vi d e n c e of pr o gr e s si v e di s e a s e o n t h e m o st r e c e nt s c a n, a f oll o w -u p i m a gi n g s c a n will b e p erf or m e d 
wit hi n [ADDRESS_208282] a gi n g (I t o I V) a n d T u m or -N o d e -M et a st a si s. 
lF or all p arti ci p a nt s wit h pr o st at e c a n c er, or f or p arti ci p a nt s wit h ot h er s oli d t u m or s wit h k n o w n or s u s p e ct e d b o n e m et a st a s e s. 
D oc u me nt N o. [ADDRESS_208283] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 3 / [ADDRESS_208284] e d at t h e s e ti m e p oi nt s a s d e e m e d a p pr o pri at e d e p e n di n g o n t h e p arti ci p a nt ' s pri m ar y m ali g n a n c y ( e . g., C A 1 9 -9 f or p arti ci p a nt s wit h p a n cr e ati c c a n c er 
or C E A f or p arti ci p a nt s wit h c ol o n c a n c er). 
nVit al si g n s will b e m e a s ur e d o n D a y 1 at 0 h o ur s ( b ef or e c ar b o pl ati n d o si n g). 
oVit al si g n s will b e m e a s ur e d o n D a y 2 of C y cl e s 1 a n d 2 at 0 h o ur s ( b ef or e M 4 3 4 4 d o si n g), o n D a y 2 of C y cl e 1 o nl y at 4 ( ± 1) h o ur s aft er M 4 3 4 4 d o si n g, a n d 
o n D a y 9 of C y cl e 1 at 0 h o ur s ( b ef or e M 4 3 4 4 d o si n g). 
p1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 2 of C y cl e s 1 a n d 2 o nl y. I n a d diti o n, o n D a y 2 of C y cl e 1 o nl y, 1 2 -l e a d 
E C G will b e m e a s ur e d 1, 2, a n d 3 h o ur s aft er M 4 3 4 4 d o si n g ( ± 1 0 mi n ut e s). 
qT o f a cilit at e ti m el y a d mi ni str ati o n of st u d y dr u g, s af et y l a b s o n D a y [ADDRESS_208285] of a n al yt e s a n d f urt h er d et ail s 
r e g ar di n g l a b or at or y t e sti n g s c h e d ul e. S e e S e cti o n 6. 2. 2 f or crit eri a f or a d mi ni str ati o n of c h e m ot h er a p y or M 4 3 4 4. 
rF e m al e p arti ci p a nt s of c hil d b e ari n g p ot e nti al o nl y. 
sR e q uir e d o nl y at M T D/ R P [ADDRESS_208286] e d d uri n g C y cl e 1 o n D a y 2 at 0 ( b ef or e d o si n g) a n d at 0. 5, 1, 1. 5, 2, 3, 4, 8, a n d 2 4 h o ur s ( D a y 3) aft er d o si n g. F or 
p arti ci p a nt s u n d er g oi n g t h e ti m e d -t u m or bi o p si e s, P K s a m pl e c oll e cti o n at [ADDRESS_208287] e d d uri n g C y cl e 1 o n D a y 9 at 0 h o ur s ( b ef or e d o si n g). 
vM [ADDRESS_208288] e d d uri n g C y cl e 1 o n D a y 2 at 0 h o ur ( b ef or e d o si n g) a n d at 0 t o 4, 4 t o 8, 8 t o 1 2, a n d 1 2 t o 2 4 h o ur s ( D a y 3) aft er 
d o si n g. 
yF or p arti ci p a nt s wit h br e a st c a n c er or o v ari a n c a n c er d uri n g C y cl e [ADDRESS_208289] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 4 / 1 5 9 T a ble 7 Tre at me nt a n d F oll o w -u p Peri o d (M 4 3 4 4 si n gle a ge nt t her a p y i n P arts C 1, C 2, a n d C 3 a n d t he 1 4 d +/ 7 d- 
sc he d ule descri be d i n P arts C 4, C 5, a n d C 6 )
E v e nt/ A s s e s s 
m e nt aC y cl e 1 ( 2 1 D a y s) C y cl e 2 ( 2 1 D a y s) S u b s e q u e nt 
c y cl e s ( 2 1 
d a y s) F oll o w -u p b
D a y 1 D a y 8 D a y 1 5 D a y 1D a y 8 D a y 1 5 D a y 1 All p arti ci p a nt s: 
S af et y  F oll o w -u p 
3 0 d a y s ( ± 7d a y s ) P arti ci p a nt s wit h o ut P D 
o nl y: 
R a di ol o gi c F oll o w -u p c
e v er y  [ADDRESS_208290] a n d ar d 1 2 -
l e a d E C G f XfX
Tri pli c at e 
1 2 -l e a d E C G 
( St a g e 1 a n d 2 
o nl y) gXg
S er u m 
c h e mi str y XhXhXhXhXhXhXhX
H e m at ol o g y XhXhXhXhXhXhXhX
Uri n e β -h C G iXjX X X
D oc u me nt N o. 
O bject N o. C CI C CI 
C CI 
M [ADDRESS_208291] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 5 / 1 5 9 E v e nt/ A s s e s s 
m e nt aC y cl e 1 ( 2 1 D a y s) C y cl e 2 ( 2 1 D a y s) S u b s e q u e nt 
c y cl e s ( 2 1 
d a y s) F oll o w -u p b
D a y 1 D a y 8 D a y 1 5 D a y 1D a y 8 D a y 1 5 D a y 1 All p arti ci p a nt s: 
S af et y  F oll o w -u p 
3 0 d a y s ( ± 7d a y s ) P arti ci p a nt s wit h o ut P D 
o nl y: 
R a di ol o gi c F oll o w -u p c
e v er y  [ADDRESS_208292] u g a d mi ni str ati o n 
M 4 3 4 4 d o si n g qC o nti n u o u s d o si n g q
P h ar m a c o ki n eti c A s s e s s m e nt s 
M 4 3 4 4 
( Pl a s m a P K 
c oll e cti o n) XrX X rXrXr
A E = A d v er s e e v e nt, β -h C G: b et a - h u m a n c h ori o ni c g o n a d otr o pi n, , C E A = C a n c er e m br y o ni c a nti g e n, C T = 
C o m p ut eri z e d t o m o gr a p h y, D N A = D e o x yri b o n u cl ei c a ci d, E C G = El e ctr o c ar di o gr a m, I C F = I nf or m e d c o n s e nt f or m, M RI = M a g n eti c r e s o n a n c e i m a gi n g,  
, P D = pr o gr e s si o n of di s e a s e, P K = P h ar m a c o ki n et i c s, R E CI S T =R e s p o n s e E v al u ati o n Crit eri a I n S oli d T u m or s ,R P 2 D = 
R e c o m m e n d e d P h a s e II d o s e , W H O = W o rl d H e alt h Or g a ni z ati o n .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
C CI C CI 
M [ADDRESS_208293] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 6 / [ADDRESS_208294] u d y Vi sit s f or g ui d a n c e o n mi s s e d a s s e s s m e nt s. 
bF oll o w -u p Vi sit will i n cl u d e a S af et y F oll o w -u p Vi sit 3 0 ( ± 7) d a y s f oll o wi n g t h e l a st d o s e of st u d y dr u g a n d R a di ol o gi c F oll o w -u p e v er y [ADDRESS_208295] u d y ( s e e S e cti o n 5. 2. 1 1 ).
cR a di ol o gi c F oll o w -u p Vi sit s ar e n ot r e q uir e d f or t h o s e p arti ci p a nt s wit h pr o gr e s si v e di s e a s e o n pri or i m a gi n g s c a n . P arti ci p a nt s s h o ul d att e n d R a di ol o gi c F oll o w -
u p Vi sit s u ntil di s e a s e pr o gr e s si o n i s o b s er v e d, n e w a nti c a n c er tr e at m e nt i s st art e d, d e at h, or t h e e n d of t h e st u d y, w hi c h e v er c o m e s fir st. F or t h e fir st [ADDRESS_208296] e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or’ s j u d g m e nt. 
eVit al si g n s will b e m e a s ur e d pr e d o s e. 
fI n St a g e 3 of P art s C 1 , C 2 , a n d C 3 : 1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 1. 
gI n St a g e s 1 a n d 2 of P art s C 1 , C 2, a n d C 3 o nl y : t ri pli c at e [ADDRESS_208297] a gi n g (I t o I V) a n d T u m or -N o d e -M et a st a si s. 
nI m a gi n g s c a n ( e . g., C T, M RI) of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d e v er y 6 w e e k s , i n a d diti o n t o i m a gi n g s c a n of ot h er b o d y ar e a s ( e. g., p el vi s), a s 
cli ni c all y i n di c at e d. I m a gi n g s c a n s m a y b e p erf or m e d ± 5d a y s b ef or e t h e e n d of i n di c at e d c y cl e s; h o w e v e r, t h e i m a gi n g s c a n m u st b e p erf or m e d b ef or e D a y 1 
d o si n g of t h e s u b s e q u e nt c y cl e. F or e a c h p arti ci p a nt , t h e s a m e i m a gi n g t e c h ni q u e s h o ul d b e u s e d t o f oll o w t h e di s e a s e (if p o s si bl e). P er R E CI S T 1. 1, o bj e cti v e 
r e s p o n s e s n e e d t o b e c o nfir m e d. C o nfir m ati o n s h o ul d b e d et er mi n e d at a s c a n n o l e s s t h a n 4 w e e k s aft er t h e ori gi n al a s s e s s m e nt of o bj e cti v e r e s p o n s e i s 
m a d e; c o nfir m ati o n of r e s p o n s e at t h e n e xt s c h e d ul e d t u m or a s s e s s m e nt i s a c c e pt a bl e. 
oIf a p arti ci p a nt di s c o nti n u e s t h e st u d y pr e m at ur el y wit h o ut e vi d e n c e of pr o gr e s si v e di s e a s e o n t h e m o st r e c e nt s c a n, a f oll o w- u p i m a gi n g s c a n will b e p erf or m e d 
wit hi n [ADDRESS_208298] u d y Part A or A 2 , or if u si n g t h e 1 4 d +/ [ADDRESS_208299] u d y P art A 3 .
rM 4 3 4 4 ( a n d m et a b olit e s a s a p pr o pri at e) pl a s m a P K s a m pl e s will b e c oll e ct e d d uri n g C y cl e 1 o n D a y 1at 0 ( b ef or e d o si n g) , b et w e e n 0. [ADDRESS_208300] e ,o n C y cl e 1 D a y 8 a n d D a y 1 5 ( at t h e st art a n d e n d o f t h e vi sit, at l e a st [ADDRESS_208301] e s) , c o nti n ui n g o n D a y 1 of e v er y s e c o n d c y cl e d uri n g C y cl e s 2 -8 a n d e v er y f o urt h c y cl e fr o m C y cl e 1 2 o n w ar d s .I n c a s e of t h e 1 4 d +/ [ADDRESS_208302] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 7 / [ADDRESS_208303] or at or y Assess me nts ( M 4 3 4 4 si n gle a ge nt t her a p y i n P a rts C 1, C 2 a n d C 3 a n d t he 1 4 d +/ 7 d- sc he d ule 
descri be d i n P arts C 4, C 5, a n d C 6) 
E v e nt/ A s s e s s m e nt a
C y cl e [ADDRESS_208304] u d y Vi sit s f or g ui d a n c e o n mi s s e d a s s e s s m e nt s. 
bF oll o w -u p Vi sit will i n cl u d e a S af et y F oll o w -u p Vi sit 3 0 ( ± 7) d a y s f oll o wi n g t h e l a st d o s e of st u d y dr u g .
fSt a g e [ADDRESS_208305] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 8 / 1 5 9 T a ble 9 Tre at me nt a n d F oll o w -u p Peri o d ( M 4 3 4 4 si n gle a ge nt t her a p y i n P arts C 4, C 5 a n d C 6 , e xce pt f or t he 
1 4 d +/ 7 d- sc he d ule )
E v e nt/ A s s e s s m e nt aC y cl e 1 ( 2 8 D a y s) C y cl e 2 ( 2 8 D a y s) S u b s e q u e nt 
c y cl e s ( 2 8 
d a y s) F oll o w -u p b
D a y 1 D a y 8D a y 1 5 D a y2 2 D a y 1 D a y 8D a y 1 5 D a y2 2 D a y 1 All 
p arti ci p a nt s: 
S af et y  
F oll o w -u p 
3 0 d a y s 
( ± 7d a y s) P arti ci p a nt s 
wit h o ut P D 
o nl y: 
R a di ol o gi c 
F oll o w -u p c
e v er y  [ADDRESS_208306] a n d ar d 1 2 -l e a d E C G fXfX
Tri pli c at e 1 2 -l e a d E C G 
( St a g e 1 a n d 2 o nl y) gX
S er u m c h e mi str y XiXhXhX X hXhXhXhX
H e m at ol o g y XhXhXhX X hXhXhXhX
Uri n e β -h C G iXjX X X
C o n c o mit a nt 
m e di c ati o n s C o nti n u o u s fr o m si g ni n g of I C F t hr o u g h S af et y F oll o w -u p Vi sit 
A E s 
Cli ni c al di s e a s e 
a s s e s s m e nt k X X X X
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208307] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 4 9 / 1 5 9 E v e nt/ A s s e s s m e nt aC y cl e 1 ( 2 8 D a y s) C y cl e 2 ( 2 8 D a y s) S u b s e q u e nt 
c y cl e s ( 2 8 
d a y s) F oll o w -u p b
D a y 1 D a y 8D a y 1 5 D a y2 2 D a y 1 D a y 8D a y 1 5 D a y2 2 D a y 1 All 
p arti ci p a nt s: 
S af et y  
F oll o w -u p 
3 0 d a y s 
( ± 7d a y s) P arti ci p a nt s 
wit h o ut P D 
o nl y: 
R a di ol o gi c 
F oll o w -u p c
e v er y  [ADDRESS_208308] u g A d mi ni str ati o n 
M 4 3 4 4 d o si n g q3 d a y s o n/ 4 d a y s off ( D a y 1 -3, 8 -1 0, 1 5 -1 7, 2 2 -2 4) 
7 d a y s o n/ 7 d a y s off ( D a y s 1 -7, 1 5 -2 1) 
5 d a y s o n/ 2 d a y s off ( D a y 1- 5, 8 -1 2, 1 5 -1 9, 2 2 -2 6) q
P h ar m a c o ki n eti c A s s e s s m e nt s 
M 4 3 4 4 ( Pl a s m a P K 
c oll e cti o n) r XrXrXrXrXr
A E = A d v er s e e v e nt, β -h C G: b et a - h u m a n c h ori o ni c g o n a d otr o pi n, , C E A = C a n c er e m br y o ni c a nti g e n, C T = 
C o m p ut eri z e d t o m o gr a p h y, , E C G = El e ctr o c ar di o gr a m, I C F = I nf or m e d c o n s e nt f or m, M RI = M a g n eti c r e s o n a n c e i m a gi n g,  
, P D = pr o gr e s si o n of di s e a s e, P K = P h ar m a c o ki n eti c s, R E CI S T =R e s p o n s e E v al u ati o n Crit eri a I n S oli d T u m or s ,R P 2 D = 
R e c o m m e n d e d P h a s e II d o s e , W H O = W o rl d H e alt h Or g a ni z ati o n 
aPl e a s e s e e S e cti o n 6. 2. [ADDRESS_208309] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 0 / 1 5 9 bF oll o w -u p Vi sit will i n cl u d e a S af et y F oll o w -u p Vi sit 3 0 ( ± 7) d a y s f oll o wi n g t h e l a st d o s e of st u d y dr u g a n d R a di ol o gi c F oll o w -u p e v er y [ADDRESS_208310] u d y ( s e e S e cti o n 6. 2. 4 ).
cR a di ol o gi c F oll o w -u p Vi sit s ar e n ot r e q uir e d f or t h o s e p arti ci p a nt s wit h pr o gr e s si v e d i s e a s e o n pri or i m a gi n g s c a n . P arti ci p a nt s s h o ul d att e n d R a di ol o gi c F oll o w -
u p Vi sit s u ntil di s e a s e pr o gr e s si o n i s o b s er v e d, n e w a nti c a n c er tr e at m e nt i s st art e d, d e at h, or t h e e n d of t h e st u d y, w hi c h e v er c o m e s fir st. F or t h e fir st [ADDRESS_208311] e d p h y si c al e x a mi n ati o n s will b e p erf or m e d a s cli ni c all y i n di c at e d i n t h e I n v e sti g at or’ s j u d g m e nt. 
eVit al si g n s will b e m e a s ur e d pr e d o s e. 
fI n St a g e 3 of P art s C 4, C 5, a n d C 6: 1 2 -l e a d E C G will b e m e a s ur e d b ef or e M 4 3 4 4 d o si n g ( u p t o 6 0 mi n ut e s b ef or e) o n D a y 1. 
gI n St a g e s 1 a n d 2 of P art s C 4, C 5, a n d C 6o nl y : t ri pli c at e [ADDRESS_208312] a gi n g (I t o I V) a n d T u m or -N o d e -M et a st a si s. 
nI m a gi n g s c a n ( e . g., C T, M RI) of c h e st a n d a b d o m e n s h o ul d b e p erf or m e d e v er y 6 w e e k s , i n a d diti o n t o i m a gi n g s c a n of ot h er b o d y ar e a s ( e. g., p el vi s), a s 
cli ni c all y i n di c at e d. I m a gi n g s c a n s m a y b e p erf or m e d ± 5d a y s b ef or e t h e e n d of i n di c at e d c y cl e s; h o w e v er, t h e i m a gi n g s c a n m u st b e p erf or m e d b ef or e D a y 1 
d o si n g of t h e s u b s e q u e nt c y cl e. F or e a c h p arti ci p a nt , t h e s a m e i m a gi n g t e c h ni q u e s h o ul d b e u s e d t o f oll o w t h e di s e a s e (if p o s si bl e). P er R E CI S T 1. 1, o bj e cti v e 
r e s p o n s e s n e e d t o b e c o nfir m e d. C o nfir m ati o n s h o ul d b e d et er mi n e d at a s c a n n o l e s s t h a n 4 w e e k s aft er t h e ori gi n al a s s e s s m e n t of o bj e cti v e r e s p o n s e i s 
m a d e; c o nfir m ati o n of r e s p o n s e a t t h e n e xt s c h e d ul e d t u m or a s s e s s m e nt i s a c c e pt a bl e. 
oIf a p arti ci p a nt di s c o nti n u e s t h e st u d y pr e m at ur el y wit h o ut e vi d e n c e of pr o gr e s si v e di s e a s e o n t h e m o st r e c e nt s c a n, a f oll o w -u p i m a gi n g s c a n will b e p erf or m e d 
wit hi n [ADDRESS_208313] u d y Part A 3 .
rM 4 3 4 4 ( a n d m et a b olit e s a s a p pr o pri at e) pl a s m a P K s a m pl e s will b e c oll e ct e d a s d e s cri b e d i n S e cti o n  7. 6. 1. [ADDRESS_208314] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 1 / [ADDRESS_208315] or at or y Assess me nts ( M 4 3 4 4 si n gle a ge nt t her a p y i n P arts C 4, C 5 a n d C 6 ,e xce pt f or t he 1 4 d +/ 7 d- 
sc he d ule )
E v e nt/ A s s e s s m e nt aC y cl e 1 C y cl e 2 S u b s e q u e nt C y cl e s Di s e a s e Pr o gr e s si o n or 
S af et y  F oll o w -u p bD a y 1 D a y 1 5 D a y 1 D a y 1 5 D a y 1
D N A = D e o x yri b o n u cl ei c a ci d, P B M C = P eri p h er al bl o o d m o n o n u cl e ar c ell s. 
aPl e a s e s e e S e cti o n 6. 2. [ADDRESS_208316] u d y Vi sit s f or g ui d a n c e o n mi s s e d a s s e s s m e nt s. 
bF oll o w -u p Vi sit will i n cl u d e a S af et y F oll o w -u p Vi sit 3 0 ( ± 7) d a y s f oll o wi n g t h e l a st d o s e of st u d y dr u g. 
e 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
C CI C CI 
M [ADDRESS_208317] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 2 / [ADDRESS_208318] u d y is s p o ns ore d b y : Merc k K Ga A ,Dar msta dt, Ger ma n y a n d E M D Ser o n o 
Researc h & De vel o p me nt I nstit ute, I nc., Billerica, M A, U S A i n N ort h A merica. 
T he st u d y will be c o n d ucte d at a p pr o xi matel y  [ADDRESS_208319] u d y  
will i ncl u d e t he U K, t he U S A, the Net herla n ds a n d S pai n .
T he C o or di nati n g I n vesti gat or ( ), 
re prese nt s all I n vesti gat or s f or decisi o ns a n d disc ussi o ns re gar di n g t his st u d y , c o nsiste nt wit h t he 
I nter nati o nal C o u ncil f or Har m o nisati o n (I C H) T o pic E 6 G o o d C li nical Practice ( G C P; hereafter 
referre d t o as I C H G C P ). T he C o or di nati n gI n vesti gat or will pr o vi d ee x pert me dical i n p ut a n d 
a d vice relati n g t o st u d y desi g n a n d e xec uti o n a n d is res p o nsi ble f or t he re vie w a n d si g n off of t he 
cli nical st u d y re p ort o n be half of all I n vesti gat ors .
Si g nat ure pa ges f or t he Pr ot oc ol Lea d a n d t he C o or di nati n g I n vesti gat or as well as a list of S p o ns or 
res p o nsi ble pers o ns are i n A p pe n di x I .
T he st u d y will a p pear i n t he f oll o wi n g cli nical trial re gistries: Cli nical Trials. g o v a n d E u dra C T .
Details of str uct ures a n d ass ociate d pr oce d ures will be defi ne d i n a se parate Ma n ual of O perati o ns , 
w hic h will be pre pare d u n der t he s u per visi o n of t he Cli nical St u d y Lea der. 
3 B ac k gr o u n d I nf or m ati o n 
Ca ncer is a gr o u p of diseases c haracterize d b y  d y sre g ulati o n of cell differe ntiati o n, pr oliferati o n, 
a n d s ur vi val. I n a d va nce d sta ges, t u m or cells ca n s prea d t o ot he r areas of t he b o d y i ncl u di n g vital 
or ga ns a n d b o ne, w hic h ca n be fa tal if n ot br o u g ht u n der c o ntr ol (A merica n Ca ncer S ociet y 2 0 1 1) . 
T hr o u g h a d va nce me nts i n detecti o n, s ur ger y , a n d t hera p y, patie nts’ pr o g n oses are ge nerall y 
i m pr o vi n g, a n d 5- ye ar s ur vi val rates f or a n u m ber of ca ncers are risi n g. H o we ver, t he nee d f or 
better treat me nt o pti o ns re mai ns. T he I nter nati o nal A ge nc y f or Researc h o n Ca ncer esti mates t hat 
t otal ca ncer -relate d deat hs w orl d wi de i n 2 0 0 8 were 7. 6 milli o n, w hic h is e x pecte d t o rise t o 
1 3. 2 milli o n ca ncer deat hs b y  2 0 3 0 (A merica n Ca ncer S ociet y 2 0 1 1 , Ferla y  2 0 1 0 ).
De o x yri b o n ucleic aci d (D N A )- da ma gi n g a ge nts a n d i o nizi n g ra diati o n (I R) are wi del y  u se d as 
sta n dar d of care f or t he treat m e nt of ma n y s oli d t u m ors. H o we ver, f or m ost patie nts, t he y  pr o vi de 
o nl y  m o dest be nefit d ue t o hi g hl y p r oficie nt cell ular pr ocesses t hat are a ble t o detect a n d re pair t he 
da ma ge d D N A (Ola usse n [ADDRESS_208320] 2 0 1 1 ).
3. 1 Scie ntific R ati o n ale 
T he pr otei n ki nase ata xia tela n giectasia m utate d ( A T M) a n d Ra d 3 -relate d ( A T R) are t he pri mar y  
me diat or of a n i m p orta nt D N A da ma ge s ur veilla nce a n d re pair pat h wa y  t hat res p o n ds t o 
re plicati o n stress ( R S) (Ci m pric h 2 0 0 8 ). Re plicati o n stress arises w he n t he cell's D N A re plicati o n 
mac hi ner y  atte m pts t o c o p y  t hr o u g h a n u nres ol ve d da ma ge lesi o n. S uc h e ve nts are c o m m o n after 
cells are treate d wit h D N A -da ma gi n g a ge nts. Left u nres ol ve d, R S ca n lea d t o d o u ble -stra n d D N A 
D oc u me nt N o. 
O bject N o. P P D 
C CI 
C CI 
M [ADDRESS_208321] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 3 / 1 5 9 brea ks ( D S B) a n d cell deat h. T he R S pat h wa y  i s cl osel y  a ss ociate d wit h a D S B re pair pat h wa y  
me diate d b y  t he A T R -relate d ki nase, A T M (Kasta n 2 0 0 4) . I n hi biti o n of A T R i n n o nca ncer cells 
has bee n s h o w n t o lea d t o acti vati o n of a c o m pe nsat or y  A T M me diate d res p o nse t hat pr otects cells 
fr o m t he let hal c o nse q ue nces of u nre paire d R S (Rea per 2 0 1 1) . I n  c o ntrast, ma n y ca ncer cells 
de pe n d o n A T R f or s ur vi val fr o m D N A da ma ge as a res ult of defects i n t he A T M si g nali n g 
pat h wa y  a n d/ or as a res ult of hi g h bac k gr o u n d le vels of R S t hat ca n arise fr o m a n u m ber of 
mec ha nis ms, i ncl u di n g e x pressi o n of cert ai n o nc o ge nes (Ca ncer Ge n o me Atlas N 2 0 1 2 , 
Di n g 2 0 0 8, Gree n ma n 2 0 0 7 , Jia n g 2 0 0 9 ). S uc h defects i n A T M s i g nali n g ca n ca use a de pe n de nce 
o n A T R f or s ur vi val fr o m R S ca use d b y  t reat me nt wit h D N A -da ma gi n g a ge nts (Rea per 2 0 1 1,  
T ole d o 2 0 1 1,  M ur ga 2 0 0 9 , N g hie m 2 0 0 2,  Sa n gster -G uit y 2 0 1 1,  N g hie m 2 0 0 1) . Acc or di n gl y, 
w hile n o nca ncer cells ha ve bee n s h o w n t o t olerate c o m bi nati o ns of A T R i n hi bit ors a n d 
D N A -da ma gi n g dr u gs, it is e x pecte d t hat a n A T R i n hi bit or will se nsitize ma n y  c a ncer cells t o 
vari o us D N A - da ma gi n g a ge nts (Rea per 2 0 1 1 ). Hi g h le vels of R S are e vi de nt i n s o me ca ncer cells 
e ve n i n t he a bs e nce of D N A -da ma gi n g a ge nts. T his ca n res ult fr o m e x pressi o n of o nc o ge nes t hat 
dri ve d y sre g ulate d re plicati o n, a h y p o xic e n vir o n me nt, or fr o m defects i n ot her D N A re pair 
pat h wa y s. T his hi g h R S i n ca ncer cells ca n dri ve a relia nce o n A T R f or s ur vi val a n d t h us, A T R 
i n hi bit ors ma y  ha ve be nefit as si n gle a ge nts (Gila d 2 0 1 0 , Sc h o p p y  2 0 1 2 , M ur ga 2 0 1 1 , Pi[INVESTIGATOR_6054] 2 0 1 2 , 
Ha m m o n d 2 0 0 4 ).
M 4 3 4 4 (i nitiall y  de vel o pe d b y  Verte x P har mace uticals I nc or p orate d u n der t he c o de V X - 8 0 3) is a 
p ote nt a n d selecti ve i n hi bit or of A T R (i n hi biti o n c o nsta nt < 1 5 0 p M) wit h a c o nce ntrati o n res ulti n g 
i n 5 0 % ma xi mal i n hi biti o n of [ADDRESS_208322] attri b uta ble t o acti vati o n of 
c o m pe nsat or y , A T M -me diate d, D N A re pair si g nali n g (Rea per 2 0 1 1 ). 
M utati o ns i n s pecific D N A da ma ge res p o nse relate d ge nes (i ncl u di n g A RI D 1 A, A T R X/ D A X X 
a n d A T M) ha ve bee n s h o w n t o i ncrease relia nce o n A T R si g nali n g f or t u m or cell s ur vi val a n d 
gr o wt h (Fl y n n 2 0 1 5,  Willia ms o n 2 0 1 6,  Mi n 2 0 1 7 ). P u blis he d data s u g gest t hat l oss - of- f u ncti o n 
m utati o ns i n s pecific t u m or ge nes i n v ol ve d i n t he D N A da ma ge re pair pr ocess as ca n di dates t o 
pre dict se nsiti vit y  t oA T R i n hi bit ors as m o n ot hera p y . Willia ms o n a n d c o -a ut h ors s h o we d i n a n 
ri b o n ucleic aci d i nterfere nce S cree ni n g i n cell li nes t hat A RI D 1 A was t he t o p hit ge ne t hat was 
s y nt hetic all ylet hal wit h t he A T R i n hi bit or V X - 8 2 1, a n d t hat t here was a n oticea ble statisticall y 
si g nifica nt differe nce i n se nsiti vit y  t o M 6 6 2 0 ( V X - 9 7 0) bet wee n t he A RI D1 A wil d ty pe a n d 
m ut ate d xe n o grafts (Willia ms o n 2 0 1 6) .Fl y n n a n d c oa ut h ors de m o nstrate d i n vitr o a n d i n vi v o t hat 
t u m or cells preser vi n g c hr o m os o me i nte grit y  t hr o u g h o ut t he alter nati ve le n gt he ni n g of tel o mer e
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208323] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 4 / 1 5 9 pr ocess, a mec ha nis m ass oc iate d wit h l oss - of- f u ncti o n m utati o ns i n eit her t he ge nes A T R X or 
D A X X w hic h i n v ol ves D N A h o m ol o g o us rec o m bi nati o n , are se nsiti ve t o A T R i n hi biti o n 
(Fl y n n 2 0 1 5 ). A ntit u m or acti vit y  o f M 4 3 4 4 as m o n ot hera p y has bee n s h o w n i n precli nical 
xe n o graft har b ori n g s uc h m utati o ns (Verte x Re p ort E 0 4 5 3 -U 1 6 0 7 -G 2 9 2 & S K - N- F 1 _ V X - 8 0 3). 
The c o -i nacti vati o n of A T M a n d A T R f u ncti o ns res ults i n s y nt hetic let halit y , w hic h has bee n 
s h o w n i n a gastric ca ncer xe n o graf t m o del carr y i n g a m utati o n i n A T M wit h t he A T R i n hi bit or 
A Z D 6 7 3 8 (Mi n 2 0 1 7) .T o get her, t hese data s u p p ort t he rati o nal et hat patie nts wit h s oli d t u m ors 
har b ori n g l oss - of- f u ncti o n m utati o ns i n A RI D [ADDRESS_208324] u d y  S p o n s or a nal ys is c o n d ucte d i n Se pte m ber 2 0 1 8 o n data of T he Ca ncer 
Ge n o me Atlas ( T C G A) i n t he Nati o nal Ca ncer I nstit ute Ge n o mic Data C o m m o ns ( N CI  G D C), t he 
fre q ue nc y  o f l oss of f u ncti o n m utati o ns i n A RI D 1 A, A T R X, D A X X, A T M is e x pecte d t o be 6. 7 %, 
3. 3 %, 0. 2 % , 2 . 1 %, res pecti vel y, i n t he o nc ol o g ic patie nt p o p ulati o n ( defi niti o n of “l oss of 
f u ncti o n” is re p orte d i n Secti o n  7. 7. 5 ). T he i n dicati o ns wit h t he hi g hest pre vale nce of m utati o ns 
are i n e n d o metrial carci n o ma, st o mac h a de n ocarci n o ma, ur ot helial carci n o ma, a n d 
c h ola n gi ocarci n o ma f or A RI D 1 A ( 3 0 %, 2 0 %, 1 4 %, 1 1 % of cases, res pecti vel y ), i n l o wer gra de 
gli o ma a n d sarc o ma f or A T R X ( 3 1 % a n d 1 1 %, res pecti vel y), a n d c ol o n a de n ocarci n o ma f or A T M 
( 1 1 %). 
3. 2 T o xic ol o g y a n d C o m p o u n d S afet y 
M 4 3 4 4 has bee n e val uate d i n n o n- G o o d La b orat or y  Pr actice ( G L P) d ose -ra n ge fi n di n g a n d G L P 
t o xic ol o g y  st u dies. F oll o wi n g BI Wa d mi nistrati o n of M 4 3 4 4 at d oses of 1 0, 3 0, a n d 4 5 m g/ k g f or 
[ADDRESS_208325] u d y , a ma xi m u m t olerate d d ose ( M T D) of 4 5 m g / k g 
was esta blis he d f or rats (I T R La b orat ories Re p ort f or 7 2 1 7 1 2 0 1 3 ). I n a G L P st u d y , w he n M 4 3 4 4 
was a d mi nistere d BI Wt o rats at d oses of 3, 1 0, a n d 3 0 m g/ k g f or 2 8 d a y s(M PI  [INVESTIGATOR_177587] h f or 8 6 3 -
1 6 5 2 0 1 4 ), t he i de ntifie d tar get or ga ns of t o xicit y  w ere c o nsiste nt wit h b ot h t he p har mac ol o g y  of 
A T R i n hi biti o n (R uza n ki na 2 0 0 7) a n d t he n o n -G L P fi n di n gs a n d i ncl u de d: b o ne marr o w 
(re ge nerati o n) wit h c orres p o n di n g c ha n ges t o t he he mat o p oietic s y ste m (re d ucti o ns i n w hite bl o o d 
cell [ W B C] a n d re d bl o o d cell [ R B C] mass); t h y m us (l y m p h oi d de pleti o n); s plee n ( decrease d 
l y m p h oc y tes/e xtra me d ullar y  h e mat o p oiesis); li ver (e xtra me d ullar y  h e mat o p oiesis); a n d testes 
(s per mat oc y te/s per mati d de ge nerati o n wit h c o nc o mita nt oli g os per mia/ ger m cell de bris i n 
e pi [INVESTIGATOR_121732] d y mi des) (M PI  [INVESTIGATOR_177587] h f or 8 6 3- 1 6 5 2 0 1 4 ). All fi n di n gs, wit h t he e xce pti o n of t h ose i n t he 
testes, ha d res ol ve d b y  t he e n d of t he 1 4- d a y  r ec o ver y  p eri o d (M PI  R esearc h f or 8 6 3 - 1 6 5 2 0 1 4) 
h o we ver, a d urati o n of 1 4 da y s is i ns ufficie nt f or s p er m pr o d ucti o n t o c o m pletel y  r ec o ver 
(Creas y2 0 0 2) . A se verel y  t o xic d ose t o 1 0 % of t he p o p ulati o n c o ul d n ot be deter mi ne d i n rats. 
I n a n o n -G L P [ADDRESS_208326] u d y  c o n d ucte d i n d o gs at d oses of 3, 1 0, a n d 3 0 m g/ k g 
BI W, a si n gle d ose of 3 0 m g/ k g res ulte d i n m ori b u n dit y  d ue t o se vere gastr oi ntesti nal ( GI) t o xicit y ; 
b o d y  w ei g ht l oss a n d c o nti n ue d deteri orati n g healt h le d t o t he earl y ter mi nati o n of the hi g h -d ose 
( 3 0 m g/ k g) gr o u p o n St u d y  D a y 3(I T R La b orat ories Re p ort f or 6 1 3 8 8 2 0 1 3 ). M 4 3 4 4 was als o 
p o orl y  t olerate d at 1 0 m g / k g res ulti n g i n e mesis, i na p pete nce, li q ui d st o ol, br o w n/ gree n material 
i n t he ca ge tra y , a n d b o d y  w ei g ht l oss ( u p t o 2 3 %); h o we ver, effects n ote d at 3m g/ k g were 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208327] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 5 / 1 5 9 mi ni mal. Base d o n t hese fi n di n gs, it was c o ncl u de d t hat t he M T D was e xce e de d at 1 0 m g/ k g (I T R 
La b orat ories Re p ort f or 6 1 3 8 8 2 0 1 3 ). 
I n  a G L P 2 8- d a y  s t u d y  c o n d ucte d i n d o gs assessi n g BI Wa d mi nistrati o n at d oses of 1, 2, a n d 
4m g/ k g, M 4 3 4 4 was p o orl y  t olerate d (s oft/ water y / m uc oi d feces, re d material i n t he feces a n d/ or 
i n t he ca ge tr a y , a n d b o d y  w ei g ht l oss) at t he hi g hest d ose ( 4 m g / k g) (M PI  R esearc h Re p ort f or 
8 6 3- 1 6 6 2 0 1 4) . M ori b u n dit y , d u e t o GI  t o xicit y  a n d e xtre me wei g ht l oss ( 1 4 %), o bser ve d i n 
1hi g h -d ose ( 4 m g / k g) male le d t o t he earl y sacrifice of t hat a ni mal o n St u d y  D a y 2 4 
(M PI [INVESTIGATOR_177587] h Re p ort f or 8 6 3- 1 6 6 2 0 1 4) . C o nsiste nt wit h t he n o n- G L P fi n di n gs a n d t he 
p har mac ol o g y  o f A T R i n hi biti o n (R uza n ki na 2 0 0 7) , tar get or ga ns of t o xicit y  i de ntifie d i n t his G L P 
st u d y  i n d o gs at d oses of ≥ 2 m g/ k g were: b o ne marr o w (re ge nerati o n) wit h c orres p o n di n g c ha n ges 
i n t he he mat o p oietic s y ste m ( decrease i n R B C mass); s plee n (e xtra me d ullar y  h e mat o p oiesis); li ver 
(e xtra me d ullar y  h e mat o p oiesis); t h y m us (l y m p h oi d de pleti o n); GI  ( i nfla m mati o n of la mi na 
pr o pria a n d g ut ass ociate d l y m p h oi d tiss ue); a n d testes (s per ma t oc y te/s per mati d de gra dati o n a n d 
sec o n dar y  e ffect o n e pi [INVESTIGATOR_121732] d y mi des; ger m cell de bris) (M PI  R esearc h Re p ort f or 8 6 3- 1 6 6 2 0 1 4) . 
F oll o wi n g a 1 4- d a y  r ec o ver y  p eri o d, all he mat ol o g y  f i n di n gs ha d res ol ve d ,a n d a n on g oi n g 
re ge nerati ve res p o nse was e vi de nt i n t he b o ne marr o w, t h y m us, s plee n, a n d li ver. A d diti o nall y , 
t he fi n di n gs n ote d i n t he GI  ha d res ol ve d at t he 2 m g/ k g d ose; h o we ver, as e x pecte d, t he testic ular 
fi n di n gs ha d n ot res ol ve d at t he e n d of t he rec o ver y  p eri o d (M PI  R esearc h Re p ort f or 8 6 3 -1 6 6 
2 0 1 4) si nce d urati o n of 1 4 d a y s is n ot s ufficie nt f or s per m pr o d ucti o n t o c o m pletel y rec o ver 
(Creas y 2 0 0 2 ). Base d o n t hese data, t he hi g hest n o nse verel y  t o xic d ose ( H N S T D) i n d o gs is 
c o nsi dere d t o be 2m g/ k g BI W. T he a ni mal -t o -h u ma n e x p os ure m ulti ple calc ulate d o n a n area 
u n der t he c o nce ntrati o n vers us ti me c ur ve ( A U C) basis at t he H N S T D is e x pecte d t o be 2 -f ol d t he 
pr ojecte d h u ma n e x p os ure at t he efficaci o us d ose. 
I n a d diti o n t o t o xic ol o g y data f or M 4 3 4 4 , Verte x P har mace uticals I nc or p orate d a n d Merc k K Ga A 
als o ha ve o btai ne d i nitial cli nical safet y data o n V X - 9 7 0/ M [ADDRESS_208328] u dies, M S 2 0 1 9 2 3 - 0 0 0 1 a n d 
V X 1 3 - 9 7 0- 0 0 2 , i n t h e U S Aa n d U K . M 6 6 2 0 has bee n a d mi nistere d i n Merc k -/Verte x -s p o ns ore d 
st u dies t o o ver 3 0 0 partici pa nt s wit h a d va nce d s oli d t u m ors, eit her as a si n gle a ge nt or i n 
c o m bi nati o n wit h eit her ge mcita bi ne or cis plati n. 
F urt her m ore, i nitial cli nical safet y data are a vaila ble fr o m 4 0 partici pa nt s recei vi n g M 4 3 4 4 at d oses 
ra n gi n g fr o m 1 0 m g t o 1 2 0 0 m g) o btai ne d i n t he o n g oi n g Part A of t his st u d y a n d [ADDRESS_208329] u d y  0 0 0 1 Part B 1 w h o recei ve d M 4 3 4 4 at d oses of 3 5 0 t o 5 0 0 m g i n c o m bi nati o n wit h 
car b o plati n at t he d ose A U C 5 . Refer t o t he c urre nt versi o n of t he I n vesti gat or’s Br oc h ure ( M 4 3 4 4 
I B) f or f urt her details. 
Base d o n t he e val uati o n of safet y d ata fr o m St u d y  0 0 0 1, ele vati o ns i n he patic tra nsa mi nases ( A L T 
a n d A S T) ha ve bee n esta blis he d as a ne w i m p orta nt p ote ntial ris k ass ociate d wit h t he 
a d mi nistrati o n of M 4 3 4 4. 
M 4 3 4 4 ca uses h y per bilir u bi ne mia ( pre d o m i na ntl y  i n direct or u nc o nj u gate d bilir u bi n) via 
i n hi biti o n of bilir u bi n gl uc ur o ni dati o n b y  U G T 1 A 1. I nitiall y , seri o us a d verse e ve nts ( S A Es) of 
i ncrease d bl o o d bilir u bi n a n d h y per bilir u bi ne mia were re p orte d as d ose -li miti n g t o xicities ( D L Ts) 
i n [ADDRESS_208330] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 6 / 1 5 9 t he defi niti o n of a D L T was re vise d i n a 2 0 1 6 pr ot oc ol a me n d me nt t o e xcl u de i ncreases i n bilir u bi n 
t hat are assesse d as arisi n g fr o m i n hi biti o n of bilir u bi n gl uc ur o ni dati o n, as l o n g as t he bilir u bi n 
le vel re mai ns bel o w 1 5 m g/ d L ( 2 5 7 μ m ol/ L ) (see Secti o n 5. 2. 6 ).
I n  P art A, bilir u bi n ele vati o ns were d ose -de pe n de nt, o bser ve d at d oses ≥ [ADDRESS_208331] u g a n d was se vere 
(i .e. Gra de ≥3) a n d was n ot t y pi[INVESTIGATOR_1306] y ass ociate d wit h ot her a d verse c o nse q ue nces. T he i nci de nce 
of i nc rease d bl o o d bilir u bi n as a n S A E was als o d ose - de pe n de nt, a n d was re p orte d at d oses 
≥ [ADDRESS_208332] u d y  0 0 0 1 Part A, 4 partici pa nts 
of 7partici pa nts ( 5 7. 1 %) ha d S A Es of bl o o d bilir u bi n i ncrease d. I n Part B 1, 3 partici pa nts ( 2 3. 1 %) 
re p orte d A Es of bl o o d bilir u bi n i ncrease d ( 1 partici pa nt at eac h of t he 3 M 4 3 4 4 d oses of 3 5 0, 4 0 0, 
a n d 5 0 0 m g); 1 partici pa nt ( 7. 7 %) re p orte d a n S A E of h y per bilir u bi ne mia w hile recei vi n g 4 0 0 m g 
M 4 3 4 4. 
I n  P art A, D L Ts c o nfir me d i n d o se escalati o n meeti n gs ( D E Ms) occ urre d i n 3 of 4 0 partici pa nts 
i n t he safet y  s et. O ne partici pa nt i n t he 1, 0 5 0 m g gr o u p ha d D L Ts of A L T a n d A S T i ncrease d, 
bl o o d bilir u bi n i ncrease d, a n d ne utr o pe nia. T w o partici pa nts i n t he 1, 2 0 0 m g gr o u p ha d a D L T of 
bl o o d bilir u bi n i ncrease d. N o D L Ts occ urre d at M 4 3 4 4 d oses fr o m 1 0 t o 7 0 0 m g t wice wee kl y. 
I n Part B 1, D L Ts c o nfir me d i n D E Ms occ urre d i n 4 of 1 3 partici pa nts i n t he safet y set. All D L Ts 
were re p orte d i n partici pa nts recei vi n g M 4 3 4 4 5 0 0 m g + A U C 5 car b o plati n. Three partici pa nts 
ha d a D L T of ne utr o pe nia; D L Ts of fe brile ne utr o pe nia, gastr oi ntesti nal i nfla m mati o n, 
t hr o m b oc y t o pe nia, a n d v o miti n g were re p orte d i n [ADDRESS_208333] u g reacti o ns ( A D Rs) f or M [ADDRESS_208334] u d y 0 0 0 1 Part A, na usea 
occ urre d i n 6 7. 5 % of partici pa nts a n d v o miti n g i n 4 7. 5 %. T hese e ve nts were us uall y  n o nseri o us, 
of Gra de 1 or Gra de 2 i nte nsit y, a n d ma n y occ urre d o n t he sa me da y  as M 4 3 4 4 a d mi nistrati o n ; t he 
maj orit y  di d n ot res ult i n i nterr u pti o n or per ma ne nt disc o nti n uati o n of M [ADDRESS_208335] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 7 / [ADDRESS_208336] u d y O bjecti ves 
4. 1 Pri m ar y O bjecti ves 
4. 1. 1 P art A 
T o e val uate t he safet y a n d t olera bilit y of m ulti ple asce n di n g d oses of si n gle a ge nt 
M 4 3 4 4 a d mi nistere d BI W i n partici pa nt s wit h a d va nce d s oli d t u m ors 
T o deter mi ne t he M T D a n d/ or rec o m me n de d P hase II d ose (R P 2 D ) of si n gle a ge nt 
M 4 3 4 4 a d mi nistere d BI W ( M T D Si n gle BI W ) i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 1. 2 P art A 2
T o e val uate t he safet y a n d t olera bilit y  o f m ulti ple asce n di n g d oses of si n gle a ge nt 
M 4 3 4 4 w he n a d mi nistere d i n a t wice dail y or o nce dail y d ose sc he d ule i n partici pa nt s 
wit h a d va nce d s oli d t u m ors 
T o deter mi ne t he M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d i n a t wice 
dail y  or o nce dail y d ose sc he d ule i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 1. 3 P art A 3
T o e val uate t he safet y a n d t olera bilit y  o f m ulti ple asce n di n g d oses of si n gle a ge nt 
M [ADDRESS_208337] u g h oli da y  d ose sc he d ule i n partici pa nt s wit h 
a d va nce d s oli d t u m ors 
T o deter mi ne t he M T D a n d/ or R P [ADDRESS_208338] u g 
h oli da y  d ose sc he d ule i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 1. 4 P art B 1 
T o e val uate t he safet y a n d tolera bilit y  o f M 4 3 4 4 w he n a d mi nistere d i n c o m bi nati o n 
wit h car b o plati n i n partici pa nts wit h a d va nce d s oli d t u m ors 
T o deter mi ne t he M T D a n d/ or R P 2 D of M 4 3 4 4 a d mi nistere d i n c o m bi nati o n wit h 
car b o plati n i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 1. 5 All P arts C
T o e val uate t he safet y,  t olera bilit y , a n d efficac y  i n ter ms of c o nfir me d o bjecti ve 
res p o nse of M 4 3 4 4 w he n a d mi nistere d i n partici pa nts wit h s oli d t u m or har b ori n g 
l oss - of- f u ncti o n m utati o ns i n t he ge nes A RI D 1 A ( Part sC 1 , C 4 ), A T R X a n d/ or D A X X 
( Part sC 2 , C 5 ), or A T M ( Part sC 3 , C 6 ). 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208339] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 8 / 1 5 9 4. 2 Sec o n d ar y O bjecti ves 
4. 2. 1 P art A 
T o e val uate t he p har mac o ki netics ( P K) of si n gle a ge nt M 4 3 4 4 w he n a d mi nistere d BI W
i n partici pa nt s wit h a d va nce d s oli d t u m ors 
T o assess p ote ntial a ntit u m or acti vit y of si n gle a ge nt M 4 3 4 4 w he n a d mi nistere d BI W 
i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 2. 2 P art A 2 
T o e val uate t he p har mac o ki netics ( P K) of si n gle a ge nt M 4 3 4 4 (a n d meta b olites as 
a p pr o priate) w he n a d mi nistere d i n a t wice dail y or o nce dail y d ose sc he d ule i n 
partici pa nt s wit h a d va nce d s oli d t u m ors 
T o assess a ntit u m or acti vit y  of si n gle a ge nt M 4 3 4 4 w he n a d mi nistere d i n a t wice dail y 
or o nce dail y d ose sc he d ule i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 2. 3 P art A 3
T o e val uate t he p har mac o ki netics ( P K) of si n gle a ge nt M 4 3 4 4 (a n d meta b olites as 
a p pr o priate) w he n a d mi nistere d i n a dr u g h oli da y  d ose sc he d ule i n partici pa nt s wit h 
a d va nce d s oli d t u m ors 
T o assess preli mi nar y  a ntit u m or acti vit y  o f si n gle a ge nt M [ADDRESS_208340] u g h oli da y  d ose sc he d ule i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 2. 4 P art B 1 
T o e val uate t he P K pr ofile of M 4 3 4 4 w he n a d mi nistere d i n c o m bi nati o n wit h 
car b o plati n i n partici pa nt s wit h a d va nce d s oli d t u m ors 
T o e val uate p ote ntial a ntit u m or acti vit y  a fter a d mi nisteri n g M 4 3 4 4 i n c o m bi nati o n wit h 
car b o plati n i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
4. 2. 5 All P arts C
T o f urt her e val uate efficac y  i n ter ms of c o nfir me d best o verall res p o nse, durati o n of 
res p o nse, pr o gressi o n free s ur vi val a n d o verall s ur vi val ti me of M 4 3 4 4 w he n 
a d mi nistere d i n partici pa nts wit h l oss - of- f u ncti o n m utati o ns i n t he ge nes A RI D 1 A 
( Part sC 1 , C 4 ), A T R X a n d/ or D A X X ( Part sC 2 , C 5 ), or A T M ( Part sC 3 , C 6 )
T o e val uate t he PK of M 4 3 4 4 (a n d meta b olites as a p pr o priate) i n i n di vi d ual partici pa nts 
wit h l oss - of- f u ncti o n m utati o ns .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208341] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 5 9 / [ADDRESS_208342] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 0 / [ADDRESS_208343] u d y  c o n d ucte d i n m ulti ple Parts (Parts A, 
A 2 , A 3, B 1, C 1, C 2, C 3, C 4, C 5, a n d C 6 ). Part A will esta blis h t he M T D/ R P 2 D of M 4 3 4 4 as a 
si n gle a ge nt a d mi nistere d BI W . Part A 2 will esta blis h t he M T D/ R P 2 D of M 4 3 4 4 as a si n gle a ge nt 
a d mi nistere d BI D (t wice dail y )or o nce dail y. Part A 3 is o pti o nal a n d will esta blis h t he M T D/ R P [ADDRESS_208344] y i n g a 3 -d a y s- o n/ 4 -d a y s- 
off , 5- d a y s-o n/ 2 -d a y s- off, 7- d a y s- o n/ 7- d a y s-off a n d/ or 1 4- d a y s- o n/ 7- d a y s- off sc he d ule .Part B 1 
will esta blis h t he M T D/ R P [ADDRESS_208345] u d y  was desi g ne d i n acc or da nce wit h t he E ur o pea n Me dici ne A ge nc y’s g ui da nce d oc u me nt, 
“ G ui deli ne o n Strate gies t o I d e ntif y  a n d Miti gate Ris ks f or First I n H u ma n Cli nical St u dies Wit h 
I n vesti gati o nal Me dici nal Pr o d ucts.” 
A sc he matic of t he st u d y  desi g n is i ncl u de d i n Fi g ure 1.
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208346] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 1 / [ADDRESS_208347] u d y Desi g n 
A T M = At a xi a t el a n gi e ct a si a m ut at e d, BI D = T wi c e d ail y, BI W = T wi c e w e e kl y, Q D = O n c e d ail y 
5. 1. [ADDRESS_208348] u d y , t o e val uate t he safet y , t olera bilit y, a n d P K, as well as 
esta blis h t he M T D/ R P 2 D of M 4 3 4 4 w he n a d mi nistere d as a si n gle a ge nt i n partici pa nt s wit h 
a d va nce d s oli d t u m ors. A p pr o xi matel y  2 5partici pa nt s will be i ncl u de d i n Part A. T hese 
partici pa nt s will be a d mi nistere d M 4 3 4 4 as a si n gle a ge nt, o n D a y s 1, 4, 8, 1 1, 1 5, a n d 1 8 of a 
2 1- d a y  c y cle u n der fasti n g c o n diti o ns as d escri be d i n Secti o n 6. 2. 1 .
T he ma xi m u m rec o m me n de d starti n g d ose ( M R S D) of si n gle a ge nt M [ADDRESS_208349] u d y  desi g n. O ne partici pa nt will be e nr olle d a t t he M R S D. I f t he starti n g d ose 
of M 4 3 4 4 is t olerate d i n t his partici pa nt t hr o u g h 1c y cle ( 2 1 d a y s) wit h o ut a n y  C o m m o n 
Ter mi n ol o g y  C riteria f or A d verse E ve nts ( C T C A E) Gra de [ADDRESS_208350] u d y  d r u g, t he d ose of M 4 3 4 4 m a y  be i ncrease d b y  u p t o 1 0 0 % 
i n a s u bse q ue nt partici pa nt , de pe n di n g o n t o xicities a n d t olera bilities o bser ve d. I n t his w a y , t he 
d ose of M [ADDRESS_208351] u g -relate d is o bser ve d. I n 
a d diti o n, at t he discreti o n of t he S p o ns or a n d I n vesti gat or s u p t o 2 a d diti o nal partici pa nt s ( 3 per 
c o h ort) m a y  b e e nr olle d i n t he si n gle partici pa nt c o h ort at a n y d os e le vel, irres pecti ve of t he 
t o xicit y , t o f urt her e x pl ore safet y a n d/ or P K. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208352] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 2 / [ADDRESS_208353] u g -relate d are o bser ve d i n a si n gle partici pa nt c o h ort, t he d ose of M 4 3 4 4 will be i ncrease d b y  
u p t o 5 0 % i n a s u bse q ue nt c o h ort of 3 partici pa nt s: 
Na usea 
V o miti n g 
Diarr hea 
Fati g ue 
If n o D L Ts are o bser ve d t hr o u g h 1c y cle i n t his e x pa n de d c o h ort of 3partici pa nt s, t he d ose will 
be i ncrease d b y  u p t o 5 0 % a n d e val uate d i n a ne w c o h ort of 3partici pa nt s, f oll o wi n g a sta n dar d 
3 + 3 desi g n. I n t his ma n ner, t he d ose will be i ncrease d b y  u p t o 5 0 % i n s u bse q ue nt c o h orts of 
3partici pa nt s, u ntil a D L T is o bser ve d (Fi g ure 2).
F or a n y ot her C T C A E Gra de [ADDRESS_208354] 3partici pa nt s 
( 2 a d diti o nal partici pa nt s) bef ore f urt her d ose escalati o n. If t his d ose of M 4 3 4 4 is t olerate d i n t he 
a d diti o nal 2partici pa nt s wit h o ut a D L T, t he d ose of M 4 3 4 4 will be i ncrease d b y  u p t o 5 0 % a n d 
e val uate d i n a ne w c o h ort of 3 partici pa nt s. If n o D L Ts are o bser ve d t hr o u g h 1 c y cle i n t his c o h ort 
of 3partici pa nt s, t he d ose will be i ncrease d b y  u p t o 5 0 % a n d e val uate d i n a ne w c o h ort of 
3partici pa nt s, f oll o wi n g a sta n dar d 3 + 3 desi g n. I n t h is ma n ner, t he d ose will be i ncrease d b y  u p 
t o 5 0 % i n s u bse q ue nt c o h orts of 3 partici pa nt s, u ntil a D L T is o bser ve d (Fi g ure 2).
If a si n gle D L T occ urs d uri n g t he si n gle partici pa nt c o h ort d ose escalati o n, t he n 2a d diti o nal 
partici pa nt s will be e nr olle d a n d e val uate d at t hat sa me d ose le vel of M 4 3 4 4 t o e x pa n d t he c o h ort 
size t o 3partici pa nt s. If n o D L Ts are o bser ve d i n t he 2a d diti o nal partici pa nt s, t he n 3a d diti o nal 
partici pa nt s will be e val uate d at t he sa me d ose le vel of M 4 3 4 4 , f or a t otal c o h ort size of 
6partici pa nt s. If a si n gle D L T occ urs d uri n g t he 3 + 3d ose escalati o n i n a 3- partici pa nt c o h ort, 
t he n 3a d diti o nal partici pa nt s will be e nr olle d a n d e val uate d at t hat sa me d ose le vel of M 4 3 4 4 i n 
or der t o e x pa n d t he c o h ort size t o 6partici pa nt s. If t here are n o f urt her D L Ts i n t he a d diti o nal 
partici pa nt s, t he n u p t o a 5 0 % d ose escalati o n ma y  p r ocee d i n a s u bse q ue nt c o h ort of 3partici pa nt s. 
If t here are ≥2D L Ts i n t he i nitial c o h ort of 3partici pa nt s, d ose escalati o n will cease, a n d t he d ose 
le vel bel o w will be e x pa n de d t o [ADDRESS_208355] ore t he safet y  a n d t olera bi lit y  of t his d ose. Si milarl y , if a c o h ort 
of 3partici pa nt s nee ds t o be e x pa n de d t o 6partici pa nt s d ue t o ≥ [ADDRESS_208356] ore t he safet y  a n d t olera bilit y  of t his i nter me diate d ose (Fi g ure 2). 
T he M T D Si n gle BI W will be t he hi g hest d ose le vel at w hic h t here is n o m ore t ha n 1D L T i n 
6partici pa nt s (Fi g ure 2). If, at t he discre ti o n of t he S p o ns or a n d I n vesti gat or s, t he t o xicit y  a n d 
t olera bilit y  p r ofile of M [ADDRESS_208357] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 3 / [ADDRESS_208358] u die d at t he M T D Si n gle BI W at 
t he discreti o n of t he S p o ns or a n d I n vesti gat or s. If at a gi ve n d ose le vel bef ore M T D, o bser ve d 
e x p os ure e xcee ds tar get e x p os ure of A U C = 7 0 0 n g hr/ m L, t his d ose le vel m a y  b e c o nsi dere d as 
t he R P 2 D a n d Part B 1m a y  be i nitiate d. 
D uri n g si n gle a ge nt M 4 3 4 4 treat me nt, c o m p uterize d t o m o gra p h y ( C T) sca ns will be perf or me d 
e ver y  2 c y cles d uri n g t he i nitial 6c y cles of t he pla n ne d treat me nt peri o d a n d e ver y  3 c y cles 
t hereafter f or t h ose partici pa nt s c o nti n ui n g be y o n d 6 c y cles or as cli nicall y  i n dicate d. Partici pa nt s 
will c o nti n ue o n treat me nt u ntil t here is e vi de nce of disease pr o gressi o n (as deter mi ne d usi n g 
Res p o nse E val uati o n Criteria i n S oli d T u m ors [R E CI S T 1. 1] [Sc her 2 0 0 8 ])or treat me nt is n o 
l o n ger t olerate d. If a partici pa nt disc o nti n ues t he st u d y  p re mat urel y wit h o ut e vi de nce of 
pr o gressi ve disease o n t he m ost rece nt sca n, a f oll o w - u p C T sca n will be perf or me d wit hi n 2 1 d a y s 
after c o m pleti o n of t he fi nal 2 1- da y  c y cle of t hera p y. F or all partici pa nt s wit h pr ostate ca ncer, or 
f or partici pa nt s wit h ot her s oli d t u m ors wit h k n o w n or s us pecte d b o ne metastases, b o ne sca ns will 
be perf or me d as descri be d i n Ta ble 3at t he e n d of e ver y  4 c y cles u ntil disease pr o gressi o n. I n 
a d diti o n, at t he be gi n ni n g of C y cles 1, 3, a n d 5, partici pa nt s wit h o varia n ca ncer will ha ve ser u m 
ca ncer a nti ge n 1 2 5 ( C A - 1 2 5) (R usti n 2 0 0 4 )assesse d a n d partici pa nt s wit h pr ostate ca ncer will 
ha ve ser u m P S A assesse d. If treat me nt is e xte n de d b e y o n d 6c y cles, C A - 1 2 5 or P S A will be 
meas ure d at t he be gi n ni n g of e ver y 3 c y cles or m ore fre q ue ntl y  as cli nicall y i n dicate d. A d diti o nal 
ser ol o gic t u m or mar kers ma y  b e c ollecte d as dee me d a p pr o priate de pe n di n g o n t he partici pa nt 's  
pri mar y  m ali g na nc y  (e . g., ca ncer a nti ge n 1 9- 9 ( C A 1 9 -9) f or partici pa nt s wit h pa ncreatic ca ncer or 
ca ncer e m br y o nic a nti ge n ( C E A) f or partici pa nt s wit h c ol o n ca ncer). Disease res p o nse i n pr ostate 
ca ncer partici pa nt s m a y  b e deter mi ne d usi n g t he Rec o m me n dati o ns of t he Pr ostate Ca ncer Cli nical 
Trials W or ki n g Gr o u p ( P C W G 2) a n d R E CI S T 1. 1 (Sc her 2 0 0 8 ).
I n tra partici pa nt d ose escalati o n :
I ntra partici pa nt d ose escalati o n is n ot per mitte d, e xce pt i n t he case w here t he M [ADDRESS_208359] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 4 / 1 5 9 Fi g ure 2 P art A: D ose Esc al ati o n Sc he m atic f or M 4 3 4 4 as a Si n gle A ge nt 
C T C A E = C o m m o n T er mi n ol o g y Crit eri a f or A d v er s e E v e nt s, D L T = d o s e li miti n g t o xi cit y, M T D Si n gl e BI W= T h e 
m a xi m u m t ol er at e d d o s e of si n gl e a g e nt M [ADDRESS_208360] er e d t wi c e w e e kl y , P K = P h ar m a c o ki n eti c 
Pr o vi si o n al d o s e e s c al ati o n s c h e m e i s f or ill u str ati v e p ur p o s e s. N u m b er of d o s e e s c al ati o n  gr o u p s, n u m b er of 
p arti ci p a nt s p er gr o u p, a n d a m o u nt of d o s e e s c al ati o n s m a y diff er, a s d e s cri b e d i n S e cti o n 5. 1. 1 .
a At t h e di s cr eti o n of t h e S p o n s or a n d I n v e sti g at or s u p t o 2 a d diti o n al p arti ci p a nt s ( 3 p er c o h ort) m a y b e e nr oll e d 
i n t h e si n gl e p arti ci p a nt c o h ort at a n y d o s e l e v el, irr e s p e cti v e of t h e t o xi cit y, t o f urt h er e x pl or e s af et y a n d/ or P K. 
b I n cl u d e s C T C A E Gr a d e [ADDRESS_208361] u g- r el at e d. 
c Li mit e d t o i n cl u d e o nl y Gr a d e 2 t o xi citi e s of n a u s e a, v o miti n g, di arr h e a, a n d/ or f ati g u e t h at ar e p o s si bl y, 
pr o b a bl y, or d efi nit el y d r u g -r el at e d. 
5. 1. [ADDRESS_208362] u d y , t o e val uate t he safet y, t olera bilit y , a n d P K, as well as 
esta blis h t he M T D/ R P 2 D of M 4 3 4 4 w he n a d mi nistere d as a si n gle a ge nt i n partici pa nt s wit h 
a d va nce d s oli d t u m ors i n a de nser sc he d ule t ha n e val uate d i n Part A. Ca n di date partici pa nts wit h 
a d va nce d s oli d t u m ors carr yi n g alterati o ns t hat are s us pecte d t o se nsitize f or treat me nt wit h a n 
A T R i n hi bit or (es peciall y  t h ose defi ne d f or t he Parts C) ma y  be prefere ntiall y  e nr olle d. 
A p pr o xi matel y  3 1 partici pa nt s will be i ncl u de d i n Part A 2. Partici pa nt s i n Part A 2 will i nitiall y be 
a d mi nistere d M 4 3 4 4 as a si n gle a ge nt BI D o n a dail y  r e gi me n a n d u n der fasti n g c o n diti o ns as 
descri be d i n Secti o n 6. 2. 1 . 
T he M 4 3 4 4 starti n g d ose i n Part A 2 will be 1 0 0 m g (si n gle d ose) a d mi nistere d BI D (20 0 m g  d ail y) . 
T he d ose escalati o n of M 4 3 4 4 will f oll o w a 3 + 3 desi g n .D ose escalati o ns will occ ur i n ste ps of 
5 0 m g or 1 0 0 m g  per d ose (Fi g ure 3).S u bse q ue nt d ose le vel swill be deter mi ne d i n a gree me nt 
bet wee n I n vesti gat ors a n d S p o ns or . 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208363] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 5 / [ADDRESS_208364] c y cle i n a d ose c o h ort of 3partici pa nt s, t he d ose will 
be escalate d t o t he ne xt d ose le vel. If a si n gle D L T occ urs d uri n g t he 3 + 3 d ose escalati o n i n a 
3- partici pa nt c o h ort, t he n 3a d diti o nal partici pa nt s will be e nr olle d a n d e val uate d at t hat sa me d ose 
le vel of M 4 3 4 4 i n or de r t o e x pa n d t he c o h ort size t o 6 partici pa nt s. If t here are n o f urt her D L Ts i n 
t he a d diti o nal partici pa nt s, t he n t he d ose escalati o n ma y  p r ocee d i n a s u bse q ue nt c o h ort of 
3partici pa nt s. 
If t here are ≥ [ADDRESS_208365] ore t he safet y a n d t olera bilit y of t his i nter me diate d ose (Fi g ure 3) . 
T he M T D will be t he hi g hest d ose le vel at w hic h t here is n o m ore t ha n 1D L T i n 6partici pa nt s
(Fi g ure 3) .If, at t he discreti o n of t he S p o ns or a n d I n vesti gat ors, t he t o xicit y  a n d t olera bilit y p r ofile 
of M [ADDRESS_208366] ore d at t he 
discreti o n of t he S p o ns or a n d I n vesti gat ors. T he si n gle dail y  s tarti n g d ose m a y  n ot e xcee d t he t otal 
dail y  d ose of t he M T D of t he BI D sc he d ule. T he starti n g d ose of a n y ne w sc he d ule will be 
deter mi ne d base d o n a vaila ble safet y a n d/ or P K data i n a gree me nt bet wee n t he S p o ns or a n d 
In vesti gat or s. D ose escalati o n w o ul d f oll o w t he sa me pri nci p le s as descri be d a b o ve. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208367] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 6 / 1 5 9 Fi g ure 3 P art A 2: D ose Esc al ati o n Sc he m atic f or M 4 3 4 4 wit h De nse M o n ot her a p y 
Sc he d ule 
N ot e: T hi s s c h e m ati c a p pli e s f or a n y d o si n g s c h e d ul e i n P art A 2 
A b br e vi ati o n s: D L = d o s e l e v el; D L T = d o s e -li miti n g t o xi cit y. 
5. 1. [ADDRESS_208368] u d y, t o e val uate t he safet y, t olera bilit y , a n d P K, as 
well as esta blis h t he M T D/ R P [ADDRESS_208369] u g holi da y  s c he d ule . 
Differe nt sc he d ules wit h eit her 3 d a y s Q D or BI D d osi n g f oll o we d b y  4  d a y s of pa usi n g ( 3 d +/ 4 d -), 
5 d a y s of Q D or BI D d osi n g f oll o we d b y  2 d a y s of pa usi n g ( 5 d +/ 2 d -), 7 d a y s of Q D or BI D d osi n g 
f oll o we d b y  7 d a y s of pa usi n g ( 7 d +/ 7 d -) or 1 4 da y s of Q D or BI D d osi n g f oll o we d b y  7 d a y s of 
pa usi n g ( 1 4 d +/ 7 d- ) m a y  b e e x pl ore d un der fasti n g c o n diti o ns as descri be d i n Secti o n  6. 2. 1.  O ne 
c y cle will c o nsist of 4wee ks f or a t otal of 2 8 da ys e xce pt f or t he 1 4 d +/ [ADDRESS_208370] ore d i n Part A 3 m a y  be 3 da y s of BI D d osi n g 
f oll o we d b y  4 d a y s of pa usi n g ( 3 d +/ 4 d -) a n d 7 da y s of Q D d osi n g f oll o we d b y  7 d a y s of pa usi n g 
(7 d +/ 7 d -). Ot her d osi n g h oli da y  s c he d ul es ma y be e x pl ore d if a gree d b y  t he Sp o ns or a n d 
In vesti gat ors . D iffere nt sc he d ules m a y  be o pe n c o nc urre ntl y, a n d c o nc urre nt sc he d ules m a y  e nr oll 
i n a sta g gere d ma n ner, e. g. e nr oll me nt i n 3 d +/ 4 d -d ose le vel (D L ) 1 w o ul d be c o m plete d bef ore 
starti n g e nr oll me nt i n 7 d +/ [ADDRESS_208371] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 7 / [ADDRESS_208372] ore d BI D 
sc he d ule. 
A R P 2 D ( d ose a n d s c he d ule) will be deter mi ne d fr o m Part A [ADDRESS_208373] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 8 / 1 5 9 Part A 3 a n d Parts C ma y e nr oll i n parallel b ut e nr oll me nt i n Part sC will be pri oritize d vers us 
Part A 3 : 
Ca n di date partici pa nts wit h a d va nce d s oli d t u m ors carr yi n g t he q ualif y i n g m utati o ns 
f or Part sC (s ee Secti o n 7. 7. 5 f or f ull details )s h o ul d be c o nsi dere d f or e nr oll me nt i n 
Parts C 1, C 2 or C 3 bef ore bei n g c o nsi dere d f or partici pati o n i n Part A 3 . 
If a partici pa nt is n ot eli gi ble for Part s C, t he partici pa nt ma y  b ec o nsi dere d f or 
partici pati o n i n Part A 3 (see  Fi g ure 5, Sc he matic of Eli gi bilit y  Assess me nts i n Parts C )
pr o vi de d t hat t he i ncl usi o n / e xcl usi o n criteria f or Part A 3 ar e met .
Ca n di date partici pa nts ma y  s olel y be c o nsi dere d f or partici pati o n i n Part A [ADDRESS_208374] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 6 9 / [ADDRESS_208375] u d y  d esi g n 3 + 3 d ose escalati o n t o e val uate t he safet y,  
t olera bilit y , a n d P K, as well as t o esta blis h t he M T D/ R P 2 D of M 4 3 4 4 w he n a d mi nistere d i n 
c o m bi nati o n wit h car b o plati n i n partici pa nt s wit h a d va nce d s oli d t u m ors. 
F o r eac h M 4 3 4 4 d ose le vel teste d, partici pa nt s will recei ve car b o plati n o n D a y 1 a n d M 4 3 4 4 o n 
D a y s2 a n d 9 of a 2 1 -d a y  c ycle. M 4 3 4 4 will be a d mi nistere d u n der fasti n g c o n diti o ns as descri be d 
i n Secti o n 6. 2. 1 .
T he starti n g d ose of M 4 3 4 4 will n ot e xcee d 5 0 % of t he M 4 3 4 4 M T D Si n gle BI W or R P 2 D o btai ne d i n 
Part A. T he starti n g d ose of car b o plati n f or Part B 1 will be A U C 5 m g ∙ mi n/ m L . T he starti n g d oses 
of M 4 3 4 4 a n d car b o plati n will be e val uate d i n a c o h ort of 3 partic i pa nt s. 
Safet y  d ata, i ncl u di n g a d verse e ve nts (A Es ), la b orat or y  v al ues, a n d electr ocar di o gra m (E C G )
res ults, o btai ne d t hr o u g h t he e n d of C y cle 1, as well as a vaila ble P K data (as nee de d), will be 
assesse d t o deter mi ne t he ne xt d ose le vel of M 4 3 4 4 . Eac h d os e le vel will be e val uate d i n a ne w 
c o h ort of partici pa nt s. 
If t he i nitial d ose of M 4 3 4 4 i n c o m bi nati o n wit h car b o plati n at A U C = 5 m g ∙ mi n/ m L  i s t olerate d 
i n a c o h ort of 3 partici pa nt s wit h o ut a si n gle D L T t hr o u g h t he e n d of C y cle 1, t he n i n s u bse q ue nt 
c o h o rts of 3partici pa nt s eac h, t he M 4 3 4 4 d ose m a y  b e escalate d b y  u p t o 5 0 %, u ntil a M 4 3 4 4 
c o m bi nati o n M T D or R P 2 D wit h car b o plati n A U C = 5 m g ∙ mi n/ m L is reac he d (Fi g ure 4). T he 
M T D is defi ne d as t he hi g hest t olerate d d ose at w hic h t here is n o m ore t ha n 1D L T i n 6partici pa nt s 
treate d wit h b ot h M 4 3 4 4 a n d car b o plati n. I n s u bse q ue nt c o h orts, t he car b o plati n d ose m a y  b e 
i ncrease d t o yi el d a tar get A U C of 6 m g ∙ mi n/ m L , w hile eit her kee pi n g t he d ose of M 4 3 4 4 at t he 
M T D/ R P 2 D esta blis he d wit h car b o plati n A U C = 5 m g ∙ mi n/ m L  c o nsta nt, or de- escalati n g t o l o wer 
M 4 3 4 4 d ose le vels, i n or der t o esta blis h t he M T D/ R P 2 D of M 4 3 4 4 wit h car b o plati n 
A U C = 6 m g ∙ mi n/ m L (Fi g ure 4).
If t he i nitial d ose of M 4 3 4 4 wit h car b o plati n A U C =5m g ∙ mi n/ m L is n ot t olerate d, t he n eit her t he 
car b o plati n d ose m a y  b e re d uce d t o yi el d a n A U C of 4m g ∙ mi n/ m L  o r t he M 4 3 4 4 d ose ma y  b e 
re d uce d b y  ≥ 2 5 %. T hese d oses will be e x pl ore d i n s u bse q ue nt c o h orts, at t he discreti o n of t he 
S p o ns or a n d I n vesti gat or s, u ntil t he M T D or R P 2 D of M 4 3 4 4 wit h car b o plati n 
A U C = 4 or 5 m g ∙ mi n/ m L (Fi g ure 4) is o btai ne d. 
O nce t he M T D of t he c o m bi nati o n or t he R P [ADDRESS_208376] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 0 / 1 5 9 partici pa nt sm a y  b e  s t u die d at t hat d ose le vel t o better defi ne t he t o xicit y , t olera bilit y , a n d P K of 
M 4 3 4 4 a n d car b o plati n. 
At all d ose le vels of M 4 3 4 4 , partici pa nts will c o nti n ue treat me nt u ntil t here is e vi de nce of disease 
pr o gressi o n (as deter mi ne d usi n g R E CI S T 1. 1) or treat me nt is n o l o n ger t olerate d. I m a gi n g sca ns 
(e. g., C T a n d ma g netic res o na nce i ma gi n g [M RI ]) will be per f or me d e ver y  [ADDRESS_208377] 
6c y cles of treat me nt a n d e ver y  3 c y cles t hereafter f or t h ose partici pa nt s c o nti n ui n g be y o n d 
6c y cles, or as cli nicall y i n dicate d. F or eac h partici pa nt , t he sa me i ma gi n g tec h ni q ue s h o ul d be 
use d t o f oll o w t he disease (if p ossi ble). B o ne sca n will be perf or me d as descri be d i n Ta ble 6at t he 
e n d of C y cle 4 a n d e ver y 4 t o 6 c ycles t hereafter f or partici pa nt s c o nti n ui n g be y o n d 6 c y cles or as 
cli nicall y  i n dicate d. If t here is e vi de nce of pr o gressi ve disease as deter mi ne d usi n g R E CI S T 1. 1, 
t he partici pa nt ’s treat me nt will be disc o nti n ue d. I n a d diti o n, at t he be gi n ni n g of C y cles 1, 3, a n d 
5, partici pa nt s wit h o v aria n ca ncer will ha ve ser u m C A -1 2 5 assesse d, a n d partici pa nt s wit h 
pr ostate ca ncer will ha ve ser u m P S A assesse d. If treat me nt is e xte n de d be y o n d 6 c y cles, C A -1 2 5 
or P S A will be meas ure d at t he be gi n ni n g of e ver y  3 c y cles or m ore fre q ue ntl y as cli nicall y 
in dicate d. A d diti o nal ser ol o gic t u m or mar kers ma y be c ollecte d as dee me d a p pr o priate de pe n di n g 
o n t he partici pa nt 's pri mar y  m ali g na nc y  ( e. g., C A 1 9 - 9 f or partici pa nt s wit h pa ncreatic ca ncer or 
C E A f or partici pa nt s wit h c ol o n ca ncer). Disease res p o nse i n pr os tate ca ncer partici pa nt s m a y  b e 
deter mi ne d usi n g t he Rec o m me n dati o ns of t he P C W G 2 a n d R E CI S T 1. 1 (Sc her 2 0 0 8 ).
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208378] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 1 / [ADDRESS_208379] ati n 
( P art B 1) 
BI W  = T wi c e W e e kl y, M T D = M a xi m u m t ol er at e d d o s e, M T D Si n gl e BI W =M a xi m u m t ol er at e d d o s e of M [ADDRESS_208380] er e d BI W  fr o m P art A, M T D c ar b o =M a xi m u m t ol er at e d d o s e of M [ADDRESS_208381] u d y  P art A, A 2 or A3. 
Parts C 1, C 2, a n d C 3 ma y be i nitiate d i n parallel or i n a sta g gere d ma n ner usi n g a d ose a n d sc he d ule 
deter mi ne d t o be a R P 2 D i n eit her Part A or Part A 2 at t he discreti o n of t he S p o ns or a n d 
I n vesti gat ors. A d diti o nal Parts C 4, C 5, a n d/ or C [ADDRESS_208382] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 2 / 1 5 9 Part sC 1 a n d C 4 will e nr oll partici pa nt s w h ose t u m or carr y a l oss - of- f u ncti o n m utati o n i n t he ge ne 
f or A RI D 1 A .
Part sC 2 a n d C 5 will e nr oll partici pa nt s w h ose t u m or carr y  a  l oss -of -f u ncti o n m utati o n i n t he ge nes 
f or A T R X a n d/ or D A X X (lea di n g t o a n alter nati ve le n gt he ni n g of tel o meres- p ositi ve p he n ot y p e ). 
Part sC 3 a n d C 6 will e nr oll partici pa nt s w h ose t u m or carr y a l oss - of- f u ncti o n m utati o n i n t he ge ne 
f or A T M .
Fi g ure 5pr o vi des a sc he matic of eli gi bilit y  assess me nts i n Parts C. 
Fi g ure 5 Sc he m atic of Eli gi bilit y Assess me nts i n P arts C 
a L o s s -of -f u n cti o n m ut ati o n( s) i n A RI D [ADDRESS_208383] 
c o nfir m t h e   eli gi bilit y ( pr e s e n c e of m ut ati o n s) pri or t o p erf or mi n g a n y of t h e a d diti o n al Scr e e ni n g 
a s s e s s m e nt s (l o w er p art of t h e fi g ur e). If i nf or m ati o n o n bi o m ar k er m ut ati o n s i s a v ail a bl e at ti m e of I nf or m e d C o n s e nt, 
t h e p ati e nt i s all o w e d t o p erf or m t h e bi o p s y a n al y si s a n d t h e r e m ai n d er of Scr e e ni n g pr o c e d ur e s i n p ar all el ( u p p er 
p art of t h e fi g ur e). 
c A bi o p s y o bt ai n e d aft er t h e e n d of t h e pr e vi o u s tr e at m e nt r e gi m e n i s al s o a c c e pt a bl e. If c oll e cti o n of a fr e s h 
t u m or bi o p s y i s n ot p o s si bl e f or m e di c al r e a s o n( s) a n d a bi o p s y o bt ai n e d aft er t h e e n d of t h e pr e vi o u s tr e at m e nt 
r e gi m e n i s n ot a v ail a bl e, a v ail a bl e ar c hi v al t u m or m at eri al m a y b e u s e d ( hi st ori c al d at a s h o ul d n o t b e u s e d t o c o nfir m 
bi o m ar k er st at u s). 
d  O nl y aft er c o nfir m ati o n fr o m t h e c e ntr al l a b of t h e pr e s e n c e of t u m or m ut ati o n s ( a n d all ot h er 
i n cl u si o n / e x cl u si o n crit eri a ar e m et) c a n p arti ci p a nt s st art t h e tr e at m e nt p eri o d. 
e If a n al y si s of bi o p s y d o e s n ot r e v e al a q u alif yi n g m ut ati o n , b ut all ot h er I n cl u si o n / E x cl u si o n crit eri a ar e m et, 
t h e n t h e ca n di d at e p arti ci p a nt m a y b e c o n si d er e d f or p arti ci p ati o n i n P art A 3. 
Partici pa nts ma y be selecte d f or Scree ni n g base d o n l ocall y  a vaila ble data s h o wi n g prese nce of 
≥ 1 selecti o n bi o mar kers ( e. g. fr o m arc hi val t u m or material ). P artici pa nts wit h k n o w n p ositi ve 
bi o mar ker stat us at t he ti me of c o nse nt , acc or di n g t o l ocall y  a vaila ble data, ca n u n der g o t he 
Scree ni n g Bi o ps y a nal y sis a n d t he rest of Scree ni n g assess me nts c o nc urre ntl y(Ta ble 2) .
Partici pa nts wit h u n k n o w n bi o mar ker stat us at t he ti me of c o nse nt ca n o nl y u n der g o t he Scree ni n g 
assess me nts o nce t he prese nce of ≥ 1 selecti o n bi o mar kers (defi ne d i n Secti o n 7. 7. 5 ) is c o nfir me d. 
T he bi o ps y  a nal y sis will c o nsist of a n assess me nt of t he prese nce of s uc h m utati o ns b y  a ce ntral 
trial assa y  or b y a n assa y wit h a p pr o priate re g u lat or y  stat us .T his assess me nt s h o ul d be c o n d ucte d 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208384] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 3 / 1 5 9 o n a fres h t u m or bi o ps y ( or a bi o ps y t hat was o btai ne d after t he e n d of t he pre vi o us treat me nt 
re gi me n). If t his is n ot p ossi ble f or me dical reas o n(s), a vaila ble arc hi val t u m or material ma y  b e 
use d f or t hi s assess me nt ( hist orical data s h o ul d n ot be use d t o c o nfir m bi o mar ker stat us). 
Partici pa nts will c o nse nt t o S cree ni n g pr oce d ures pri or t o a n y Scree ni n g acti vities .
Treat me nt will c o nti n ue u ntil disease pr o gressi o n, u nacce pta ble t o xicit y , partici pa nt’s wit h dra wal 
or a n y  o t her reas o n t o e n d st u d y  t reat me nt. After disease pr o gressi o n, partici pa nt s will be 
f oll o we d -u p f or s ur vi val u ntil t he En d of St u d y . T u m or assess me nt acc or di n g t o R E CI S T 1. [ADDRESS_208385] 6 c ycles, t he n e ver y 9 wee ks 
t hereafter u ntil disease pr o gressi o n or start of ne w a nti -ca ncer treat me nt li ne. 
Eac h of t he selecte d  p o p ulati o ns (a n y Part C) will f oll o w a si n gle ar m 3- sta ge desi g n. 
T he i nitial sta ge will c o nsist of 9 partici pa nts i n eac h part. If 1 or m ore res p o nses ( partial res p o nse 
[P R ]or c o m plete res p o nse [ C R ], as per R E C IS T 1. 1) are o bser ve d i n a part, t his part will pr ocee d 
t o t he Sta ge 2, a d di n g 1 1 partici pa nts t o a t otal of n= [ADDRESS_208386] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 4 / [ADDRESS_208387] b y  d a ma gi n g D N A; h o we ver, resista nce 
t o t hese a ge nts is c o m m o n. T his resista nce ca n be attri b ute d t o effecti ve D N A da ma ge re pair 
pr ocesses t hat i ncl u de t he pat h wa y me diate d b y A T R. I n n o ncli nical e x peri me nts, A T R i n hi biti o n 
b y  M 4 3 4 4 has bee n s h o w n t o mar ke dl y e n ha nce t he a ntica ncer effects of D N A -da ma gi n g a ge nts 
s uc h as car b o plati n i n a ra n ge of h u ma n ca ncer cell li nes a n d pa rtici pa nt -deri ve d e x pla nts. I n  
a d diti o n, M 4 3 4 4 e x hi bits m o n ot hera p y efficac y  i n a  m o use xe n o graft m o del of c ol orectal ca ncer 
c haracterize d b y  d efecti ve A T M si g nali n g (Verte x Re p ort K 2 3 5 2 0 1 4 )a n d m o dels c haracterize d 
as utilizi n g a n alter nati ve le n gt he ni n g of tel o meres mec ha nis m (Fl y n n 2 0 1 5 ).
Parts A, A 2, a n d B [ADDRESS_208388] u d y  3 + 3 desi g ns t o 
esta blis h R P 2 Ds of eit he r si n gle a ge nt M 4 3 4 4 treat me nt or of t he c o m bi nati o n of M 4 3 4 4 wit h 
car b o plati n . Part A 3 use sa B OI N desi g n f or d ose escalati o n. I n vie w of t he n o ncli nical t o xicities 
o bser ve d, safet y assess me nts will be carrie d o ut at eac h i n vesti gati o nal ce nter. T he decis i o n t o 
decrease t he ma g nit u de of d ose escalati o n of M 4 3 4 4 bet wee n c o h orts t o less t ha n 1 0 0 % will be 
base d o n re vie w of dr u g -relate d or p ossi bl y  d r u g -relate d D L Ts a n d n o n- D L T A Es of Gra de 2 or 
hi g her, ot her safet y tre n ds, a n d/ or res ults fr o m P K data as s pec ifie d i n Secti o n 5. 1. Parts C ai m at 
esta blis hi n g safet y a n d de m o nstrati n g a ntit u m or acti vit y of si n gle a ge nt M [ADDRESS_208389] u d y  i n d o gs (M PI  [INVESTIGATOR_177587] h Re p ort f or 8 6 3 -1 6 6 2 0 1 4 ). T he M R S D of 1 0 m g is 1/ 6 t h t he 
h u ma n e q ui vale nt d ose ( H E D) of t he H N S T D deter mi ne d i n d o gs, w hic h was t he m ost se nsiti ve 
s pecies. 
After a n i nitial partici pa nt recei ves M 4 3 4 4 at t he M R S D, d ose escalati o n wil l c o nti n ue i n 
s uccessi ve c o h orts wit h a 1 0 0 % i ncrease (i.e. d o u bli n g of d ose), u nless a tre n d i n n o n- D L T Gra de 2 
or hi g her C T C A E gra de t o xicit y  is o bser ve d. At t hat p oi nt, de pe n di n g o n re vie w of all safet y a n d 
a vaila ble P K data, d ose escalati o n will be c o n d ucte d as descri be d i n Secti o n 5. 2. 1 0 u ntil t he M 4 3 4 4 
M T D is i de ntifie d. D oses ma y  i ncrease b y  l ess t ha n 1 0 0 % or less t ha n 5 0 % at a n y p oi nt, if 
i n dicate d base d o n re vie w of safet y a n d P K data. I n  a d diti o n, f oll o wi n g re p orts of a D L T, a n 
i nter me diate l o wer d ose ma y  be e val uate d i n a ne w c o h ort of partici pa nt s. 
T he M R S D of 1 0 m g  i s a p pr o xi matel y  1 / 9 t h t he pre dicte d o pti mall y efficaci o us d ose base d o n 
m o use xe n o graft m o dels of 9 0 m g (Verte x Re p ort K 0 8 4 2 0 1 4). Wit h si n gle -partici pa nt c o h orts 
a n d 1 0 0 % d ose escalati o n bet wee n c o h orts, a p pr o xi matel y  [ADDRESS_208390] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 5 / [ADDRESS_208391] u d y M S 2 0 1 9 2 2 - 0 0 0 1 (f or merl y  V X 1 4 - 8 0 3- 0 0 1), t he ma xi m u m a d mi nistere d 
d ose was 1 2 0 0 m g, t wice wee kl y. At t his d ose, t he o bser ve d plas ma e x p os ure, a vera ge 
c o nce ntrati o n (Ca v g ), was bel o w t he tar get efficaci o us e x p os ure deter mi ne d i n precli nical m o dels 
testi n g M [ADDRESS_208392] u d y  M S 2 0 1 9 2 2 -0 0 0 1 is desi g ne d t o e val uate w het her s ufficie nt C a v g ca n b e ac hie ve d 
a n d is t olerate d t o s u p p ort M 4 3 4 4 use as m o n ot hera p y. T he BI D dail y re gi me n t hat will be 
e val uate d i n Part A 2 is base d o n (i) precli nical xe n o graft st u dies, a n d (ii) cli nical P K data o btai ne d 
fr o m Part A, descri be d bel o w. If t he BI D re gi me n is c o nsi dere d u nfa v ora ble, a ne w sc he d ule wit h 
o nce dail yd osi n g ma y  be e x pl ore d at t he discreti o n of t he S p o ns or a n d I n vesti gat ors. 
F urt her m ore, i n Part A 3, dr u g h oli da y sc he d ule (s) ma y  be e x pl ore d (see S ecti o n 5. 1. 3 f or details) . 
Ge nerall y , A T R si g nali n g is re q uire d t o e na ble ca ncer cells t o pr o gress t hr o u g h t o S/ G 2 -p hase, a n d 
i n hi biti o n of A T R let hall y  c o m pr o mises t his pr ocess. Re peate d or pr ol o n ge d A T R i n hi biti o n is 
e x pecte d t o res ult i n i ncrease d a ntit u m or effica c y  ( M 6 6 2 0 I n vesti gat or Br oc h ure ). F or M [ADDRESS_208393] u dies of M 4 3 4 4 i n A L T + m o dels de m o nstrate t hat 
i ncrease d fre q ue nc y  o f d osi n g is ass ociate d wit h, a n d p ossi bl y  r e q uire d f or o pti mal a ntit u m or 
acti vit y  i n t he m o n ot hera p y setti n g (Verte x Re p ort E 0 4 5 3 -U 1 6 0 7 2 0 1 6 )w hile mai ntai ni n g 
t olera bilit y  b ase d o n b o d y  w ei g ht a n d m ortalit y. T hese data s u g gest t hat pr ol o n ge d or re peate d 
in hi biti o n of A T R n ot o nl y  p ote ntiates t he c y t ot o xic effects of D N A da ma ge, b ut it m a y  a ls o be 
efficaci o us as m o n ot hera p y  i n ca ncers w hic h are relia nt o n A T R si g nali n g (Fl y n n 2 0 1 5 ).Of n ote , 
si milar a ntit u m or acti vit y was o bser ve d f or t he sa me t otal wee kl yd ose w he n a d mi nistere d o nce 
dail y  o r t wice dail y i n t h e prec li nical st u d y (Verte x Re p ort E 0 4 5 3 -U 1 6 0 7 2 0 1 6). Dail y  d osi n g of 
M 4 3 4 4 m o n ot hera p y of 2 0 m g/ k g per da y ( 1 0 m g/ k g BI D a n d 2 0 m g/ k g o nce dail y ) de m o nstrate d 
i ncrease d a ntit u m or acti vit y  c o m pare d t o e ver y  o t her or e ver y  3 r d d a y  d osi n g i n t he S K N F 1 
( ne ur o blast o ma utilizi n g t he alter nati ve le n gt he ni n g of tel o meres pat h wa y ) xe n o graft m o del. 
Si milar res ults were als o o btai ne d i n t he G 2 9 2 ( A L T p ositi ve) oste osarc o ma m o del. T hese 
precli nical data s u g gest t hat s ustai ne d A T R i n hi biti o n i n t he m o n ot hera p y setti n g a n d hi g h 
a ntit u m or acti vit y  m a y  b e  a c hie ve d wit h m ore fre q ue nt BI D d osi n g c o m pare d wit h t wice wee kl y 
d osi n g. 
T u m or gr o wt h i n hi biti o n m o deli n g of t he S K N F 1 a n d G 2 9 2 xe n o graft data was perf or me d a n d 
i de ntifie d t he plas ma c o nce ntrati o n ( C a v g ) t hat m ust be mai ntai ne d t o ac hie ve t u m or stasis. T his 
val ue was use d as a tar get t o ac hie ve i n h u ma n. 
I n li g ht of t he relati vel y s h ort half -life of M 4 3 4 4 ( 1 - 4 h, esti mate d i n Part A V X - 8 0 3 ( M 4 3 4 4) 
I n vesti gat or’s Br oc h ure), m ore fre q ue nt di vi de d d osi n g is e x pecte d t o s u stai n A T R i n hi biti o n 
t hr o u g h o ut t he d ose i nter val wit h re d uce d fl uct uati o n, a n d a l o wer ma xi m u m c o nce ntrati o n ( C ma x ) 
re q uire d t o ac hie ve a n i ncrease d plas ma Ca v g . F urt her m ore, t he ass ociate d re d ucti o n i n Cma x ma y  
i m pr o ve safet y a n d t olera bilit y . Fi nall y , m ore fre q ue nt, s maller d oses w o ul d als o pr o vi de m ore 
ma na gea ble d oses per a d mi nistrati o n (i.e. re d uce pi[INVESTIGATOR_4382] b ur de n) t o t he partici pa nt .
Theref ore, BI D dail y  d osi n g was selecte d as t he i nitial sc he d ule f or Part A 2. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208394] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 6 / 1 5 9 A 1 0 0 -m g si n gle d ose a d mi nistere d BI D ( 2 0 0 m g dail y ) was selecte d as star ti n g d ose f or Part A 2. 
T his starti n g d ose is base d o n t he a vaila ble cli nical e x perie nce i n 3 6 partici pa nt s treate d wit h u p 
t o t he 1 2 0 0 m g t wice wee kl y d osi n g sc he d ule i n Part A. As of Dec e m ber 2 0 1 7, i n t otal 
7partici pa nts ha ve c o m plete d t he D L T peri o d at t he 1 2 0 0 m g  d ose le vel . O ne D L T of Gra de 3
fe ver was o bser ve d a n d t he criteria f or M T D were n ot yet f ulfill e d . T he 1 2 0 0 m g t wice wee kl y 
sc he d ule res ults i n a t otal wee kl y d ose of 2 4 0 0 m g . A 1 0 0- m g d ose a d mi nistere d t wice d a il y  r es ults 
i n a t otal wee kl y d ose of 1 4 0 0 m g a n d is t heref ore e x pecte d t o be a t olera ble starti n g d ose . 
W he n M 4 3 4 4 is a d mi nistere d t wice dail y, t he sec o n d dail y  d ose is h y p ot hesize d t o be o pti mall y  
a d mi nistere d at 1 2- h o ur i nter vals t o pr o vi de s ustai ne d A T R i n hi biti o n . H o we ver , a4- h o ur wi n d o w 
( 8 t o 1 6 h o urs) is per mitte d f or partici pa nt c o n ve nie nce. Si nce t he ter mi nal half -life of M [ADDRESS_208395] a 6 0 % t u m or gr o wt h i n hi biti o n. Wit h c o nti n u o us d osi n g a h u ma n 
efficaci o us d ose of a p pr o xi matel y  [ADDRESS_208396] u g h oli da y  s c he d ule (s) m a y o nl y be 
preferre d if t he y e na ble escalati o n t o hi g her d ose s per a d mi nistrati o n a n d, i deall y, are a ble t o meet 
or e xcee d t he t otal wee kl y d ose .T heref ore, Part A [ADDRESS_208397] t hat dela yi n g d osi n g of M 4 3 4 4 f or a p pr o xi matel y  2 4h o urs 
af ter t he d osi n g of D N A -da ma gi n g a ge nts will pr o m ote cell deat h i n t u m or cells (M 6 6 2 0 I B ). 
F urt her m ore, cell st u dies, a ni mal st u dies, a n d P K data s u p p ort i nfre q ue nt d osi n g of M 4 3 4 4 t o 
pr o vi de o pti mal efficac y , t olera bilit y , a n d e x p os ure i n c o m bi nati o n wit h che m ot hera p y . T he 
sta n dar d d ose of car b o plati n use d f or treat me nt of o varia n ca ncer per Nati o nal C o m pre he nsi ve 
Ca ncer Net w or k (N C C N )g ui deli nes (N C C N G ui deli nes 2 0 1 3 )is a p pr o xi matel y 
A U C = 5 m g ∙ mi n/ m L. Car b o plati n d osi n g at A U C = 4 m g ∙ mi n/ m L , or at A U C = 6 m g ∙ mi n/ m L, is 
use d i n certai n cli nical sit uati o ns or f or certai n i n dicati o ns. T he [ADDRESS_208398] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 7 / 1 5 9 a d va nce d s oli d t u m ors f or w hic h n o sta n dar d t hera p y  i s a vaila ble w hic h m a y  c o n ve y  c li nical 
be nefit, a n d/ or partici pa nt s m ust ha ve disease pr o gressi o n after at least 1pri or c he m ot hera p y 
re gi me n i n t he metastatic setti n g, a n d f or w hic h car b o plati n ( Part B 1), w o ul d be c o nsi dere d 
sta n dar d of care. I n ge neral, res p o nse rates of ma n y a d va nce d s oli d t u m ors t o se c o n d -a n d t hir d -li ne 
t hera pi[INVESTIGATOR_177588] d. T h us, t here is a p ote ntial f or t his p o p ulati o n t o be nefit fr o m t he a d diti o n of a 
c he m ot hera p y s e nsitizi n g a ge nt. 
Partici pa nt s e nr olle d i n Part sC will ha ve a d va nce d s oli d t u m ors f or w hic h n o rec o m me n de d 
sta n dar d t hera p y is a vaila ble , i.e. partici pa nts w h o ha ve e x ha uste d all sta n dar d of care o pti o ns 
acc or di n g t o N C C N G ui da nce a n d f or w h o m M 4 3 4 4 ma y  c o n ve y  c li nical be nefit. F urt her m ore, 
t he y  will be selecte d base d o n t he f oll o wi n g bi o mar kers: 
Part sC 1 or C 4 :will e nr oll partici pa nt s w h ose t u m or scarr y a l oss - of- f u ncti o n m utati o n i n 
t he ge ne A RI D 1 A 
Part sC 2 or C 5 :will e nr oll partici pa nt s w h ose t u m or carr y a l oss - of- f u ncti o n m utati o n i n 
A T R X a n d/ or D A X X 
Part sC 3 or C 6 :will e nr oll partici pa nt s w h ose t u m or car r y  a l oss- of- f u ncti o n m utati o n i n 
t he ge ne A T M .
T he se bi o mar kers f or pa rtici pa nts selecti o n will be assesse d b y  a ce ntral trial assa y or b y a n assa y 
wit h a p pr o priate re g ulat or y  stat us (see Secti o n 5. 1. 4 ).
5. 2. [ADDRESS_208399] u dies i n rat a n d d o g, t he 
f oll o wi n g tar get or ga ns f or M 4 3 4 4 t o xicit y  ha ve bee n i de ntifie d: he mat o p oietic s y ste m ( decrease 
i n R B C a n d or W B C); s plee n (e xtra me d ullar y  h e mat o p oiesis); li ver (e x tra me d ullar y 
he mat o p oiesis); t h y m us (l y m p h oi d de pleti o n); a n d testes (s per mat oc y te/s per mati d de gra dati o n a n d 
sec o n dar y  e ffect o n e pi [INVESTIGATOR_121732] d y mi des; ger m cell de bris) (I T R La b orat ories Re p ort f or 7 2 1 7 1 2 0 1 3 , 
M PI  [INVESTIGATOR_177587] h Re p ort f or 8 6 3 -1 6 5 2 0 1 4 , I T R L a b orat ories Re p ort f or 6 1 3 8 8 2 0 1 3 ,M PI  [INVESTIGATOR_177587] h 
Re p ort f or 8 6 3- 1 6 6 2 0 1 4) . A d diti o nall y , i n d o gs, GI  w as als o n ote d as a tar get (i nfla m mati o n of 
la mi na pr o pria a n d g ut ass ociate d l y m p h oi d tiss ue) (M PI  [INVESTIGATOR_177587] h Re p ort f or 8 6 3 -1 6 6 2 0 1 4 ). 
Base d o n t hese fi n di n gs, partici pa nt s will be m o nit ore d wee kl y d uri n g C y cle 1, a n d at least t wice 
per c y cle t hereafter f or a d verse effects t o t he b o ne marr o w or li ver. Male partici pa nt s i n Parts A 
a n d B [ADDRESS_208400] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 8 / [ADDRESS_208401] t o c o nti n ue, will disc o nti n ue 
treat me nt. 
5. 2. 5 I ncl usi o n of S peci al P o p ul ati o ns 
F or defi niti o n of partici pa nts f or Parts C, please se e Secti o n  5. 2. 3. 
5. 2. 6 Defi niti o n of D ose Li miti n g T o xicit y 
Partici pa nt s will be m o nit ore d f or D L Ts t hr o u g h o ut d osi n g c ycles. D L Ts will be defi ne d usi n g t he 
Nati o nal Ca ncer I nstit ute ( N CI) C T C A E ( Part A a n d B 1: Versi o n 4. 0 ; Part sA 2 , A 3 : Versi o n 5 . 0 ). 
A D L T is defi ne d as relate d or p ossi bl y  dr u g -relate d: 
Ne utr o pe nia Gra de 4 f or > 7d a y s d urati o n or re q uiri n g he m o p oietic gr o wt h fact ors 
oIn t he e ve nt of Gra de [ADDRESS_208402] be perf or me d n o m ore 
t ha n 7da y s after t he o nset of t he e ve nt t o deter mi ne if a D L T has occ urre d. T he 
partici pa nt will be cl osel y  m o nit ore d u ntil res ol uti o n t o Gra de 3 or less .
Fe brile ne utr o pe nia ( fe ver of u n k n o w n ori gi n wit h o ut cli nicall y  o r micr o bi ol o gicall y 
d oc u me nte d i nfe cti o n i n t he setti n g of Gra des 3 or 4 ne utr o pe nia) 
I n fecti o n ( d oc u me nte d cli nicall y  o r micr o bi ol o gicall y ) wit h Gra des 3 or 4 ne utr o pe nia 
(a bs ol ute ne utr o p hil c o u nt < 1. 0 x 1 0 9/ L) 
T hr o m b oc y t o pe nia Gra de 3: 
oass ociate d wit h cli nicall y si g nifica nt blee di n g 
ore q uiri n g platelet tra nsf usi o n or he m o p oietic gr o wt h fact ors 
T hr o m b oc y t o pe nia Gra de 4 f or > [ADDRESS_208403] be perf or me d n o 
m ore t ha n 7 d a y s after t he o n set of t he e ve nt t o deter mi ne if a D L T has occ urre d. 
T he partici pa nt will be cl osel y  m o nit ore d u ntil res ol uti o n t o Gra de 3 or less .
Gra des 3 or 4 t o xicit y  t o or ga ns ot her t ha n t he b o ne marr o w i ncl u di n g Gra des 3 a n d 4 
bi oc he mical A Es a n d D L Ts, e xcl u di n g t he f oll o wi n g: 
oGra de 3 na usea or v o miti n g i n partici pa nt s w h o ha ve n ot recei ve d o pti mal treat me nt 
wit h a nti- e metics 
oGra de 3 diarr hea i n partici pa nt s w h o ha ve n ot recei ve d o pti mal treat me nt wit h 
a nti -diarr heal 
oGra de 3 fati g ue 
oA n y  G ra de 3 ele vati o n of as partate a mi n otra nsferase ( A S T ) “ a n d ” “ or ”ala ni ne 
a mi n otra nsferase (A L T )lasti n g ≤ 7 d a y s(i n t he e ve nt of a Gra de 3 or hi g her 
ele vati o n i n A L T or A S T, f oll o w - u p la b orat or y  a ssess me nts s h o ul d be perf or me d 
e ver y  4 8 t o 7 2 h o urs u ntil re d uce d t o Gra de 2 or less ). 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208404] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 7 9 / 1 5 9 A n y  G ra de 3 or 4 i ncrease i n bilir u bi n u nless t he i ncrease is assesse d as arisi n g fr o m 
i n hi biti o n of bilir u bi n gl uc ur o ni dati o n. If t he i ncrease i n bilir u bi n is assesse d as arisi n g 
fr o m i n hi biti o n of bilir u bi n gl uc ur o ni dati o n, t he n o nl y  bilir u bi n le vels a b o ve 1 5 m g/ d L 
( 2 5 7 µ m ol/ L) will be c o nsi dere d D L Ts 
Deat h d ue t o dr u g -relate d c o m plicati o ns 
Car diac: 
oQ Tc pr ol o n gati o n ( a n y  Q Tc i nter val ≥ 5 0 0 msec or a n y c ha n ge i n Q Tc i nter val 
≥ 6 0 msec fr o m baseli ne) o n E C G, u nless relate d t o a n electr ol yt e a b n or malit y  a n d 
pr ol o n gati o n res ol ves wit h c orrecti o n of electr ol yt e a b n or malit y
oA n y  o f t he f oll o wi n g ( C T C A E criteria): Gra de 2 or greater ve ntric ular arr h yt h mia 
(sec o n d or t hir d de gree atri o ve ntric ular bl oc k), se vere s ustai ne d/s y m pt o matic si n us 
bra d ycar dia less t ha n 4 5 b p m or si n us tac h yc ar dia >1 2 0 b p m n ot d ue t o ot her 
ca uses ( e. g., fe ver), persiste nt s u pra ve ntric ular arr h y t h mia (e. g. ,u nc o ntr olle d/ ne w 
atrial fi brillati o n, fl utter, atri o ve ntric ular n o dal tac h y car dia, etc.) lasti n g m ore t ha n 
2 4 h o urs, ve ntric ular tac h y car dia defi ne d as > 9 beats i n a r o w or a n y  l e n gt h of 
t orsa des de p oi ntes ( p ol y m or p hic ve ntric ular tac h y car dia wit h l o n g Q Tc), or 
u ne x plai ne d rec urre nt s y nc o pe 
oS y m pt o ms s u g gesti ve of c o n gesti ve heart fail ure wit h c o nfir me d ejecti o n fracti o n 
<4 0 % ( b y  2 D -ec h oc ar di o gra m or M ulti ple Gate d Ac q uisiti o n [ M U G A] sca n) or a 
relati ve decrease > 2 0 % fr o m hist orical assess me nt of ejecti o n fracti o n perf or me d 
wit hi n 1 2 m o nt hs 
oTr o p o ni n -T: le vel w hic h is c o nsiste nt wit h m y ocar dial i nfarcti o n 
A n y  d r u g -relate d t o xicit y  t hat ca u ses i nterr u pti o n of treat me nt f or > 2 wee ks 
( 1 4 s uccessi ve d a y s). If a partici pa nt is dee me d fit t o restart treat me nt o n D a y [ADDRESS_208405] meet 1 of t he 2 criteria bel o w t o be c o nsi dere d e val ua ble f or d ose escalati o n 
decisi o ns: 
1. Partici pa nt m ust ha ve recei ve d t he f oll o wi n g mi ni m u m re q uire d d oses of st u d y  d r u g(s) i n 
C y cle 1(i .e. t he D L T peri o d) .See Secti o n 6. 2. [ADDRESS_208406] u g a d mi nistrati o n: 
Part A: at least 8 0 % ( 5 o ut of 6) of sc he d ule d M [ADDRESS_208407] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 0 / 1 5 9 Part A 2: at least 8 0 % of sc he d ule d M 4 3 4 4 d oses. O ne c y cle is defi ne d as 2 1 cale n dar 
da y s of dail y d osi n g. 
Part A 3: at least 8 0 % of sc he d ule d M 4 3 4 4 d oses. Refer t o secti o n 5. 1. 3 f or defi niti o n 
of c y cle le n gt h. 
Part B 1: car b o plati n d ose o n Da y 1 a n d M 4 3 4 4 d ose o n Da y  2. If t he a d diti o nal d osi n g 
da y  ( Da y 5) is e x pl ore d, M 4 3 4 4 d os e o n Da y 5 will be re q uire d i n a d diti o n t o t he ot her 
d oses .
Part sA/ A 2/ A 3 / B 1: C o m plia nce wit h pr o hi bite d me dici ne a n d dietar y restricti o ns 
d uri n g C ycle 1. 
Or 
2. T he partici pa nt m ust ha ve ha d a D L T bef ore t he e n d of C y cle 1. 
Partici pa nt s w h o d o n ot meet 1of t he 2criteria a b o ve will n ot be e val ua ble f or d ose escalati o n 
decisi o ns a n d will be re place d. Als o, if a n a d diti o nal partici pa nt is e nr olle d d uri n g d ose -escalati o n 
i n Part s A 2 / A 3, a n d B1i n or der t o o btai n a ti me d -t u m or bi o ps y , t he safet y or P K data fr o m t his 
a d diti o nal partici pa nt m a y  n ot be re q uire d f or ma ki n g d ose -escalati o n decisi o ns. If t he d ose 
escalati o n decisi o n ha d bee n ma de; t his a d diti o nal partici pa nt will be c o nsi dere d n o n- e val ua ble f or 
d ose escalati o n decisi o n -ma ki n g. 
5. 2. 7. [ADDRESS_208408] 1c y cle of treat me nt, ha ve a baseli ne 
assess me nt d uri n g Scree ni n g, will be e val ua ble f or res p o nse a n d f or disease pr o gressi o n or 
s ur vi val .
5. 2. 8 Scree ni n g 
Scree ni n g Visit assess me nts are liste d i n Ta ble 1f or Parts A, A 2, A 3 , a n d B 1. Scree ni n g Visit 
assess me nts are liste d i n  Ta ble 2f or Parts C. 
Partici pa nts will c o nse nt t o Scree ni n g pr oce d ures pri or t o a n y Scree ni n g acti vities. 
I n Parts C, partici pa nts will u n der g o a Scree ni n g Bi o ps y  (Ta ble 2) t o c o nfir m/assess t he selecti o n 
bi o mar kers (l oss - of- f u ncti o n m utati o ns i n t he ge nes A RI D 1 A f or Part sC 1 a n d C 4 , i n A T R X 
a n d/ or D A X X i n Part sC 2 a n d C 5 , a n d A T M i n Part sC 3 a n d C 6 ): 
Partici pa nts wit h k n o w n p ositi ve bi o mar ker stat us at t he ti me of c o nse nt , acc or di n g t o 
l ocall y  a vaila ble data, ca n u n der g o t he Scree ni n g Bi o ps y a nal y sis a n d t he rest of 
Scree ni n g assess me nts c o nc urre ntl y(Ta ble 2) . 
Partici pa nts wit h u n k n o w n bi o mar ker stat us at t he ti me of c o nse nt ca n o nl y u n der g o t he 
Scree ni n g assess me nts o nce t he prese nce of ≥ [ADDRESS_208409] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 1 / 1 5 9 ce ntral trial assa y  o r b y  a n assa y  w it h a p pr o priate re g ulat or y  s tat us ( bi o ps y  r es ults 
e x pecte d wit hi n 2 1 da y s) . 
Scree ni n g assess me nts t o c o nfir m t hat partici pa nt s meet t he selecti o n criteria will be c o m plete 
wit hi n 2 1 da y sfr o m ti me of c o nse nt i n Parts A, A 2, A 3 , a n d B 1 a n d wit hi n 4 2 da y si n Pa rts C 
(all o wi n g f or Bi o ps y  res ults t o bec o me a vaila ble bef ore t he rest of t he Scree ni n g assess me nts ca n 
be c o n d ucte d) bef ore t he first d ose of st u d y  dr u g f or all partici pa nt s. 
If a partici pa nt is a Scree n Fail ure f or Part C, t he pa rtici pa nt m a y  b e c o nsi dere d f or partici pati o n 
i n Part A 3 . Scree ni n g res ults fr o m Part C m a y be use d t o deter mi ne eli gi bilit y f or Part A 3 wit h n o 
necessit y t o re peat t he assess me nts (at t he Sp o ns or’s discreti o n) . H o we ver, if start of treat me nt i n 
Part A 3 is pla n ne d o utsi de of t he 2 1- d a y wi n d o w (see pre vi o us para gra p h ), t he f oll o wi n g 
assess me nts m ust be re peate d: 
Pri or a n d c o nc o mita nt me dicati o ns: 
Wei g ht a n d vital si g ns 
P h y sical e xa mi nati o n 
Cli nical disease assess me nt 
He mat ol o g y 
C oa g ulati o n 
Ser u m c he mistr y 
Uri nal y sis 
A Es 
T he I n vesti gat or ( or a n a p pr o priate a ut h orize d desi g nee at t he I n vesti gat or site) will o btai n 
i nf or me d c o nse nt fr o m eac h partici pa nt . If t he ti me bet wee n Scree ni n g a n d d osi n g e xcee ds t he 
s pecifie d Scree ni n g Wi n d o w as a res ult of o perati o nal dela y s ( e. g., dela y e d dr u g s hi p me nt, dela y 
i n ce ntral trial assa y  r es ults, cli nic cl os ures or s h ort -ter m, re versi ble me dical c o n diti o ns 
[e. g., i nter ve ni n g u p per res pi[INVESTIGATOR_1305] y  i ll ness, c orrecti ble a ne mia]), t he n partici pa nt s d o n ot re q uire 
rescree ni n g if la b orat or y res ul ts wit hi n 7d a y s of t he first d ose of st u d y  d r u g meet t he eli gi bilit y 
criteria. Partici pa nt s w h o are u na ble t o d ose wit hi n t he Scree ni n g Wi n d o w beca use of s u bsta ntial 
c o m plicati o ns of disease pr o gressi o n will be re place d. 
T o pre pare f or st u d y  p artici pati o n , partici pa nt s will be i nstr ucte d o n t he Li fest yl e G ui deli nes 
( Secti o n 6. 6. 3 ) a n d use of c o nc o mita nt me dicati o ns ( Secti o n 6. 6 ). A partici pa nt w h o q ualifie d, b ut 
di d n ot e nr oll f or a n earlier c o h ort, m a y  b e use d i n a s u bse q ue nt c o h ort wit h n o re q uire d rescree ni n g 
if t he D a y 1 la b orat or y  r es ults a n d W orl d Healt h Or ga nizati o n ( W H O) Perf or ma nce Stat us meet 
t he eli gi bilit y  c riteria. A c hest a n d a b d o mi nal i ma gi n g sca n a n d, if cli nicall y  i n dicate d, a pel vic 
i ma gi n g sca n m ust be re peate d if m ore t ha n [ADDRESS_208410] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 2 / 1 5 9 Partici pa nt s w h o fail Scree ni n g o nce m a y  b e rescree ne d if, i n t he I n vesti gat or ’s o pi [INVESTIGATOR_9384] o n, t he reas o n 
f or i nitial scree n fail ure is d ue t o a clearl y te m p orar y  c o n diti o n (e. g., i nc o m plete rec o ver y  f r o m 
rece nt s ur ger y ; i na de q uate ti me fra me fr o m pri or c he m ot hera p y ). 
5. 2. [ADDRESS_208411] researc h or ga nizati o n 
( C R O) i n v ol ve d i n assisti n g sites a n d t h e Sp o ns or wit h m o nit ori n g partici pa nt safet y. T he Me dical 
M o nit ori n g Pla n will descri be t he a ntici pate d fre q ue nc y  a n d mea ns of c o m m u nicati o n bet wee n 
Sp o ns or, sites, a n d C R Os t o re vie w partici pa nt data t o i nf or m decisi o ns o n d ose escalati o n bet wee n 
c o h orts. 
Decisi o ns re gar di n g d ose escalati o n bet wee n c o h orts i n Parts A, A [ADDRESS_208412] u d y  sites, a n d me dical re prese ntati ves 
fr o m t he C R Os (if a p pr o priate) after a re vie w of safet y  i nf or ma ti o n. A Es occ urri n g u p t o a n d 
i ncl u di n g t he e n d of C y cle 1 will be re vie we d as s o o n as t he y  a re a vaila ble f or a gi ve n c o h ort. 
D L Ts t hat m a y  h a ve occ urre d t hr o u g h t he e n d of C y cle 1 of t he c urre nt c o h ort, as well as D L Ts 
t hat ha ve occ urre d i n pri or c o h orts i n later c y cles, will be i de ntifie d. 
T he M 4 3 4 4 M T D will pri maril y be deter mi ne d b y D L Ts t hat occ ur u p t o a n d i ncl u di n g t he e n d of 
t he D L T peri o d . T he M 4 3 4 4 M T D is defi ne d usi n g t he N CI -C T C A E ( Parts A a n d B 1: Versi o n 4. 0 ; 
Part sA 2 a n d A 3 :Versi o n 5. 0 ). If ≥2o ut of u p t o 6partici pa nt s at t he sa me d ose le vel ha ve a D L T, 
as defi ne d i n Secti o n 5. 2. 6,  t he M [ADDRESS_208413] u d y  i n a gree me nt bet wee n S p o ns or 
a n d I n vesti gat ors. It m a y  n ot be hi g her t ha n t he M T D .
5. 2. 1 1 F oll o w -u p 
Partici pa nt si n Parts A, A 2, A 3 , a n d B 1 , re gar dless of reas o n f or disc o nti n uati o n, will ha ve a Safet y 
F oll o w - u p Visit 1 4 da y s ( ± 7 da y s) f oll o wi n g t he last d ose of st u d y  d r u g, duri n g w hic h t he 
pr oce d ures liste d i n Ta ble 3, Ta ble 4,Ta ble 5, a n d Ta ble 6will be c o m plete d. Partici pa nts i n 
Parts C will ha ve a Safet y F oll o w - u p Visit 3 0 d a y s ( ± 7d a y s) f oll o wi n g t he last d ose of st u d y  d r u g, 
pr oce d ures liste d i n  Ta ble 7, Ta ble 8, Ta ble 9, a n d  Ta ble [ADDRESS_208414] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 3 / [ADDRESS_208415] u d y  cl os ure .
Data m a y  b e o btai ne d eit her per r o uti ne site partici pa nt f oll o w - u p (if t he site c o nti n ues t o f oll o w 
t he partici pa nt ) or via tele p h o ne, electr o nic, or mail c o m m u nicati o n. T he f oll o wi n g i nf or mati o n 
s h o ul d be o btai ne d, if p ossi ble, o n a 3 -m o nt hl y  basis: 
If t he partici pa nt is decease d, a n d if s o, date of deat h a n d w het her deat h is relate d t o 
pri mar y  mali g na nc y 
If t he partici pa nt is ali ve, if t he disease pr o gresse d, a n d if s o, w hat is t he date of 
pr o gressi o n 
If t he partici pa nt starte d o n a s u bse q ue nt li ne of t hera p y  f or t he pri mar y  m ali g na nc y , 
a n d if s o, date of starti n g ne w t hera p y
If t he partici pa nt is decease d, has pr o gressi ve disease, or has starte d o n ne w t hera p y 
t he n f urt her f oll o w- u p i nf or mati o n d oes n ot nee d t o be c ollecte d. 
L ost -t o -F oll o w -U p 
A partici pa nt will be c o nsi dere d l ost t o f oll o w - u p if he or s he re peate dl y  f ails t o ret ur n f or 
sc he d ule d visits a n d is u na ble t o be c o ntacte d b y t he st u d y  site. 
T he f oll o wi n g acti o ns m ust be ta ke n if a partici pa nt fails t o ret ur n t o t he cli nic f or a re q uire d st u d y 
visit: 
T he site m ust atte m pt t o c o ntact t he partici pa nt a n d resc he d ule t he misse d visit as s o o n 
as p ossi ble, c o u nsel t he partici pa nt o n t he i m p orta nce of mai ntai ni n g t he assi g ne d visit 
sc he d ule a n d ascerta i n if t he partici pa nt wa nts t o or s h o ul d c o nti n ue i n t he st u d y .
Bef ore a partici pa nt is dee me d “l ost t o f oll o w -u p”, t he I n vesti gat or or desi g nee m ust 
ma ke e ver y  e ff ort t o re gai n c o ntact wit h t he partici pa nt: 1) w here p ossi ble, ma ke 3 
tele p h o ne calls; 2) if necessar y , se n d a certifie d letter ( or a n e q ui vale nt l ocal met h o d) t o 
t he partici pa nt’s last k n o w n maili n g a d dress, a n d 3) if a partici pa nt has gi ve n t he 
a p pr o priate c o nse nt, c o ntact t he partici pa nt’s ge neral practiti o ner f or i nf or mati o n. T hese 
c o ntact at te m pts s h o ul d be d oc u me nte d i n t he partici pa nt’s me dical rec or d. 
S h o ul d t he partici pa nt c o nti n ue t o be u nreac ha ble, he/s he will be c o nsi dere d t o ha ve 
wit h dra w n fr o m t he st u d y. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208416] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 4 / [ADDRESS_208417] u d y assess me nts n ot part of t he partici pa nt ’s 
r o uti ne me dical care, t he I n vesti gat or will e ns ure t hat t he partici pa nt or t he partici pa nt ’s le gal 
re pr ese ntati ve has pr o vi de d writte n i nf or me d c o nse nt f oll o wi n g t he pr oce d ure descri be d i n 
Secti o n 9. 2 .
5. 3. 1 I ncl usi o n Criteri a 
1. Me n a n d w o me n ≥ 1 8 ye ars of a ge 
2. Disease stat us: 
Part s A, A 2 , a n d A 3 : Partici pa nt s wit h [ADDRESS_208418] ol o gicall y  o r c y t ol o gicall y  c o nfir me d mali g na nt 
a d va nce d s oli d t u m ors f or w hic h n o sta n dar d t hera p y  i s a vaila ble w hic h ma y  c o n ve y  c li nical 
be nefit 
Part B 1 : Partici pa nt s wit h [ADDRESS_208419] ol o gicall y  o r c y t ol o gicall y c o nfir me d mali g na nt a d va nce d 
s oli d t u m ors f or w hic h n o sta n dar d t hera p y is a vaila ble w hic h ma y  c o n ve y cli nical be nefit, 
a n d/ or partici pa nt s m ust ha ve pr o gresse d after at least 1 pri or c he m ot hera p y  r e gi me n i n t he 
metastatic setti n g, a n d f or w hic h car b o plati n w o ul d be c o nsi dere d sta n dar d of car e
Parts C: Partici pa nt s wit h [ADDRESS_208420] ol o gicall y  o r c y t ol o gicall y c o nfir me d mali g na nt a d va nce d 
s oli d t u m ors f or w hic h n o rec o m me n de d sta n dar d t hera p y is a vaila ble (i.e. partici pa nts w h o 
ha ve e x ha uste d all sta n dar d of care o pti o ns acc or di n g t o N C C N G ui da nce) whic h ma y 
c o n ve y  c li nical be nefit, a n d w h ose t u m or has at least 1 of t he f oll o wi n g bi o mar kers as 
deter mi ne d b y  a ce ntral trial assa y  o r b y  a n assa y  w it h a p pr o priate re g ulat or y  s tat us (see 
Secti o n  7. 7. 5 f or f urt her details): 
oC 1 or C 4: l oss - of- f u ncti o n m utati o ns i n t he ge ne A RI D 1 A 
oC 2 or C 5: l oss - of- f u ncti o n m utati o ns i n t he ge nes A T R X a n d/ or D A X X 
oC 3 or C 6: l oss - of-f u ncti o n m utati o n i n t he ge ne A T M 
T his ma n dat or y  b i o mar ker assess me nt m ust be c o n d ucte d d uri n g Scree ni n g o n a fres h t u m or 
bi o ps y  ( or a bi o ps y  o btai ne d after t he e n d of t he pre vi o us treat me nt re gi me n). If t his is n ot 
p ossi ble f or me dical reas o n(s), a vaila ble arc hi val t u m or material ca n be use d ( hist orical data 
s h o ul d n ot be use d t o c o nfir m bi o mar ker stat us) .
3. Meas ura ble disease eit her acc or di n g t o R E CI S T criteria (Versi o n 1. 1 ) 
4. W H O perf or ma nce stat us of 0 or 1 
5. Life e x pecta nc y  of ≥ [ADDRESS_208421] u g a d mi nistrati o n: 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208422] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 5 / 1 5 9 He m o gl o bi n: ≥ 9. 0 g/ d L f or Parts A a n d B; ≥ 8. 0 g/ d L a n d n o bl o o d tra nsf usi o ns i n t he 
prece di n g 2 8 d a y s f or Part s C 
A bs ol ute ne utr o p hil c o u nt: ≥ 2. 0 x 1 0 9/ L 
Platelet c o u nt: ≥ 1 2 5 x 1 0 9/ L 
Ser u m bilir u bi n: ≤ 1. 5 x u p per li mit of n or mal ( U L N), e xce pt i n t he case of k n o w n or 
s us pecte d Gil bert’s s y n dr o me 
A L T, A S T, a n d al kali ne p h os p hatase (li ver ori gi n): ≤ 2. 5 x U L N or ≤ 5 x U L N i n prese nce 
of li ver metastases 
Ser u m al b u mi n: ≥ 2. 5 g/ d L 
Esti mate d gl o mer ular filtrati o n rate: ≥ 5 0 m L / mi n f or Parts A a n d B; ≥ 4 0 m L / mi n f or 
Part s C 
Pr ot hr o m bi n ti me: < 1. 2 5 x U L N 
I n  a d diti o n, t here s h o ul d n ot be ot her cli nicall y  s i g nifica nt meta b olic or he mat ol o gic 
a b n or malities t hat are u nc orrecta ble or t hat re q uire o n g oi n g, rec urre nt p har mac ol o gic 
ma na ge me nt. 
7. Si g n a n d date a n i nf or me d c o nse nt d oc u me nt 
8. Willi n g a n d a ble t o c o m pl y  w it h sc he d ule d visits, treat me nt pla n, lifest y le, la b orat or y  t ests, 
c o ntrace pti ve g ui deli nes, a n d ot her st u d y pr oce d ures .
5. 3. 2 E xcl usi o n Cri teri a 
1. Ra di ot hera p y, u nless brief c o urse f or palliati ve t hera p y , e n d ocri ne t hera p y , tar get -s pecific 
t hera p y, i m m u n ot hera p y , or c he m ot hera p y d uri n g t he 4wee ks ( 6 wee ks f or nitr os o ureas a n d 
Mit o m y ci n -C, a n d 4 wee ks f or i n vesti gati o nal me dici nal pr o d ucts) or 4dr u g half -li ves bef ore 
first d ose of st u d y  dr u g, w hic he ver is greater 
2. Part B 1 : M ore t ha n 6c y cles of pri or t hera p y wit h car b o plati n, u nless disc usse d wit h a n d 
a p pr o ve d b y t he Me dical M o nit or. 
3. O n g oi n g t o xic ma nifestati o ns of pre vi o us treat me nts. E xce pti o n s t o t his are al o pecia or certai n 
Gra de 1 t o xicities, w hic h i n t he o pi [INVESTIGATOR_9384] o n of t he I n vesti gat or s h o ul d n ot e xcl u de t he partici pa nt 
Part B 1: A n y k n o w n hist or y  o f Gra de 4 t hr o m b oc y t o pe nia wit h a n y pri or c he m ot hera p y 
re gi me n ( n ot a p plica ble f or Parts C) 
4. Brai n metastases u nless as y m pt o matic, treate d, sta ble, a n d n ot re q uiri n g ster oi ds f or at least 
4wee ks bef ore first d ose of st u d y  dr u g 
5. Fe male partici pa nt s w h o are alrea d y pre g na nt or lactati n g, or pla n t o bec o me pre g na nt wit hi n 
[ADDRESS_208423] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 6 / [ADDRESS_208424] o m y or ha ve bee n a me n orr heic f or o ver 2 ye ars 
wit h a Scree ni n g ser u m f ollicle -sti m ulati n g h or m o ne ( F S H) le vel wit hi n t he la b orat or y ’s 
refere nce ra n ge f or p ost me n o pa usal fe males 
6. Male partici p a nt s wit h part ners of c hil d beari n g p ote ntial m ust a gree t o a d here t o c o ntrace pti o n 
g ui deli nes i n Secti o n 7. 5. 2. [ADDRESS_208425] u d y  d r u g are 
e xcl u de d 
7. Maj or s ur ger y  ≤ [ADDRESS_208426] u g or i nc o m plete rec o ver y  fr o m a pri or 
maj or s ur gical pr oce d ure 
8. Car diac c o n diti o ns as f oll o ws: 
Cli nicall y  si g nifica nt car di o vasc ular e ve nt wit h i n [ADDRESS_208427] u d y e ntr y: 
oc o n gesti ve heart fail ure re q uiri n g t hera p y
ou nsta ble a n gi na pect oris 
om y ocar dial i nfarcti o n 
oClass II/ III/ I V car diac disease ( Ne w Y or k Heart Ass ociati o n) 
oprese nce of se vere val v ular heart disease 
oprese nce of a ve ntric ular arr h yt h mia re q uiri n g treat me nt 
Hist or y  o f arr h y t h mia t hat is s y m pt o matic or re q uires treat me nt ( C T C A E Gra de 2), 
s y m pt o matic or u nc o ntr olle d atrial fi brillati o n des pi[INVESTIGATOR_148484], or as y m pt o matic s ustai ne d 
ve ntric ular tac h y car dia. Partici pa nt s wit h atrial fi bril lati o n c o ntr olle d b y me dicati o n are 
per mitte d 
U nc o ntr olle d h y perte nsi o n ( bl o o d press ure ≥1 6 0/ 1 0 0 des pi[INVESTIGATOR_040] o pti mal t hera p y )
Sec o n d or t hir d de gree heart bl oc k wit h or wit h o ut s y m pt o ms 
Q Tc > 4 7 0 msec ( b y eit her Fri dericia’s or Baz ett’s c orrecti o n) n ot d ue t o electr ol y te 
a b n or malit y  a n d t hat d oes n ot res ol ve wit h c orrecti o n of electr ol yt es 
Hist or y  of c o n ge nital l o n g Q T s y n dr o me 
Hist or y of t orsa des de p oi ntes ( or a n y  c o nc urre nt me dicati o n wit h a k n o w n ris k of i n d uci n g 
t orsa des de p oi ntes) 
Cli nicall y -si g nifica nt a b n or malit y , i ncl u di n g ejecti o n fracti o n bel o w n or mal i nstit uti o nal 
li mits, prese nt o n tra nst h oracic ec h ocar di o gra m perf or me d at Scree ni n g, f or Parts A a n d B 
9. Pri or b o ne marr o w tra ns pla nt or e xte nsi ve ra di ot hera p y t o greater t ha n 1 5 % of b o ne marr o w 
[ADDRESS_208428] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 7 / 1 5 9 1 1. A n y  o t her c o n diti o n w hic h i n t he I n vesti gat or ’s o pi [INVESTIGATOR_9384] o n w o ul d n ot ma ke t he partici pa nt a g o o d 
ca n di date f or t he cli nical st u d y , i ncl u di n g: 
Hist or y  of HI V -1, HI V - 2 , or u nres ol ve d He patitis B or u nres ol ve d H e patitis C i nfecti o n 
Hi g h me dical ris k beca use of n o n mali g na nt s y ste mic disease i ncl u di n g acti ve u nc o ntr olle d 
i nfecti o n 
Pa rtici pa nt s w h o ha ve bee n dia g n ose d wit h Li -Fra u me ni S y n dr o me or wit h ata xia 
tela n giectasia 
1 2. C urre nt mali g na ncies of ot her t y pes, wit h t he e xce pti o n of a de q uatel y treate d c o ne -bi o psie d 
i n sit u carci n o ma of t he cer vi x uteri a n d basal or s q ua m o us cell carci n o m a of t he s ki n; pri or 
ca ncer t hat has bee n i n re missi o n f or at least 3 ye ars w o ul d n ot be e xcl u de d 
1 3. C urre nt t hera p y: 
Partici pa nt s recei vi n g treat me nt wit h me dicati o ns t hat are k n o w n t o be str o n g i n hi bit ors or 
i n d ucers of c yt oc hr o me P 4 5 0 ( C Y P) [ADDRESS_208429] u d y . E xa m ples of str o n g C Y P 3 A 4 
i n hi bit ors or i n d ucers are pr o vi de d i n  Ta ble 1 3 
Partici pa nt s recei vi n g treat me nt wit h pr ot o n -p u m p i n hi bit ors t hat ca n n ot be disc o nti n ue d at 
least [ADDRESS_208430] u d y . E xa m ples of 
pr ot o n -p u m p i n hi bit ors are pr o vi de d i n  Ta ble 1 3 
F or Part B 1: partici pa nt s recei vi n g treat me nt wit h ot ot o xic or ne p hr ot o xic me dicati o ns t hat 
ca n n ot be disc o nt i n ue d at least [ADDRESS_208431] u d y  w ill n ot ca use a partici pa nt t o be i neli gi ble. If a s h ort 
c o urse of t hera p y  w it h ne p hr ot o xic or ot ot o xic me dicati o n is a ntici pate d a n d re q uire d , 
car b o plati n or cis plati n s h o ul d be disc o nti n ue d u ntil 7 da y s after t his c o urse is c o m plete d 
Partici pa nts recei vi n g pri or treat me nt wit h a n y A T R in hi bit or 
[ADDRESS_208432] u d y will be c hec ke d at Scree ni n g f or Parts A, A 2, A 3 , a n d B 1 
(see  Ta ble 1) a n d Parts C (see Ta ble 2) .
5. [ADDRESS_208433] be wit h dra w n fr o m M 4 3 4 4 if a n y  of t he f oll o wi n g occ ur :
Partici pa nt wit h dre w c o nse nt 
Partici pa nt l ost t o f oll o w u p 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208434] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 8 / 1 5 9 Partici pati o n i n a n ot her cli nical st u d y or start of ne w a nti -ca ncer treat me nt 
N o nc o m plia nce of st u d y dr u g d osi n g or st u d y pr oce d ure 
A n y  e ve nts t hat u nacce pta bl y  e n da n ger t he safet y of t he partici pa nt .
If partici pa nts dr o p o ut f or a n y reas o n ot her t ha n disease pr o gressi o n , e ver y eff ort s h o ul d be ma de 
t o c o nti n ue t o f oll o w t he partici pa nt i n t he trial f or t u m or assess me nt. 
5. 5. [ADDRESS_208435] u d y  d r u g d osi n g wi ll be 
as ke d t o ret ur n t o t he cli nica l site f or Safet y F oll o w -u p Vis it 1 4 da y s( ± 7 da ys) after t heir last d ose 
of st u d y  d r u g ( 3 0 d a y s [ ± 7 d a y s] f or Parts C) . S af et y  F oll o w - u p Visit assess me nts are prese nte d 
i n  Ta ble 3,Ta ble 4,Ta ble 5,Ta ble 6, Ta ble 7, a n d  Ta ble 9. 
If a partici pa nt d oes n ot ret ur n f or a sc he d ule d visit, reas o na ble eff ort will be ma de t o c o ntact t he 
partici pa nt . I n a n y circ u msta nce, reas o na ble eff ort will be ma de t o d oc u me nt partici pa nt o utc o me. 
T he I n vesti gat or will i n q uire a b o ut t he reas o n f or wit h dra wal, re q uest t hat t he partici pa nt ret ur n 
f or a Safet y  F oll o w -u p Visit (see Secti o n 5. 2. 1 1) , if a p plica ble ,a n d f oll o w u p wit h t he partici pa nt 
re gar di n g a n y u nres ol ve d A Es. 
It m a y  b e  a p pr o priate f or t he partici pa nt t o ret ur n t o t he cli nic f or fi nal safet y  a ssess me nts a n d t o 
be q uesti o ne d re gar di n g t heir reas o n f or wit h dra wal. Ass ess me nts ma y  i ncl u de: 
P h y sical e xa mi nati o n 
Bl o o d press ure a n d p ulse rate meas ure me nts 
E C G 
Bl o o d a n d uri ne s peci me n’s c ollecti o n (f or safet y la b orat or y t ests a n d pre g na nc y  t est, if 
a p plica ble) 
Bl o o d sa m ple f or P K a nal y sis. 
If t he partici pa nt wit h dra ws c o nse nt, n o f urt her e val uati o ns will be perf or me d, a n d n o a d diti o nal 
data will be c ollecte d. T he S p o ns or ma y  retai n a n d c o nti n ue t o use a n y  data c ollecte d bef ore s uc h 
wit h dra wal of c o nse nt. 
Partici pa nt s ma y  b e disc o nti n ue d fr o m st u d y  d r u g f or t o xicit y  o r lac k of efficac y , as s pecifie d i n 
Secti o n 6. 4. 
F or partici pa nts i n Parts Cw h o ha ve n ot pr o gresse d, see Secti o n  5. 2. [ADDRESS_208436] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 8 9 / [ADDRESS_208437] d 
at t he S p o ns or’s discreti o n. 
5. [ADDRESS_208438] u g or c o m parat or fr o m t he mar ket f or safet y reas o ns. 
Healt h A ut h orities a n d I n de pe n de nt Et hics C o m mittees (I E Cs)/I nstit uti o nal Re vie w B oar ds (I R Bs) 
will be i nf or me d a b o ut t he disc o nti n uati o n of t he st u d y i n acc or da nce wit h a p plica ble re g ulati o ns. 
5. [ADDRESS_208439] u d y  will e n d w he n: 
All partici pa nts i n Parts A, A 2 , a n d A 3 ha ve c o m plete d t he Safet y F oll o w - u p V isit 1 4 
da y s ( ± 7 da y s) after t he last d ose of t he st u d y  dr u g ,A N D 
All partici pa nts i n Parts B [ADDRESS_208440] u d y 
T he ter m “I n vesti gati o nal Me dici nal Pr o d uct” refers t o a n acti ve s u bsta nce or a place b o bei n g 
teste d or use d as a refere nce t hera p y i n a cli nical st u d y, i ncl u di n g pr o d ucts t hat ha ve a mar keti n g 
a ut h orizati o n b ut are f or m ulate d ,pac ka ge d , or a d mi nistere d differe ntl y  fr o m t he a ut h orize d f or m, 
use d f or a n u na ut h orize d i n dicati o n, or use d t o gai n f urt her i nf or mati o n a b o ut t he a ut h orize d f or m .
6. [ADDRESS_208441] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 0 / [ADDRESS_208442] u d y . Sites will use car b o plati n as s u p plie d b y  
t heir p har mac y .
6. 2 D os a ge a n d A d mi nistr ati o n 
6. 2. 1 A d mi nistr ati o n 
M 4 3 4 4 , 5 0 m g ta blets , will be a d mi nistere d orall y wit h 2 4 0 m L  ( 8fl ui d o u nces) of a m bie nt 
te m perat ure water .Car b o plati n will be a d mi nistere d via i ntra ve n o us i nf usi o n. 
M [ADDRESS_208443] u d y ; all partici pa nt s will 
a bstai n fr o m all f o o d f or at least [ADDRESS_208444] d ose pri or t o eac h P K sa m ple is t o be rec or de d o n t he 
electr o nic case re p ort f or m ( e C R F ).
All partici pa nt s will f oll o w t he dietar y  a n d meal restricti o ns o utli ne d i n Secti o n 6. 6. 3. [ADDRESS_208445] u g bef ore s wall o wi n g. 
Partici p a nt s will be i nstr ucte d n ot t o lie d o w n (sitti n g i n a n u pri g ht or recli ni n g p ositi o n is 
acce pta ble) f or 2h o urs after ta ki n g t he st u d y  d r u g, e xce pt w he n re q uire d f or st u d y  p r oce d ures. 
W he n M [ADDRESS_208446] u g A d mi nistr ati o n 
W he n cli nical c he mistr y a n d/ or he mat ol o g y  l a b orat or y  t esti n g is re q uire d bef ore a d mi nistrati o n of 
c he m ot hera p y or M 4 3 4 4 as prese nte d i n t he Sc he d ule of Assess me nts (Ta ble 3, Ta ble 4, Ta ble 5,
Ta ble 6, Ta ble 7,  a n d Ta ble 9), t he la b orat or y  c riteria s pecifie d i n Ta ble [ADDRESS_208447] u g, t his  la b orat or y testi n g ma y be perf or me d 
u p t o 3 da y s bef ore d o si n g. 
After C ycl e1, D a y 1, if a partici pa nt d oes n ot meet 1 or m ore criteria, d osi n g ma y  be pa use d a n d 
res u me d o nce t he la b orat or y  a b n or malit y (ies) has res ol ve d wit h or wit h o ut me dical i nter ve nti o n, 
at t he discreti o n of t he I n vesti gat or a n d Me dical Mo nit o r. 
D oc u me nt N o. 
O bject N o. C CI C CI 
C CI 
M [ADDRESS_208448] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 1 / [ADDRESS_208449] er e d a
H e m o gl o bi n ≥9. 0 g/ d L (P art s A a n d B) 
≥ 8 . 0 g/ d L ( P art sC) ≥7. 0 g/ d L 
(if a s y m pt o m ati c) ≥7. 0 g/ d L 
(if a s y m pt o m ati c) 
A b s ol ut e n e utr o p hil v al u e ≥2. 0 x1 0 9/ L ≥1. 5 x1 0 9/ L ≥1. 5 x1 0 9/ L 
Pl at el et c o u nt ≥1 2 5 x1 0 9/ L ≥1 0 0 x1 0 9/ L ≥1 0 0 x1 0 9/ L 
A S T, A L T, a n d A L P (li v er 
ori gi n) ≤2. 5 xU L N or ≤ [ADDRESS_208450] a s e s ≤2. 5 xb a s eli n e v al u e 
or ≤ [ADDRESS_208451] a s e s ≤2. 5 xb a s eli n e v al u e 
or ≤ [ADDRESS_208452] a s e s 
E sti m at e d gl o m er ul ar 
filtr ati o n r at e ≥5 0 m L/ mi n ( P art s A a n d 
B) 
≥4 0 m L/ mi n ( P art sC) D o e s n ot m e et D L T 
crit eri a D o e s n ot m e et D L T 
crit eri a 
T ot al bilir u bi n ( s er u m) b≤1. 5 xU L N ≤1 5 m g/ d L ≤1 5 m g/ d L 
S er u m al b u mi n ≥2. 5 g/ d L ≥2. 5 g/ d L ≥2. 5 g/ d L 
A L P = Al k ali n e p h o s p h at a s e, A L T =Al a ni n e a mi n otr a n sf er a s e, A S T = a s p art at e a mi n otr a n sf er a s e; 
D L T =D o s e -li miti n g t o xi cit y, U L N = U p p er li mit of n or m al 
a B a s e d o n m o st c urr e nt l a b or at or y v al u e s a v ail a bl e. L a b or at or y t e sti n g will b e c o n d u ct e d a s d e s cri b e d i n 
T a bl e 3, T a bl e 4, T a bl e 5, T a bl e 6, T a bl e 7, a n d  T a bl e 9;  a d diti o n al t e sti n g will n ot b e r e q uir e d t o c o nfir m t h e s e 
v al u e s pri or t o e v er y d o s e. 
b P arti ci p a nt s wit h k n o w n or s u s p e ct e d Gil b ert’ s s y n dr o m e ar e e x e m pt fr o m s er u m bilir u bi n e x cl u si o n. 
6. 2. 3 D ose M o dific ati o n f or T o xicit y 
N o d ose m o dificati o ns of M 4 3 4 4 ma y  b e ma de d uri n g C y cle 1 of Parts A, A 2 , A 3 , or B 1, e xce pt 
as s pecifie d i n Secti o ns 5. 1. 1 a n d 5. 1. 3. 
P arts A, A 2 , a n d A 3 :
D oses of M 4 3 4 4 m a y  b e re d uce d ot her t ha n i n C y cl e 1 of Part s A, A 2 ,a n d A 3 f or t o xicit y  u si n g 
t he f oll o wi n g g ui deli nes: 
F or Gra de 4 he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 2 5 % 
F or Gra de 3 n o n- he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 2 5 % 
F or Gra de 4 n o n- he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 5 0 % 
P art s A 2 , A 3 :
Pa rtici pa nts i n Part sA [ADDRESS_208453] u d y 
treat me nt at a re d uce d d ose pr o vi de d t he reacti o n has res ol ve d t o baseli ne val ue or Gra de ≤ [ADDRESS_208454] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 2 / [ADDRESS_208455] u d y  treat me nt. 
See Secti o n  5. 2. 6 f or a d diti o nal details of t o xicit y  m o dificati o ns. 
P art B 1 :
D oses of M 4 3 4 4 a n d/ or car b o plati n m a y  b e re d uce d or dela y e d b e y o n d C y cle [ADDRESS_208456] of t he partici pa nt . I n t his case t he d ose 
of eit her t he c he m ot hera pe utic a ge nt a n d/ or M [ADDRESS_208457] 2 5 %. 
I n case of Gra de 3 or hi g her t o xicit y  ( e xcl u di n g fati g ue or na usea/ v o miti n g/ diarr hea 
a de q uatel y ma na ge d b y  s u p p orti ve care), treat me nt will be i nterr u pte d a n d m a y  b e 
res u me d w he n all t o xicities ha ve ret ur ne d t o Gra de 2 or l o wer, at t he discreti o n of t he 
I n vesti gat or .D ose m o dificati o ns ma y  b e a p plie d acc or di n g t o t he rec o m me n dati o ns 
gi ve n f or Parts A , A 2 , a n d A 3 (see a b o ve). 
F or t he f oll o wi n g he mat ol o gic t o xicities, o nce t he t o xicit y  h as ret ur ne d t o Gra de 2 or 
l o wer, d osi n g ca n be res u me d at a l o wer d ose of c he m ot hera p y 
(car b o plati n =A U C 4m g ∙ mi n/ m L  o r 2 5 % re d ucti o n i n d ose of c he m ot hera p y) a n d/ or 
l o wer d ose of M 4 3 4 4 ( 2 5 % re d ucti o n) :
Gra de 4 t hr o m b oc y t o pe nia 
Fe brile ne utr o pe nia ( gr o wt h fact or s u p p ort, per site pr ot oc ol, ma y  b e use d i n lie u of d ose 
re d ucti o n) 
Gra de 4 ne utr o pe nia lasti n g m ore t ha n 7 d a y s ( gr o wt h fact or s u p p ort, per site pr ot oc ol, ma y 
be use d i n lie u of d ose re d ucti o n) 
F or t he f oll o wi n g n o n -he mat ol o gic t o xicitie s, o nce t he t o xicit y  has ret ur ne d t o Gra de 2 
or l o wer, d osi n g ca n be res u me d at a l o wer d ose of c he m ot hera p y  ( car b o plati n = A U C 
4m g ∙ mi n/ m L  or 2 5 % re d ucti o n i n d ose of c he m ot hera p y) a n d/ or l o wer d ose of M 4 3 4 4 
( 2 5 % re d ucti o n) :
Gra de 3 n o n- he mat ol o gic t o xici t y  ( e xce pt f or fati g ue or na usea, v o miti n g, or diarr hea 
a de q uatel y c o ntr olle d b y me dicati o n) 
A n y  Gra de 2 or l o wer n o n -he mat ol o gic t o xicit y  re q uiri n g d ose dela y  of m ore t ha n 2 wee ks 
F or Gra de 4 n o n- he mat ol o gic t o xicit y , treat me nt will be i nterr u pte d a n d ma y b e 
res u me d at a l o wer d ose of c he m ot hera p y (car b o plati n = A U C 4 m g ∙ mi n/ m L  o r 2 5 % 
re d ucti o n d ose of c he m ot hera p y ) a n d at a l o wer d ose of M 4 3 4 4 ( 2 5 % re d ucti o n) w he n 
t o xicit y  has ret ur ne d t o Gra de [ADDRESS_208458] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 3 / [ADDRESS_208459] u d y  a n d t he 
partici pa nt m a y  be be nefitti n g fr o m t hera p y, t he n at t he discreti o n of t he I n vesti gat or , t he d oses of 
M 4 3 4 4 or c he m ot hera p y ma y  be f urt her re d uce d. 
P arts C:
D oses of M 4 3 4 4 ma y  be re d uce d f or t o xicit y  usi n g t he f oll o wi n g g ui deli nes: 
F or Gra de 4 he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 2 5 % 
F or Gra de 3 n o n- he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 2 5 % 
F or Gra de 4 n o n- he mat ol o gic t o xicit y : t he d ose of M 4 3 4 4 will be re d uce d b y 5 0 % 
I n  a gree me nt bet wee n I n vesti gat or a n d S p o ns or, a n y  d ose re d ucti o n f or t o xicit y  d e viati n g fr o m t he 
a b o ve g ui deli nes ma y  be a p plie d .
6. 2. [ADDRESS_208460] u d y  v isits t hat are misse d beca use of cli nic or partici pa nt u na vaila bilit y  ( e. g., f or reas o ns of 
p u blic h oli da y , cli nic cl os ure, ur ge nt pers o nal matter, tra ns p o rtati o n pr o ble ms), s h o ul d be ma de 
u p w he n a n d if reas o na bl y p ossi ble. 
F or Part sA [ADDRESS_208461] u g ( wit h t he e xce pti o n of M 4 3 4 4 d oses sc he d ule d t o occ ur 2 4 h o urs after 
car b o plati n, d osi n g i n C y cle 1 of Part B1) s h o ul d be ta ke n wit hi n 2d a y s ( 4 8 h o urs) of t he 
sc he d ule d d ose. If m ore t ha n 4 8 h o urs ha ve tra ns pi[INVESTIGATOR_1312] d si nce t he sc he d ule d d ose, t he n t he d ose 
s h o ul d be s ki p pe d a n d will be c o nsi dere d a misse d d ose f or t he p ur p ose of e val ua bilit y  i n C y cle 1 
of Parts A or B 1. F or d oses of M 4 3 4 4 t hat are sc he d ule d t o occ ur 2 4 h o urs after car b o plati n d osi n g 
i n C y cle 1 of Part B1, if m ore t ha n 3 6 h o urs ha ve tra ns pi[INVESTIGATOR_1312] d si nce t he d ose of c he m ot hera p y 
(i.e., m ore t ha n 1 2 h o urs fr o m t he sc he d ule d d ose of M 4 3 4 4 ), t he M [ADDRESS_208462] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 4 / 1 5 9 Partici pa nt s m a y  be scree ne d i n parallel or sta g gere d ma n ner f or Parts A 2 , A 3, a n d Ca n d will be 
e nr olle d i nt o Parts Cacc or di n g t o t he m olec ular lesi o n of t heir t u m or (see Secti o n  5. 1. 4 f or details). 
If a partici pa nt’s t u m or has m ore t ha n o ne q ualif y i n g m olec ular lesi o n, t he partici pa nt will be 
assi g ne d t o all res pecti ve st u d y  parts. 
6. [ADDRESS_208463] u g f or t o xicit y  or lac k of efficac y , as f oll o ws: 
Partici pa nt s e x perie nci n g n o nre versi ble or life -t hreate ni n g t o xicit y  m a y  b e disc o nti n ue d 
fr o m st u d y dr u g at t he I n vesti gat or ’s discreti o n. Partici pa nt s w h o e x perie nce re versi ble 
a n d n o nlife -t hreate ni n g t o xicit y  a n d, i n t he j u d g me nt of t he I n vesti gat or , w h o m a y  b e 
e x hi biti n g cli nical be n efit, ma y  r es u me t hera p y  a fter t he t o xicit y  h as decrease d t o 
Gra de 2 or bel o w 
Partici pa nt s w h o e x perie nce a D L T d uri n g C y cle [ADDRESS_208464] u d y  d r u g 
Partici pa nt s wit h pr o gressi ve disease b e y o n d C y cle [ADDRESS_208465] u d y me dicati o n ma y  be gi ve n at t he I n vesti gat or ’s discreti o n. 
Resc ue me dicati o ns ma y be a d mi nistere d t o a d dress i neffecti ve treat me nt, a ntici pate d a d verse 
reacti o ns or a ntici pate d e mer ge nc y  sit uati o ns. 
C o nc o mita nt treat me nt wit h t he f oll o wi n g c o m p o u n ds t o mai ntai n a castrate le vel of te st oster o ne 
i n partici pa nts wit h pr ostate ca ncer is per mitte d: le u pr oli de,  g osereli n , tri pt oreli n , histreli n, 
de gareli x, a birater o ne, e nzal uta mi de, a n d nil uta mi de. F or t hese c o m p o u n ds, n o ris k f or dr u g -dr u g -
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208466] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 5 / [ADDRESS_208467] t hat M 4 3 4 4 is a s u bstrate of C y t oc hr o me P 4 5 0 (C Y P ) 
3 A 4 (Verte x Re p ort K 2 2 0 2 0 1 4, Verte x Re p ort K 0 6 4 2 0 1 4) a n d s y ste mic e x p os ure ma y  b e 
affecte d b y  c o nc o mita nt me dicati o ns t hat are str o n g C Y P [ADDRESS_208468]. Base d u p o n i n 
vitr o data, M 4 3 4 4 is n ot a p ote nt i n hi bit or or i n d ucer of h u ma n C Y P e nz y mes i n is olate d e nz y m e 
s y ste ms a n d t heref ore t he pr o ba bilit y of M 4 3 4 4 i nteracti o n wit h ot her me dicati o ns t hat are 
s u bstrates of C Y P meta b olis m i s e x pecte d t o be l o w. H o we ver, I n vesti gat or s s h o ul d use sta n dar d 
preca uti o ns w he n prescri bi n g me dicati o ns, as wit h a n y  n o vel t hera pe ut ic f or w hic h t here is li mite d 
cli nical e x perie nce. 
Partici pa nt s will a bstai n fr o m c o nc o mita nt me dicati o ns as descri be d i n Ta ble [ADDRESS_208469] u d y .
Partici pa nt s s h o ul d n ot recei ve pr o p h yl actic treat me nt wit h he mat o p oietic gr o wt h 
fact ors, a nti -e metic, a n d a nti -diarr heal me dicati o ns d uri n g C y cle [ADDRESS_208470] ors (e. g., gra n ul oc y te -c ol o n y sti m ulati n g fact or )s h o ul d n ot be use d i n 
Part B1d uri n g C y cle 1. Ot her wise, a nti -e metics, a nti -diarr heals , a n d gr o wt h fact ors ca n 
be use d f or partici pa nt s i n Part B [ADDRESS_208471] u d y , per i nstit uti o nal practice f or 
a d mi nistrati o n of car b o plati n a n d t o treat s y m pt o ms. 
T he I n vesti gat or s h o ul d refer t o t he pac ka ge i nserts f or car b o plati n f or g ui da nce o n 
pr o hi bite d me diati o ns d uri n g treat me nt wit h t his a ge nt (Car b o plati n S m P C ). 
Partici pa nt s e nr olle d i n Part B [ADDRESS_208472] u d y will n ot ca use a partici pa nt t o be i neli gi ble. If a s h ort c o urse of 
t hera p y w it h ne p hr ot o xic or ot ot o xic me dicati o n is a ntici pate d a n d re q uire d, car b o plati n 
or cis plati n s h o ul d be disc o nti n ue d u ntil 7 da y s after t his c o urse is c o m plete d. 
Me dicati o ns ta ke n fr o m [ADDRESS_208473] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 6 / [ADDRESS_208474] e d M e di c ati o n/ F o o d/ A cti vit ySt u d y  P eri o d 
S cr e e ni n g P eri o d Tr e at m e nt P eri o d 
F o o d 
Gr a p efr uit/ gr a p efr uit j ui c e 
S e vill e or bl o o d or a n g e s N o n e all o w e d wit hi n 
7d a y s b ef or e t h e fir st 
d o s e of st u d y dr u g N o n e all o w e d t hr o u g h t h e 
S af et y F oll o w -u p Vi sit 
Str o n g C Y P 3 A 4 i n hi bit or s or i n d u c er s 
E x a m pl e s of str o n g C Y P 3 A 4 i n hi bit or s 
i n cl u d e cl arit hr o m y ci n, itr a c o n a z ol e, 
He p atiti s C vir u s a n d HI V pr ot e a s e 
i n hi bit or s, k et o c o n a z ol e, n ef a z o d o n e, 
p o s a c o n a z ol e, t elit h o m y ci n, a n d 
v ori c o n a z ol e. 
E x a m pl e s of p ot e nt C Y P [ADDRESS_208475]. J o h n’ s w ort aN o n e all o w e d wit hi n 
7d a y s b ef or e t h e fir st 
d o s e of st u d y dr u g N o n e all o w e d t hr o u g h t h e 
S af et y F oll o w -u p Vi sit 
A nti -e m eti c s or a nti -di arr h e al s All o w e d f or s y m pt o m 
m a n a g e m e nt Pr o p h yl a cti c u s e n ot 
all o w e d d uri n g C y cl e 1 of 
P art A. All o w e d if gi v e n p er 
i n stit uti o n al pr a cti c e 
(P art s B a n d C), or f or 
s y m pt o m m a n a g e m e nt 
H e m at o p o ieti c gr o wt h f a ct or s N ot all o w e d f or P art s A or 
BPr o p h yl a cti c u s e n ot 
all o w e d. T h er a p e uti c u s e 
all o w e d p er i n stit uti o n al 
pr a cti c e 
N e p hr ot o xi c m e di c ati o n s P art B 1 o nl y: N o n e 
all o w e d wit hi n [ADDRESS_208476] u g N o n e all o w e d t hr o u g h t h e 
S af et y F oll o w -u p Vi sit 
( e x c e pt a s s p e cifi e d i n 
S e cti o n 6. 6 )
Pr ot o n - P u m p I n hi bit or s 
E x a m pl e s of pr ot o n - p u m p i n hi bit or s i n cl u d e 
o m e pr a z ol e ( Pril o s e c ®, O m e s e c Z e g eri d ®), 
l a n s o pr a z ol e ( Pr e v a ci d ®), e s o m e pr a z ol e 
( E s o m e pr a z ol e Str o nti u m, N e xi u m ®), p a nt o pr a z ol e 
( Pr ot o ni x ®), a n d r a b e pr a z ol e ( A ci p H e x ®) N o n e all o w e d wit hi n 
7d a y s b ef or e t h e fir st 
d o s e of st u d y dr u g N o n e all o w e d u ntil 
p er m a n e nt di s c o nti n u ati o n 
of M [ADDRESS_208477] s a n d A nt a ci d s 
E x a m pl e s of H2-r e c e pt or a nt a g o ni st s 
i n cl u d e r a niti di n e ( Z a nt a c ®), f a m oti di n e 
( P e p ci d ®), ci m eti di n e ( T a g a m et ®), a n d 
ni z ati di n e ( A xi d ®). 
E x a m pl e s of a nt a ci d s i n cl u d e 
Al k a -S elt z er ®, G el u sil, M a al o x ®, 
M yl a nt a ®, P e pt o -Bi s m ol ®, R ol ai d s ®, 
a n d T u m s ® H2-r e c e pt or a nt a g o ni st s a n d a nt a ci d s c a n b e 
t a k e n wit h o ut r e stri cti o n o n all d a y s w h e n 
M [ADDRESS_208478] er e d. 
O n all d a y s w h e n M [ADDRESS_208479] er e d bt wi c e d ail y, 
n o n e ar e all o w e d u ntil p er m a n e nt di s c o nti n u ati o n of t h e 
m e di c ati o n M 4 3 4 4, u nl e s s di s c u s s e d wit h a n d 
a p pr o v e d b y t h e M e di c al M o nit or. 
C Y P = C yt o c hr o m e P [ADDRESS_208480] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 7 / [ADDRESS_208481] er e d a s d e s cri b e d i n  T a bl e 3f or P art A,  T a bl e 4f or P art A 2 a n d t h e 1 4 d +/ [ADDRESS_208482] u g will be a d mi nistere d wit h 2 4 0 m L  ( 8fl ui d o u nces) of a m bie nt te m perat ure water. 
Partici pa nt s will a bstai n fr o m all f o o d f or at least [ADDRESS_208483] u g a d mi nistrati o n. Water ca n be c o ns u m e d as desire d. 
Restricti o ns f or c o ns u m pti o n of s pecific f o o ds a n d n o n- alc o h olic be vera ges are pr o vi de d i n 
Ta ble 1 3. 
6. 6. 3. 2 Acti vit y 
Partici pa nt s will a bstai n fr o m stre n u o us e xercise (e. g., hea v y  l ifti n g, wei g ht trai ni n g, a n d aer o bics) 
f or at least [ADDRESS_208484] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 8 / [ADDRESS_208485], a n d f oll o wi n g nati o nal a n d l ocal la ws a n d re g ulati o ns. 
T he I n vesti gat or , or a n a ut h orize d desi g nee (e. g., a lice nse d p har macist), will e ns ure t hat all 
i n vesti gati o nal pr o d uct is st ore d i n a sec ure d area, u n der rec o m me n de d st ora ge c o n diti o ns, a n d i n 
acc or da nce wit h a p plica ble re g ulat or y  r e q u ire me nts ( See  Ta ble 1 4 ). T o e ns ure a de q uate rec or ds, 
all st u d y  d r u gs will be acc o u nte d f or as detaile d i n Secti o n 6. [ADDRESS_208486] u g N a m e F or m ul ati o n/ 
R o ut e D o s a g e P a c k a gi n g St or a g e 
C o n diti o n 
M 4 3 4 4 T a bl et/ Or al 5 0 m g M 4 3 4 4  
H D P E = Hi g h d e n sit y p ol y et h yl e n e .
6. [ADDRESS_208487] u gs a n d mai nte na nce of rec or ds. 
U p o n recei pt of st u d y  dr u g, t he res p o nsi ble pers o n will c hec k f or acc urate deli ver y  a n d 
ac k n o wle d ge recei pt b y  s i g ni n g or i nitiali n g a n d dati n g t he a p pr o priate d oc u me ntati o n a n d 
ret ur ni n g it t o t he l ocati o n s pecifie d . A c o p y  will be arc hi ve d f or t he I n vesti gat or Site File 
St u d y  d r u g dis pe nsi n g will be rec or de d o n t he a p pr o priate dr u g acc o u nta bilit y  f or ms s o t hat 
acc urate rec or ds will be a vaila ble f or verificati o n at eac h m o nit ori n g visit 
St u d y site st u d y  d r u g acc o u nta bilit y  rec or ds will i ncl u de t he f oll o wi n g :
oC o nfir mati o n of st u d y  dr u g recei pt ,i n g o o d c o n diti o n a n d i n t he defi ne d te m perat ure ra n ge 
oT he i n ve nt or y  of st u d y  dr u g pr o vi de d f or t he cli nical st u d y a n d pre pare d at t he site 
oT he use of eac h d ose b y eac h partici pa nt 
oT he dis p ositi o n (i ncl u di n g ret ur n, if a p plica ble) of a n y u n use d st u d y  dr u g 
oDates, q ua ntities, batc h n u m bers, kit n u m ber , e x pir y  d ates, f or m ulati o n (f or st u d y  d r u g 
pre pare d at t he site), a n d t he i n di vi d ual partici pa nt st u d y n u m bers 
T he I n vesti gat or site s h o ul d mai ntai n rec or ds , w hic h a de q uatel y d oc u me nt t h at partici pa nt s were 
pr o vi de d t he d oses s pecifie d i n t his pr ot oc ol, a n d all st u d y  dr u gs pr o vi de d were f ull y rec o ncile d. 
D oc u me nt N o. 
O bject N o. C CI C CI 
C CI C CI 
M [ADDRESS_208488] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 9 9 / [ADDRESS_208489] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 0 / [ADDRESS_208490] u d y assess me nts t hat are n ot part of r o uti ne me dical care f or t he 
partici pa nt , t he I n vesti gat or will o btai n writte n i nf or me d c o nse nt as descri be d i n Secti o n 9. 2. T he 
ti mi n g of assess me nts are prese nte d i n Ta ble 1f or Scree ni n g, Ta ble 3f or Part A, Ta ble 4f or 
Part A 2 a n d t he 1 4 d +/ 7 d- sc he d ule of Part A 3, Ta ble 5f or A3, a n d  Ta ble 6f or Part B 1. F or Parts 
C, the ti mi n g of assess me nts are prese nte d i n  Ta ble 2f or Scree ni n g a n d  Ta ble 7a n d  Ta ble 8f or 
Parts C 1, C 2, a n d C 3 a n d t he 1 4 d +/ 7 d -h oli da y  s c he d ule descri be d i n Parts C 4. C 5, a n d C 6, a n d 
Ta ble 9a n d  Ta ble 1 0 f or Parts C 4, C 5, a n d C 6 (e xce pt t he 1 4 d +/ 7 d- sc he d ule) .
Partici pa nt s i n a n y  o f t he Parts Cca n o nl y start treat me nt o nce eli gi bilit y  h as bee n c o nfir me d base d 
o n t he prese nce of t hese l oss - of- f u ncti o n m utati o ns, w hic h are defi ne d i n Secti o n 7. 7. 5,  a n d t he 
rest of Scree ni n g assess me nts .Fi g ure 5pr o vi des a sc he matic of eli gi bilit y  assess me nts i n Parts C. 
7. 2 De m o gr a p hic a n d Ot her B aseli ne C h ar acteristics 
At S cree ni n g , t he f oll o wi n g de m o gra p hic data will be c ollecte d : date of birt h , s e x ( ge n der), race , 
et h nic it y .
7. 3 P artici p a nt a n d Dise ase C h ar acteristics 
Partici pa nt a n d disease c haracteristics i ncl u de t he f oll o wi n g: me dical hist or y, hei g ht, wei g ht, t y pe 
of ca ncer (i ncl u di n g hist ol o gic s u bt y pe), t u m o r sta ge at Scree ni n g, date of ca ncer dia g n osis, pri or 
c he m ot hera p y a n d ra diati o n t hera p y , date a n d d urati o n of m ost rece nt ca ncer t hera p y, a n d W H O 
perf or ma nce stat us at baseli ne. 
7. [ADDRESS_208491] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 1 / 1 5 9 Partici pa nt s wit h meas ura ble disease will be assesse d b y  s ta n dar d criteria ( R E CI S T 1. 1) or b y 
P C W G 2criteria ( pr ostate ca ncer) . C ha n ges i n t he lar gest dia meter ( u ni di me nsi o nal meas ure me nt) 
of t he t u m or lesi o ns a n d t he s h ortest dia meter i n t he case of mali g na nt l y m p h n o des are use d i n t he 
R E CI S T criteria. Refer t o t he R E CI S T 1. 1 p u blicati o n f or a d diti o nal i nf or mati o n (Eise n ha uer 
2 0 0 9) .
Partici pa nt s m ust ha ve a n i ma gi n g sca n (e. g., C T, M RI ) at Scree ni n g t o d oc u me nt t he e xte nt of 
i nitial disease. Partici pa nt s will ha ve a c hest a n d a b d o mi na l i ma gi n g sca n (e. g., C T, M RI ) as 
a p pr o priate a n d, if cli nicall y  i n dicate d, i ma gi n g sca ns of ot her b o d y  a reas (e. g., pel vis). F or all 
Parts , partici pa nt s s h o ul d ha ve a re peat i ma gi n g sca n as descri be d i n Ta ble 3, Ta ble 4,  Ta ble 5,  
a n d  Ta ble 6.  All i ma gi n g sca ns t o assess disease pr o gressi o n s h o ul d be perf or me d usi n g si milar 
C T platf o r ms a n d i ma gi n g tec h ni q ues, i ncl u di n g t he use or a bse nce of c o ntrast, a n d s h o ul d be of 
c o nsiste nt a nat o mic l ocati o ns wit h pri or i ma gi n g sca ns, w he ne ver p ossi ble. 
I ma gi n g sca ns will be l ocall y  r ea d f or all parts of t he st u d y . T he a p plica ble o verall res p o nse 
cate g or y  f or eac h visit t hat i ncl u des disease assess me nt, base d o n e val uati o n of i ma gi n g sca n, will 
be rec or de d i n t he e C R F. Deter mi nati o n of partici pa nt st u d y  d is p ositi o n (i.e., disc o nti n uati o n or 
e xte nsi o n of t hera p y) wil l be base d o n disease pr o gressi o n as i nter prete d fr o m t he l ocal e val uati o n 
of t he i ma gi n g sca n. C o pi[INVESTIGATOR_1309] t he i ma gi n g sca ns s h o ul d be a vaila ble f or i n de pe n de nt assess me nt 
if re q uire d. 
B o ne sca ns will be perf or me d as descri be d i n Ta ble 3, Ta ble 4, Ta ble 5, Ta ble 6, Ta ble 7, a n d 
Ta ble 9.  I n a d diti o n, partici pa nt s wit h o varia n ca ncer will ha ve ser u m C A -1 2 5 assesse d (Parts A
a n d B), a n d partici pa nt s wit h pr ostate ca ncer will ha ve ser u m P S A assesse d (Parts A a n d B) as 
descri be d i n  Ta ble 3, Ta ble 4, Ta ble 5, Ta ble 6, Ta ble 7, a n d  Ta ble 9. 
T o esti mate t he a ntit u m or acti vit y of treat me nt i n partici pa nt s wit h pr ostate ca ncer, w h o are n ot 
e val ua ble at baseli ne acc or di n g t o R E CI S T 1. 1 , res p o nse will be defi ne d o n t he basis of t he 
f oll o wi n g o utc o mes; if a n y  of t hese occ ur, partici pa nt s will be c o nsi dere d t o ha ve res p o n de d: 
P S A decli ne ≥ 5 0 % criteria ( P C W G 2 ) c o nfir me d 4 wee ks or later, a n d/ or 
C o nfir me d s oft tiss ue o bjecti ve res p o nse ( R E C I S T 1. 1) (Sc her 2 0 0 8 ).
T he P C W G 2 a n d R E CI S T criteria will be use d t o deter mi ne P S A res p o nse a n d s oft tiss ue res p o nse. 
Fail ure of treat me nt will be defi ne d as: 
Pr o gressi o n b y  R E CI S T 1. 1 (Sc her 2 0 0 8 ) a n d/ or 
Pr o gressi o n of b o ne sca n (Sc her 2 0 0 8 ).
P arts C
F or all Parts C, safet y  ( occ urre nce of treat me nt -e mer ge nt a d verse e ve nts [T E A Es ]a n d 
treat me nt -relate d A Es gra de d acc or di n g t o N CI -C T C A E ) a n d efficac y  (i.e. c o nfir me d C R or P R ) 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208492] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 2 / [ADDRESS_208493] y: 
T u m or assess me nt acc or di n g t o R E C IS T 1. [ADDRESS_208494] 6 c y cles, t he n e ver y  3 c y cles t hereafter u ntil disease pr o gressi o n or start of 
ne w a nti -ca ncer treat me nt li ne .
All t u m or assess me nts s h o ul d be ma de e ver y  t i me wit h t he sa me met h o ds ( C T or M RI) use d at t he 
baseli ne assess me nt. 
I n  P arts C, partici pa nts w h o disc o nti n ue t he st u d y  t reat me nt f or reas o ns ot her t ha n disease 
pr o gressi o n or wit h dra wal of c o nse nt will c o nti n ue t u m or assess me nts acc or di n g t o t he sa me 
sc he d ule as partici pa nts recei vi n g trial treat me nt. 
O bjecti ve res p o nse, best o ver all res p o nse, d urati o n of res p o nse a n d pr o gressi o n free s ur vi val (P F S )
will be deri ve d o n t he basis of t hese t u m or assess me nts. T he assess me nt will be perf or me d b y  t he 
In vesti gat or. Per R E CI S T 1. 1, o bjecti ve res p o nses nee d t o be c o nfir me d. C o nfir mati o n s h o ul d be 
deter mi ne d at a sca n n o less t ha n 4 wee ks after t he ori gi nal assess me nt of o bjecti ve res p o nse is 
ma de; c o nfir mati o n of res p o nse at t he ne xt sc he d ule d t u m or assess me nt is acce pta ble. 
I n de pe n de nt re vie w of t he i ma gi n g -base d t u m or assess me nts ma y  b e c o n d ucte d at t he discreti o n 
of t he S p o ns or. C o pi[INVESTIGATOR_1309] t he i ma gi n g sca ns s h o ul d be a vaila ble t o all o w f or t his. 
F or o verall s ur vi val, partici pa nt s will be f oll o we d u p f or s ur vi val e ver y  [ADDRESS_208495] u d y . T he I n vesti gat or 
will re p ort a n y  A Es, w het her o bser ve d b y  t he I n vesti gat or or re p orte d b y  t he partici pa nt (see 
Secti o n 7. 5. 1. 2 ). T h e re p orti n g peri o d f or AEs is descri be d i n Secti o n 7. 5. 1. [ADDRESS_208496] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 3 / [ADDRESS_208497], 
re gar dless of ca usal relati o ns hi p wit h t his treat me nt. T heref ore, a n A E ca n be a n y u nfa v ora ble a n d 
u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y  f i n di n g), s y m pt o m, or disease te m p orall y 
ass ociate d wit h t he use of a me dici nal pr o d uct, re gar d less if it is c o nsi dere d relate d t o t he me dici nal 
pr o d uct. 
F or s ur gical or dia g n ostic pr oce d ures, t he c o n diti o n/ill ness lea di n g t o s uc h a pr oce d ure is 
c o nsi dere d as t he A E rat her t ha n t he pr oce d ure itself. 
T he I n vesti gat or is re q uire d t o gra de t he se verit yor t o xicit y of eac h A E .
I n vesti gat ors will refere nce t he Nati o nal Ca ncer I n stit ute –C o m m o n Ter mi n ol o g y Criteria f or A E s 
( C T C A E), Versi o n 4. 0, a descri pti ve ter mi n ol o g y  t hat ca n be use d f or A E re p orti n g. 
A ge neral gra di n g (se verit y /i nte nsit y ; hereafter r e ferre d t o as se verit y) scale is pr o vi de d at t he 
be gi n ni n g of t he a b o ve refere nce d d oc u me nt, a n d s pecific e ve nt gra des are als o pr o vi de d. 
If t he se verit y  f or a n A E is n ot s pecificall y  g ra de d b y  N CI -C T C A E, t he I n vesti gat or is t o use t he 
ge neral N CI -C T C A E def i niti o ns of Gra de [ADDRESS_208498] me dical 
j u d g me nt .
T he 5 ge neral gra des are: 
Gra de 1 or Mil d 
Gra de 2 or M o derate 
Gra de 3 or Se vere 
Gra de 4 or L ife -t hreate ni n g 
Gra de [ADDRESS_208499] als o be re p orte d as a n S A E. H o we ver, a 
la b orat or y  a b n or malit y o f Gra de 4, s uc h as a ne mia or ne utr o pe nia, is c o nsi dere d seri o us o nl y  i f t he 
c o n diti o n meets o ne of t he seri o us criteria s pecifie d bel o w .
If deat h occ urs , t he pri mar y  c a use of deat h or e ve nt lea di n g t o deat h s h o ul d be rec or de d a n d 
re p orte d as a n S A E. “ Fatal” will be rec or de d as t he o utc o me of t h is s pecific e ve nt a n d deat h will 
n ot be rec or de d as se parate e ve nt. O nl y, if n o ca use of deat h ca n be re p orte d (e. g., s u d de n deat h, 
u ne x plai ne d deat h), t he deat h per se mi g ht t he n be re p orte d as a n S A E. 
I n vesti gat ors m ust als o s yste maticall y assess t he ca usal relati o ns hi p of A Es t o st u d y  dr u g (s)/st u d y 
treat me nt (i ncl u di n g a n y ot her n o n -st u d y  d r u gs , ra diati o n t hera p y , etc .) usi n g t he f oll o wi n g 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208500] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 4 / [ADDRESS_208501] u d y pr oce d ures. 
U nrel ate d: N ot reas o na bl y relate d t o t he st u d y  d r u g /st u d y  t reat me nt. A E c o ul d n ot me dicall y 
( p har mac ol o gicall y/ cli nicall y ) be attri b ute d t o t he st u d y  dr u g /st u d y  treat me nt u n der 
st u d y  i nt his cli nical st u d y pr ot oc ol. A reas o na ble alter nati ve e x pla nati o n m ust be 
a vaila ble. 
Rel ate d: Reas o na bl y relate d t o t he st u d y  d r u g /st u d y  t reat me nt. A E c o ul d me dicall y 
( p har mac ol o gicall y/ cli nicall y ) be attri b ute d t o t he st u d y  dr u g /st u d y  treat me nt u n der 
st u d y  i n t his cli nical st u d y pr ot oc ol. 
A b n or m al L a b or at or y Fi n di n gs a n d Ot her A b n or m al I n vesti g ati o n al Fi n di n gs 
A b n or mal la b orat or y fi n di n gs a n d ot her a b n or mal i n vesti gati o nal fi n di n gs ( e. g., o n a n E C G trace) 
s h o ul d n ot be re p orte d as A Es u nless t he y are ass ociate d wit h cli nical si g ns a n d s y m pt o ms, lea d t o 
treat me nt disc o nti n uati o n or are c o nsi dere d ot her wise me dicall y  i m p orta nt b y  t he I n vesti gat or . If 
ala b orat or y a b n or malit y f ulfills t hese criteria, t he i de ntifie d me dical c o n diti o n (e. g., a ne mia or 
i ncrease d A L T) m ust be re p orte d as t he A E rat her t ha n t he a b n or mal val ue itself. 
Seri o us A d verse E ve nt s
AnS A E is a n y  u nt o war d me dical occ urre nce t hat at a n y  d ose: 
Res ults i n deat h. 
Is life -t hreate ni n g. “ L ife -t hreate ni n g” refers t o a n e ve nt i n w hic h t he partici pa nt is at 
ris k of deat h at t he ti me of t he e ve nt , n ot a n e ve nt t hat h y p ot heticall y  m i g ht ha ve ca use d
deat h if it was m ore se vere. 
Re q uires i n patie nt h os pi[INVESTIGATOR_1314] o n or pr ol o n g sa n e xisti n g h o s pi[INVESTIGATOR_1314] o n. 
Res ults i n persiste nt or si g nifica nt disa bilit y or i nca pacit y. 
Is a c o n ge nital a n o mal yor birt h defect. 
Is ot her wise c o nsi dere d t o be me dicall y  i m p orta nt. I m p orta nt me dical e ve nts t hat ma y 
n ot res ult i n deat h, be life -t hreate ni n g, or re q uire h os pi[INVESTIGATOR_1314] o n ma y  b e c o nsi dere d as 
S A Es w he n, base d u p o n a p pr o priate me dical j u d g me nt, t he y  m a y  j e o par dize t he 
partici pa nt or m a y  r e q uire me dical or s ur gical i nter ve nt i o n t o pre ve nt o ne of t he 
o utc o mes liste d a b o ve . E xa m ples of s uc h e ve nts i ncl u de aller gic br o nc h os pas m 
re q uiri n g i nte nsi ve treat me nt i n a n e mer ge nc y  r o o m or at h o me, bl o o d d y scrasias or 
c o n v ulsi o ns t hat d o n ot res ult i n i n patie nt h os pi[INVESTIGATOR_1314] o n, or t he de vel o p me nt of dr u g 
de pe n de nc y  or dr u g a b use .
F or t he p ur p oses of re p orti n g, a n y s us pecte d tra ns missi o n of a n i nfecti o us a ge nt via ast u d y  d r u g 
is als o c o nsi dere d a n S A E , as descri be d i n Secti o n 7. 5. 1. [ADDRESS_208502] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 5 / [ADDRESS_208503] u d y pr oce d ures (e. g. , a n 
o ver ni g ht st a y  t o facilitate i ntra ve n o us t hera p y ) are n ot c o nsi dere d S A Es. H o we ver, all e ve nts 
lea di n g t o u n pla n ne d hos pi[INVESTIGATOR_1314] o ns or u n pla n ne d pr ol o n gati o n of a n electi ve h os pi[INVESTIGATOR_1314] o n (f or 
e xa m ple, u n desira ble effects of a n y  a d mi nistere d treat me nt) m ust be d oc u me nte d a n d re p orte d as 
S A Es. 
E ve nts N ot t o Be C o nsi dere d as A Es/ S A Es 
Me dical c o n diti o ns prese nt at t he i n itial st u d y visit t hat d o n ot w orse n i n se verit y or fre q ue nc y 
d uri n g t he st u d y are defi ne d as Baseli ne Me dical C o n diti o ns a n d are n ot t o be c o nsi dere d A Es. 
A E/ S A Es O bser ve d i n Ass oci ati o n wit h Dise ase Pr o gressi o n 
Pr o gressi o n of t he disease/ dis or der bei n g st u die d assesse d b y  m eas ure me nt of lesi o ns o n 
ra di o gra p hs or ot her met h o ds as well as ass ociate d cli nical si g ns or s y m pt o ms (i ncl u di n g 
la b orat or y  a b n or malities) s h o ul d n ot be re p orte d as a n ( S) A E, u nless t he partic i pa nt ’s ge neral 
c o n diti o n is m ore se vere t ha n e x pecte d f or t he partici pa nt’s c o n diti o n a n d/ or u nless t he o utc o me 
is fatal wit hi n t he a d verse e ve nt re p orti n g peri o d (as defi ne d i n S ecti o n 7. 5. 1. 3 ).
7. 5. 1. [ADDRESS_208504] u d y visit, t he partici pa nt will be q uerie d o n c ha n ges i n his or her c o n diti o n. D uri n g t he 
re p orti n g peri o d ,a n y u nfa v ora ble c ha n ges i n t he partici pa nt ’s c o n diti o n will be rec or de d as A Es, 
re gar dless if re p orte d b y  t he partici pa nt or o bser ve d b y  t he I n vesti gat or. 
C o m plete, acc urate a n d c o nsiste nt data o n all A Es e x perie nce d f or t he d urati o n of t he re p orti n g 
peri o d ( defi ne d bel o w) will be re p orte d o n a n o n g oi n g basis i n t he a p pr o priate secti o n of t he eC R F. 
All S A Es m ust be a d diti o nall y  d oc u me nte d a n d re p orte d usi n g t he a p pr o priate Re p ort F or m as 
descri be d i n Secti o n 7. 5. 1. 4 .
It is i m p orta nt t hat eac h A E re p ort i ncl u des a descri pti o n of t he e ve nt, its d urati o n ( o nset a n d 
res ol uti o n dates a n d als o o nset a n d res ol uti o n ti mes ), w he n it is i m p orta nt t o assess t he ti me of A E 
o nset relati ve t o t he rec or de d treat me nt a d mi nistrati o n ti me, its se verit y , its ca usal relati o ns hi p 
wi t h t he st u d y treat me nt, a n y  o t her p ote ntial ca usal fact ors, a n y treat me nt gi ve n or ot her acti o n 
ta ke n , i ncl u di n g d ose m o dificati o n or disc o nti n uati o n of t he st u d y  d r u g ,a n d its o utc o me. I n  
a d diti o n, seri o us cases s h o ul d be i de ntifie d ,a n d t he a p pr o priate seri o us ness criteria d oc u me nte d. 
If a n A E c o nstit utes a D L T t his is d oc u me nte d acc or di n gl y. 
S pecific g ui da nce ca n be f o u n d i n t he e C R F C o m pleti o n a n d M o nit ori n g C o n ve nti o ns pr o vi de d 
b y  t he S p o ns or. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208505] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 6 / [ADDRESS_208506] u d y ( date of first si g nat ure of i nf or me d c o nse nt/ date of first si g nat ure of first i nf or me d 
c o nse nt) a n d c o nti n ues u ntil t he Safet y  F oll o w -u p Visit . 
A n y S A E assesse d as relate d t o t he st u d y  dr u g m ust be rec or de d a n d re p orte d w he ne ver it occ urs, 
irres pecti ve of t he ti me ela pse d si nce t he last a d mi nistrati o n of st u d y  dr u g .
7. 5. 1. [ADDRESS_208507] 
i m me diatel y  ( wit hi n a ma xi m u m of 2 4 H O U R S after bec o mi n g a ware of t he e ve nt) i nf or m t he 
S p o ns or or its desi g nee i n writi n g .All writte n re p orts s h o ul d be tra ns mitte d usi n g t he S A E Re p ort 
F or m, w hic h m ust be c o m plete d b y  t he I n vesti gat or f oll o wi n g s pe cific c o m pleti o n i nstr ucti o ns. 
I n e xce pti o nal circ u msta nces, a n S A E ( or f oll o w - u p i nf or mati o n) m a y  b e re p orte d b y  t ele p h o ne; 
i n t hese cases, a writte n re p ort m ust be se nt i m me diatel y  t hereafter b y  f a x or e- mail. Na mes, 
a d dresses, a n d tele p h o ne a n d fa x n u m b ers f or S A E re p orti n g will be i ncl u de d i n t he st u d y -s pecific 
S A E Re p ort F or m. 
Rele va nt pa ges fr o m t he e C R F m a y  b e pr o vi de d i n parallel (f or e xa m ple, me dical hist or y , 
c o nc o mita nt dr u gs). A d diti o nal d oc u me nts ma y  b e pr o vi de d b y  t he I n vesti gat or , if a vaila bl e (f or 
e xa m ple, la b orat or y  res ults, h os pi[INVESTIGATOR_134577] p ort, a ut o ps y re p ort). I n all cases, t he i nf or mati o n pr o vi de d 
o n t he S A E Re p ort F or m m ust be c o nsiste nt wit h t he data a b o ut t he e ve nt rec or de d i n t he e C R F. 
T he I n vesti gat or m ust res p o n d t o a n y re q uest f or f oll o w- u p i nf or mati o n (e. g., a d diti o nal 
i nf or mati o n, o utc o me, fi nal e val uati o n, ot her rec or ds w here nee de d) or t o a n y  q uesti o n t he 
S p o ns or/ desi g nee m a y  h a ve o n t he A E wit hi n t he sa me ti meli nes as t h ose n ote d a b o ve f or i nitial 
re p orts. T his is necessar y  t o e ns u re pr o m pt assess me nt of t he e ve nt b y  t he S p o ns or or desi g nee a n d 
(as a p plica ble) t o all o w t he S p o ns or t o meet strict re g ulat or y  t i meli nes ass ociate d wit h e x pe dite d 
safet y re p orti n g o bli gati o ns. 
Re q uests f or f oll o w -u p will us uall y  be ma de via t he res p o nsi bl e M o nit or, alt h o u g h i n e xce pti o nal 
circ u msta nces t he Gl o bal Dr u g Safet y de part me nt ma y  c o ntact t he I n vesti gat or directl y t o o btai n 
f urt her i nf or mati o n or t o disc uss t he e ve nt. 
D ose Li miti n g T o xicities 
Eac h e ve nt meeti n g t he criteria of a D L T (see Secti o n 5. 2. 6 ) m ust be rec or de d i n t he eC R F wit hi n 
[ADDRESS_208508] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 7 / 1 5 9 7. 5. 1. 5 S afet y Re p orti n g t o He alt h A ut h orities, I n de pe n de nt Et hics 
C o m mittees/ I nstit uti o n al Re vie w B o ar ds a n d I n vesti g at or s
T he S p o ns or will se n d a p pr o priate safet y n otificati o ns t o Healt h A ut h orities i n acc or da nce wit h 
a p plica ble la ws a n d re g ulati o ns. 
T he I n vesti gat or m ust c o m pl y  w it h an y  a p plica ble site -s pecific re q uire me nts relate d t o t he 
re p orti n g of S A Es ( partic ular l y deat hs) i n v ol vi n g st u d y partici pa nt s t o t he I E C/I R B t hat a p pr o ve d 
t he st u d y .
I n acc or da nce wit h I C H G C P, t he S p o ns or/ desi g nee will i nf or m t he I n vesti gat or of “fi n di n gs t hat 
c o ul d a d versel y  a ffect t he safet y of partici pa nt s, i m pact t he c o n d uct of t he st u d y or alter t he 
I E C’s/I R B’s a p pr o val/fa v ora ble o pi [INVESTIGATOR_9384] o n t o c o nti n ue t he st u d y .” I n partic ular a n d i n li ne wit h 
res pecti ve re g ulati o ns, t he S p o ns or/ desi g nee will i nf or m t he I n vesti gat or of A Es t hat are b ot h 
seri o us a n d u ne x pecte d a n d are c o nsi dere d t o be relate d t o t he a d mi nistere d pr o d uct (“s us pecte d 
u ne x pecte d seri o us a d verse reacti o ns” or S U S A Rs). T he I n vesti gat or s h o ul d place c o pi[INVESTIGATOR_167759] y 
Re p orts i n t he I n vesti gat or Site File. Nati o nal re g ulati o ns wit h re gar d t o Safet y  R e p ort n otificati o ns 
t o I n vesti gat or s will be c o nsi dere d .
W he n s pecificall y  r e q uire d b y  r e g ulati o ns a n d g ui deli nes, t he S p o ns or/ desi g nee will pr o vi de 
a p pr o priate Safet y Re p orts directl y  t o t he c o ncer ne d lea d I E C/I R B a n d will mai ntai n rec or ds of 
t hese n otificati o ns. W he n direct re p orti n g is n ot clearl y defi ne d b y  n ati o nal or site -s pecific 
re g ulati o ns, t he I n vesti gat or will be res p o nsi ble f or pr o m ptl y  n otif y i n g t he c o ncer ne d I E C/I R B of 
a n y  S afet y Re p orts pr o vi de d b y  t he S p o ns or/ desi g nee a n d of fili n g c o pi[INVESTIGATOR_167760] d 
c orres p o n de nce i n t he I n vesti gat or Site File. 
F or st u dies c o vere d b y  t he E ur o pea n Directi ve 2 0 0 1/ 2 0/ E C, t he S p o ns or’s res p o nsi bilities 
re gar di n g t he re p orti n g of S A Es/ S U S A Rs/ Safet y  Is s ues will be carrie d o ut i n acc or da nce wit h t hat 
Directi ve a n d wit h t he relate d Detaile d G ui da nce d oc u me nts. 
7. 5. 1. [ADDRESS_208509] u d y (see Secti o n 7. 5. 1. 3 ) a n d are 
assesse d f or fi nal o utc o me at t he Safet y F oll o w - u p Visit .All S A Es o n g oi n g at t he Safet y  F oll o w - u p 
Visit m ust be m o nit ore d a n d f oll o we d u p b y  t he I n vesti gat or u ntil sta bilizati o n or u ntil t he o utc o me 
is k n o w n, u nless t he partici pa nt is d oc u me nte d as “l ost t o f oll o w -u p”. Reas o na ble atte m pts t o 
o btai n t his i nf or mati o n m ust be ma de a n d d oc u me nte d. It  i s als o t he res p o nsi bilit y  o f t he 
I n vesti gat or t o e ns ure t hat a n y  n ecessar y  a d diti o nal t hera pe utic meas ures a n d f oll o w - u p p r oce d ures 
are perf or me d. 
7. 5. [ADDRESS_208510] u d y  i nter ve nti o n b y  t he I n vesti gat or (e. g., 
res ulti n g fr o m a dr u g i nteracti o n wit h a c o ntrace pti ve met h o d) are A Es. H o we ver, all pre g na ncies 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208511] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 8 / [ADDRESS_208512] be rec or de d 
i n t he A E pa ge/secti o n of t he eC R F f or b ot h pre g na ncies i n fe male partici pa nts a n d pre g na ncies  i n 
fe male part ners of male partici pa nts. T he I n vesti gat or m ust n otif y  t he S p o ns or/ desi g nee i n a n 
e x pe dite d ma n ner of a n y pre g na nc y usi n g t he Pre g na nc y Re p ort F or m, w hic h m ust be tra ns mitte d 
b y  t he sa me pr ocess s pecifie d f or S A E re p orti n g .
I n vesti gat ors m ust acti vel y  f oll o w - u p, d oc u me nt a n d re p ort o n t he o utc o me of all t hese 
pre g na ncies, e ve n if t he partici pa nts are wit h dra w n fr o m t he st u d y .
T he I n vesti gat or m ust n otif y  t he S p o ns or/ desi g nee of t hese o utc o mes usi n g t he Pre g na nc y  Re p ort 
F or m. If a n a b n or mal o utc o me occ urs, t he S A E Re p ort F or m will be use d if t he partici pa nt s ustai ns 
a n e ve nt a n d t he Pare nt -C hil d/ Fet us A d verse E ve nt Re p ort F or m if t he c hil d/fet us s ustai ns a n 
e ve nt. A n y a b n or mal o utc o me (e. g., s p o nta ne o us a b orti o n, fetal deat h, still birt h, c o n ge nital 
a n o malies, ect o pic pre g na nc y ) m ust be re p orte d i n a n e x pe dite d ma n ner, as s pecifie d i n 
Secti o n 7. 5. 1. 3, w hile n or mal o utc o mes m ust be re p orte d wit hi n [ADDRESS_208513] u d y  i nter ve nti o n. T he S p o ns or/ desi g nee m ust be n otifie d wit h o ut dela y  a n d 
t he partici pa nt m ust be f oll o we d as i n dicate d a b o ve. 
L act ati o n 
It is u n k n o w n if M [ADDRESS_208514] d ose of M 4 3 4 4. Male 
partici pa nts treate d wit h M 4 3 4 4 are a d vise d t o use effecti ve c o ntrace pti o n a n d t o a v oi d fat heri n g 
a c hil d d uri n g a n d u p t o 3 m o nt hs after treat me nt . P artici pa nts s h o ul d be i nf or me d t hat fer tilit y 
mi g ht be i m paire d l o n g- ter m a n d ma y  o pt t o cr y o preser ve s per m or o va pri or t o treat me nt. 
Fe male partici pa nt s of c hil d beari n g p ote ntial ( defi ne d bel o w) a n d m ale partici pa nt s wit h part ners 
of c hil d beari n g p ote ntial m ust a d here t o c o ntrace pti o n g ui deli nes as descri be d bel o w. 
W o m a n of C hil d be ari n g P ote nti al 
A w o ma n is c o nsi dere d fertile f oll o wi n g me narc he a n d u ntil bec o mi n g p ost me n o pa usal u nless 
per ma ne ntl y sterile, as s pecifie d bel o w. 
If fertilit y  is u nclear (e. g., a me n orr hea i n a d olesce nts or a t hletes) a n d a me nstr ual c y cle ca n n ot be 
c o nfir me d bef ore t he first d ose of st u d y  i nter ve nti o n, c o nsi der a d diti o nal e val uati o n. 
A w o ma n of c hil d beari n g p ote ntial is n ot :
1. Pre me narc hal 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208515] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 0 9 / 1 5 9 2. A pre me n o pa usal fe male wit h 1 of t he f oll o wi n g: 
oD oc u me nte d h ys terect o m y 
oDoc u me nte d bilateral sal pi n gect o m y 
oD oc u me nte d bilateral o o p h orect o m y
D oc u me ntati o n ca n c o me fr o m t he site pers o n nel’s re vie w of t he fe male’s me dical rec or ds, 
me dical e xa mi nati o n, or me dical hist or y  i nter vie w. 
F or a fe male wit h per ma ne nt i nfertilit y  d ue t o a n alter nate me dical ca use ot her t ha n t he a b o ve, 
(e. g., m ulleria n a ge nesis, a n dr o ge n i nse nsiti vit y ), In vesti gat or discreti o n a p plies t o deter mi ne 
st u d y  e ntr y .
3. A p ost me n o pa usal fe male 
oA p ost me n o pa usal state is defi ne d as n o me nses f or 1 2 m o nt hs wit h o ut a n 
alter nati ve me dical ca use. 
A hi g h F S H le vel i n t he p ost me n o pa usal ra n ge ma y  b e use d t o c o nfir m 
a p ost me n o pa usal state i n a fe male n ot usi n g h or m o nal c o ntrace pti o n 
or h or m o nal re place me nt t hera p y  ( H R T). H o we ver, i n t he a bse nce of 
[ADDRESS_208516] be use d fr o m t he 2 8 da y s (f or fe male partici pa nts) or fr o m 
t he Scree ni n g Visit (f or male partici pa nts) bef ore first d ose of st u d y  d r u g t hr o u g h [ADDRESS_208517] u g a n d i ncl u de t he f oll o wi n g: 
I m pla nta ble pr o gest o ge n -o nl y  h or m o ne c o ntrace pti o n ass ociate d wit h i n hi biti o n of 
o v ulati o n 
I ntra uteri ne de vice (I U D) 
I ntra uter i ne h or m o ne -releasi n g s ys te m (I U S) 
Bilateral t u bal occl usi o n 
Vasect o mize d part ner: a hi g hl y e ffecti ve c o ntrace pti ve met h o d pr o vi de d t hat t he part ner 
is t he s ole se x ual part ner of a W O C B P a n d t he a bse nce of s per m has bee n c o nfir me d. 
Ot her wise, use a n a d diti o nal hi g hl y effecti ve met h o d of c o ntrace pti o n. T he 
s per mat o ge nesis c y cle is a p pr o xi matel y  9 0 da y s. 
N otes: 
C o ntrace pti ve use b y  m e n or w o me n is c o nsiste nt wit h l ocal re g ulati o ns o n t he use of 
c o ntrace pti ve met h o ds f or cli nical st u d y  partici pa nts. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208518] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 0 / 1 5 9 Hi g hl y eff ecti ve met h o ds are t h ose wit h a fail ure rate of <1 % per ye ar w he n use d 
c o nsiste ntl y  a n d c orrectl y . T y pi[INVESTIGATOR_177589] o m t h ose w he n use d 
c o nsiste ntl y  a n d c orrectl y .
If l ocall y  r e q uire d, i n acc or da nce wit h Cli nical Trial Facilitati o n Gr o u p g ui deli nes, 
acce pta ble c o ntrace pti ve met h o ds are li mite d t o t h ose w hic h i n hi bit o v ulati o n as t he 
pri mar y  m o de of acti o n. 
Peri o dic a bsti ne nce (cale n dar, s y m pt ot her mal, p ost -o v ulati o n met h o ds), wit h dra wal 
(c oit us i nterr u pt us), s per mici des o nl y , a n d lactati o n al a me n orr hea met h o d are n ot 
acce pta ble met h o ds of c o ntrace pti o n f or t his st u d y . Male c o n d o m a n d fe male c o n d o m 
ca n n ot be use d t o get her ( d ue t o ris k of fail ure wit h fricti o n). 
Male partici pa nt s m ust n ot d o nate s per m fr o m t he Scree ni n g Visit t hr o u g h [ADDRESS_208519] u g. C he mistr y a n d he mat ol o g y  testi n g will 
be perf or me d o n t he da ys  s pecifie d i n t he Sc he d ule of Assess me nts (see Ta ble 1, Ta ble 2, Ta ble 3, 
Ta ble 4, Ta ble 5,Ta ble 6, Ta ble 7, a n d  Ta ble 9).
T he list of a nal y tes f or eac h pa nel is s h o w n i n  Ta ble [ADDRESS_208520] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 1 / [ADDRESS_208521] P a nels 
S er u m C h e mi str y aH e m at ol o g y aUri n al y si s a, d 
Gl u c o s e 
Bl o o d ur e a nitr o g e n/ Ur e a b
Cr e ati ni n e 
S o di u m 
P ot a s si u m 
C al ci u m 
C hl ori d e 
M a g n e si u m 
Bi c ar b o n at e 
I n or g a ni c p h o s p h at e 
T ot al bilir u bi n 
Dir e ct bilir u bi n 
T ot al pr ot ei n 
Al b u mi n 
Cr e ati n e ki n a s e c
Al k ali n e p h o s p h at a s e 
A s p art at e a mi n otr a n sf er a s e 
Al a ni n e a mi n otr a n sf er a s e 
L a ct at e d e h y dr o g e n a s e 
Uri c a ci d c
T h yr oi d sti m ul ati n g h or m o n e cH e m o gl o bi n 
Er yt hr o c yt e s 
M e a n c or p u s c ul ar h e m o gl o bi n 
M e a n c or p u s c ul ar h e m o gl o bi n 
c o n c e ntr ati o n 
M e a n c or p u s c ul ar v ol u m e 
R eti c ul o c yt e s 
Pl at el et s 
L e u k o c yt e s 
Diff er e nti al ( a b s ol ut e a n d/ or p er c e nt e): 
E o si n o p hil s 
B a s o p hil s 
N e utr o p hil s 
L y m p h o c yt e s 
M o n o c yt e s 
C o a g ul ati o n st u di e s a, c 
A cti v at e d p arti al t hr o m b o pl a sti n ti m e 
Pr ot hr o m bi n ti m e 
Pr ot hr o m bi n ti m e I nt er n ati o n al 
N or m ali z e d R ati o L e u k o c yt e e st er a s e 
Ni trit e 
Ur o bili n o g e n 
Uri n e pr ot ei n 
p H 
Uri n e bl o o d 
S p e cifi c gr a vit y 
Uri n e k et o n e 
Uri n e bilir u bi n 
Uri n e gl u c o s e 
a L a b s will b e p erf or m e d at S cr e e ni n g ( P art s A, A 2, A 3 , a n d B 1 : T a bl e 1; P art s C 1, C 2, a n d C 3:  T a bl e 2) a n d 
at s p e cifi e d ti m e s d uri n g t h e Tr e at m e nt a n d F oll o w - u p P eri o d (T a bl e 3, T a bl e 4, T a bl e 5, T a bl e 6, T a bl e 7, a n d 
T a bl e 9).
b If bl o o d ur e a nitr o g e n c a n n ot b e c oll e ct e d, ur e a m a y b e s u b stit ut e d . 
c  Cr e ati n e ki n a s e, uri c a ci d, t h yr oi d sti m ul ati n g h or m o n e, a n d c o a g ul ati o n p ar a m et er s will o nl y b e t e st e d at 
S cr e e ni n g. T h yr oi d sti m ul ati n g h or m o n e n ot r e q uir e d f or P art A [ADDRESS_208522] oster o ne will be meas ure d at Scree ni n g a n d Safet y F oll o w -u p i n male partici pa nt s 
i n Parts A a n d B. 
Ser ol o gic t u m or mar kers, i ncl u di n g P S A or C A - 1 2 5, will be meas ure d as per t he Sc he d ule of 
Assess me nts (Ta ble 1,  Ta ble 2,  Ta ble 3,  Ta ble 4, Ta ble 5, Ta ble 6, Ta ble 7,  a n d Ta ble 9) f or 
partici pa nt s wit h rele va nt t u m ors. A d diti o nal ser ol o gic t u m or  m a y  b e c ollecte d at ti me 
p oi nts s pecifie d i n t he Sc he d ule of Assess me nts as dee me d a p pr o priate, de pe n di n g o n t he 
partici pa nt 's pri mar y  m ali g na nc y  ( e. g. , C E A f or partici pa nt swit h c ol o n ca ncer or C A [ADDRESS_208523] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 2 / 1 5 9 partici pa nt s wit h pa ncreatic ca ncer). Of n ote, ser ol o gic t u m or mar ker data sh o ul d n ot be use d f or 
R E CI S T res p o nse assess me nts or f or treat me nt decisi o ns. 
Pre g na nc y  t esti n g f or fe male partici pa nt s of c hil d beari n g p ote ntial (i ncl u des t h ose wit h t u bal 
li gati o n): 
At Scree ni n g, o n Da y 1 of C ycle 1, a n d c o nti n ui n g t hr o u g h t he Safet y F oll o w -u p Visit, 
fe male partici pa nt s of c hil d beari n g p ote ntial will be f oll o we d wit h uri ne β- h u ma n 
c h ori o nic g o na d otr o pi n ( β- h C G) testi n g a n d, w h e n t here are n o sc he d ule d st u d y  visits, 
wit h uri ne h o me pre g na nc y  test kits pr o vi de d b y  t he site; a n d 
Bi m o nt hl y  ( a p pr o xi matel y  e ver y  8 wee ks) f or 6m o nt hs f oll o wi n g t he last d ose of st u d y 
dr u g wit h a uri ne h o me pre g na nc y  test kits pr o vi de d b y t he site. 
If a ur i ne pre g na nc y  t est is p ositi ve, all st u d y  d r u g d osi n g will st o p, a n d t he pre g na nc y  w ill be 
c o nfir me d wit h a ser u m β- h C G test. If c o nfir me d, t he pre g na nc y  w ill be re p orte d, a n d t he 
partici pa nt will be per ma ne ntl y  w it h dra w n fr o m st u d y  d r u g d osi n g as disc usse d i n Secti o n 7. 5. [ADDRESS_208524] is p ositi ve, t he pr oce d ures o utli ne d i n Secti o n 7. 5. 2 will be f oll o we d. 
A d diti o nal E val uati o ns: A d diti o nal cli nical la b orat or y  e val uati o ns will be perf or me d at ot her ti mes 
if j u d ge d t o be cli nicall y a p pr o priate. 
7. 5. [ADDRESS_208525] u d y  v isits (see Ta ble 1,  Ta ble 2,  Ta ble 3,Ta ble 4,Ta ble 5, Ta ble 6,  
Ta ble 7,  a n d Ta ble 9). At ot her visits, s y m pt o m -directe d p h y sical e xa mi nati o n a n d s y m pt o m -
directe d vital si g n assess me nts ca n be perf or me d at t he discreti o n of t he I n vesti ga t or or healt hcare 
pr o vi der .
A p h y sical e xa mi nati o n will i ncl u de a re vie w of t he f oll o wi n g s y ste ms: hea d/ nec k /t h y r oi d; 
e y es/ears/ n ose/t hr oat ; res pi[INVESTIGATOR_1305] y ; car di o vasc ular; l y m p h n o des; a b d o me n; s ki n; m usc ul os keletal; 
a n d ne ur ol o gical. F or partici pa nt s i n Par ts B a n d C, a heari n g assess me nt will be perf or me d as part 
of t he p h y sical e xa mi nati o n at t he Scree ni n g Visit, o n Da y [ADDRESS_208526], a n orectal, a n d ge nital e xa mi nati o ns will be perf or me d w he n 
me dicall y i n dicate d. After Scree ni n g, a n y cli nicall y  s i g nifica nt a b n or mal fi n di n gs i n p h y sical 
e xa mi nati o ns will be re p orte d as A Es. 
Vital si g ns i ncl u de bl o o d press ure (s ys t olic a n d diast olic), te m perat ure, p ulse rate, a n d res pi[INVESTIGATOR_1313] o n 
rate. T hese will be assesse d f oll o wi n g a 5- mi n ute rest i n t he s u pi [INVESTIGATOR_050] p ositi o n. 
7. 5. 4. 2 Electr oc ar di o gr a m 
Sta n dar d 1 2- lea d E C Gs will be perf or me d usi n g a mac hi ne wit h pri nt o ut acc or di n g t o t he Sc he d ule 
of Assess me nts (Ta ble 1,  Ta ble 2,  Ta ble 3,  Ta ble 4,  Ta ble 5, Ta ble 6,  Ta ble 7,  a n d Ta ble 9). 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208527] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 3 / 1 5 9 A d diti o nal sta n dar d 1 2 -lea d E C Gs will be perf or me d at a n y ot her ti me if cli nicall y i n dicate d. T he 
perf or ma nce of all E C Gs will a d here t o t he f oll o wi n g g ui deli nes: 
T he partici pa nt will be i nstr ucte d t o rest i n t he s u pi [INVESTIGATOR_050] p ositi o n f or at least 5mi n utes 
bef ore ha vi n g a n E C G perf or me d 
If p ossi ble, t he E C G will be perf or me d bef ore a n y ot her pr oce d ures t hat ma y  a ffect heart 
rate, s uc h as bl o o d dra ws. 
T he E C G traces will be ma n uall y  r ea d at t he st u d y  s ite at t he Scree ni n g a n d Safet y F oll o w -u p 
Visits. T he E C G mac hi ne will c o m p ute t he P R, Q T, a n d Q Tc i nter vals, Q R S d urati o n, a n d heart 
rate. R R i nter vals will be calc ulate d later d uri n g a nal ys is . A pri nt o ut of t he E C G traces will be 
ma de f or safet y re vie w b y  t h e I n vesti gat or a n d mai ntai ne d wit h s o urce d oc u me ntati o n. Cli nicall y 
si g nifica nt E C G a b n or malities occ urri n g d uri n g t he st u d y  t hr o u g h t he Safet y  F oll o w -u p Visit will 
be rec or de d as A Es. 
F or partici pa nts i n Sta ges [ADDRESS_208528] oa d f or 
ce ntralize d a nal ys is will be meas ure d at t he ti mes of M 4 3 4 4 P K sa m pli n g o n Da ys 1 a n d Da y 2 of 
C y cle 1 o nl y. 
7. 6 P h ar m ac o k i netics 
7. 6. 1 Bl o o d S a m pli n g 
F or t he e val uati o n of plas ma co nce ntrati o ns of M 4 3 4 4 (a n d meta b olites as a p pr o priate) , bl o o d 
sa m ples will be c ollecte d fr o m all partici pa nt s acc or di n g t o t he Sc he d ule of Assess me nts (Ta ble 3,  
Ta ble 4,  Ta ble 5,Ta ble 6, Ta ble 7, Ta ble 8,  Ta ble 9,  a n d Ta ble 1 0 ). T hese sa m ples ma y  a ls o be 
use d f or e val uati o ns of meta b olites of M 4 3 4 4 , f or f urt her e val uati o n of t he bi oa nal y tical met h o d, 
a n d f or a nal ys es t hat pr o vi de i nf or mati o n o n t he meta b olic pat h wa y s use d b y  o r affecte d b y  
M 4 3 4 4 .
F or t he deter mi nati o n of M 4 3 4 4 (a n d meta b olites as a p pr o priate )c o nce ntrati o ns at eac h ti me p oi nt, 
a p pr o xi matel y  [ADDRESS_208529] ure or b y  a n i n d welli n g cat heter i nt o Vac utai ner ®t u bes c o ntai ni n g 
K2E D T A a ntic oa g ula nt. Detaile d P K bl o o d sa m ple c ollecti o n, pr ocessi n g, ha n dli n g, a n d st ora ge 
i nstr ucti o ns will be pr o vi de d i n t he La b orat or y  M a n ual. T he s hi p me nt a d dress a n d assa y  l a b orat or y 
c o ntact i nf or mati o n will be pr o vi de d t o t he i n vesti gati o nal site bef ore i nitiati o n of t he st u d y .
T he P K sa m pli n g sc he d ule m a y  b e m o difie d u p o n a gree me nt of t he cli nical p har mac ol o gist a n d 
I n vesti g at or s t o o pti mize t he sa m pli n g ti me f or M [ADDRESS_208530] ual ti me of d osi n g –
i ncl u di n g last pri or d ose f or pre d ose sa m ples a n d act ual P K sa m ple c ollecti o n ti mes m ust be 
d oc u me nte d at t he site a n d rec or de d o n t he e C R F .Acce pta ble wi n d o ws f or sa m pli n g ti mes are 
s h o w n i n Ta ble [ADDRESS_208531] y  t o b ot h t he fi xe d sa m pli n g ti me p oi nts, as t o t he 
b o u n daries of t he s parse sa m pli n g wi n d o ws i n Parts C.Sa m ples c ollecte d o utsi de of t hese 
acce pta ble wi n d o ws will be c o nsi dere d pr ot oc ol de viati o ns. Details of ha n dli n g t hese data will be 
s pecifie d i n t he i nte grate d a nal ys is pla n (I A P) .
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208532] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 4 / 1 5 9 T a ble 1 6 Acce pt a ble P h ar m ac o ki netic S a m pli n g Wi n d o ws 
S a m pli n g Ti m e Ti m e Fr o m S c h e d ul e d S a m pli n g All o w e d 
Pr e d o s e -1 2 0 mi n ut e s 
Fr o m 0. 5 0 u p t o ≤1 2 h o ur s aft er d o si n g ±1 5 mi n ut e s 
Fr o m > 1 2 u p t o ≤2 4 h o ur s aft er d o si n g ±6 0 mi n ut e s 
7. 6. 1. 1 P h ar m ac o k i netic S a m pli n g: P art A 
I n Part A, M 4 3 4 4 (a n d meta b olites as a p pr o priate) P K will be assesse d i n plas ma as f oll o ws: 
C y cle 1, D a y 1: 0 ( bef ore d osi n g) a n d at 0. 5, 1, 1. 5, 2, 3, 4, 8, a n d 2 4 h o urs ( D a y 2) after 
d osi n g 
C y cle 1, D a y 8: 0 ( bef ore d osi n g) a n d at 0. 5, 1, 1. 5, 2, 3, 4, 8, a n d 2 4 h o urs ( D a y 9) after 
d osi n g 
C y cle 1, Da y 1 5: 0 h o urs ( bef ore d osi n g). 
7. 6. 1. 2 P h ar m a c o k i netic S a m pli n g : P art A 2 
I n Part A 2, M 4 3 4 4 (a n d meta b olites as a p pr o priate) P K will be assesse d i n plas ma as f oll o ws: 
C y cle 1, Da y 1: 
o0h o urs ( bef ore 1st d ose) a n d at 0. 5, 1, 1. 5, 2, 3, 4, a n d 8h o urs ( bef ore 2n d 
d ose , if a p plica ble ). 
oF or partici pa nt s u n der g oi n g ti me d -t u m or bi o psies, M 4 3 4 4 P K will be 
assesse d i n plas ma as f oll o ws: C y cle 1, D a y 1: 0h o urs ( bef ore 1st d ose) a n d 
at 0. 5, 1, 1. 5, 4, 8 h o urs ( bef ore 2n d d ose , if a p plica ble ). If feasi ble, P K 
sa m ples s h o ul d als o be c ollecte d at [ADDRESS_208533] d osi n g o n Da y  1 .
oA n o pti o nal 1 2- h o ur sa m ple ( bef ore 2n d d ose , if a p plica ble )m a y  a ls o be 
c ollecte d. 
C y cle 1 Da y  2: 0 h o urs (at ti me of P B M C sa m ple bef ore D a y  2 d ose) .
C y cle 1, Da y 8: 
o0h o urs ( bef ore 1st d ose) a n d at 0. 5, 1, 1. 5, 2, 3, 4, a n d 8h o urs ( bef ore 2n d 
d ose , if a p plica ble ). A n o pti o nal 1 2- h o ur sa m ple ma y  a ls o be c ollecte d 
( bef ore 2 ndd ose, if a p plica ble). 
C y cle 1, Da y 1 5: 0 h o urs ( bef ore 1 st d osi n g), 2 h o urs . 
S u bse q ue nt c y cles o n D a y  1: 0 h o urs ( bef ore 1 st d osi n g), 2 h o urs .
7. 6. 1. 3 P h ar m ac o k i netic S a m pli n g: P art A 3 
I n Part sA 3 , M 4 3 4 4 (a n d meta b olites as a p pr o priate) P K will be assesse d i n plas ma as f oll o w s f or 
eac h of t he p ote ntial dr u g- h oli da y  sc he d ules. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208534] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 5 / 1 5 9 T a ble 1 7 P h ar m ac o ki netic S a m pli n g Sc he d ule f or P art A 3 
M 4 3 4 4 Sc he d ule P K s a m pli n g 
3 da y s o n/ 4 d a y s 
off 
Or 
5 da y s o n/ 2 d a y s 
off M 4 3 4 4 (a n d meta b olites) plas ma P K sa m ples will be c ollecte d d uri n g 
t he f oll o wi n g ti mes: 
-C y cle 1 Da y  1: pre d ose at [ADDRESS_208535] d ose at 0. 5, 1, 1. 5, 2, 3, 4 a n d 8
h o urs. A n o pti o nal sa m ple ma y  b e c ollecte d at 1 2 h o urs ( bef ore 2n d 
d ose, if BI D d osi n g). 
-C y cle 1 Da y  8: pre d ose at [ADDRESS_208536] d ose at 0. 5, 1, 1. 5, 2, 3, 4 a n d 8 
h o urs. A n o pti o nal sa m ple ma y  b e c ollecte d at 1 2 h o urs ( bef ore 2n d 
d ose, if BI D d osi n g). 
-C y cle 1 Da y  1 5: pre d o se at [ADDRESS_208537] d ose at 2 h o urs .
-S u bse q ue nt c y cles o n D a y  1 :  p re d ose at [ADDRESS_208538] d ose at 2 
h o urs 
F or partici pa nts u n der g oi n g ti me d -t u m or bi o psies, P K sa m ples o n 
C y cle 1 Da y  1 at 2 a n d 3 h o urs after d osi n g s h o ul d be c ollecte d o nl y  if 
feasi ble .
If C ycle 1, Da y 8 occ urs d uri n g a d ose i nterr u pti o n, C ycle 1, Da y  8 P K 
sa m pli n g will be c ollecte d o n C y cle 2, Da y  1 i nstea d .
7 da y s o n/ 7 d a y s 
off M 4 3 4 4 (a n d meta b olites) plas ma P K sa m ples will be c ollecte d d uri n g 
t he f oll o wi n g ti mes: 
-C y cle 1 Da y  1: pre d ose at [ADDRESS_208539] d ose at 0. 5, 1, 1. 5, 2, 3, 4 a n d 8
h o urs. A n o pti o nal sa m ple ma y  b e c ollecte d at 1 2 h o urs ( bef ore 2n d 
d ose, if BI D d osi n g). 
-C y cle 1 Da y  1 5: pre d ose at [ADDRESS_208540] d ose at 2 h o urs .
-C y cle 2D a y  1 : pre d ose at [ADDRESS_208541] d ose at 0. 5, 1, 1. 5, 2, 3, 4 a n d 8 
h o urs. A n o pti o nal sa m ple ma y  b e c ollecte d at 1 2 h o urs ( bef ore 2n d 
d ose, if BI D d osi n g). 
-S u bse q ue nt c y cles o n D a y  1 :  p re d ose at [ADDRESS_208542] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 6 / 1 5 9 1 4 da y s o n/ [ADDRESS_208543] d ose sa m ple so mitte d. 
7. 6. 1. 4 P h ar m ac o k i netic S a m pli n g: P art B 1
I n Part B 1 , f or partici pa nt s n ot u n der g oi n g ti me d -t u m or bi o psies, M 4 3 4 4 P K will be assesse d i n 
plas ma as f oll o ws: 
C y cle 1, D a y 2: 0h o urs ( bef ore d osi n g) a n d at 0. 5, 1, 1. 5, 2, 3, 4, 8, a n d 2 4 h o urs 
( Da y 3) after d osi n g 
C y cle 1, Da y 9: 0 h o urs ( bef ore d osi n g). 
I n Part B 1 , f or partici pa nt s u n der g oi n g ti me d -t u m or bi o psies, M 4 3 4 4 P K will be assesse d i n 
plas ma as f oll o ws: 
C y cle 1, D a y 2: 0h o urs ( bef ore d osi n g) a n d at 0. 5, 1, 1. 5, 4, 8, a n d 2 4 h o urs ( Da y 3) 
after d osi n g. If feasi ble, P K sa m ples s h o ul d als o be c ollecte d at 2 a n d 3 h o urs after 
d osi n g 
C y cle 1, Da y 9: 0 h o urs ( bef ore d osi n g). 
7. 6. 1. 5 P h ar m ac o k i netic S a m pli n g: P art s C 
I n Parts C 1- 3, M 4 3 4 4 (a n d meta b olites as a p pr o priate) P K will be assesse d i n plas ma usi n g s parse 
sa m pli n g d uri n g sa m ple c ollecti o n wi n d o ws as f oll o ws: 
C y cle 1, Da y 1( 3 sa m ples) : 
o0 ( bef ore d osi n g) 
obet wee n 0. [ADDRESS_208544] 1 h after t he pre vi o us sa m ple 
C y cle 1, D a y s 8 a n d 1 5: at t he start a n d e n d of t he visit, at least 1 ho urs a part ( 2 sa m ples) 
C y cle 2, Da y  1 a n d e ver y sec o n d c y cle u ntil C y cle 8, Da y  1: at t he start a n d e n d of t he 
visit, at least 1 h o ur a part ( 2 sa m ples) 
C y cle 1 2, D a y  1  a n d e ver y f o urt h c y cle: at t he start a n d e n d of t he visit, at least 1 h a part 
( 2 sa m ples) 
F or dr u g h oli da y  s c he d ules i n Parts C [ADDRESS_208545] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 7 / 1 5 9 T a ble 1 8 P h ar m ac o ki netic S a m pli n g Sc he d ule f or P arts C 4, C 5, a n d C 6 
M 4 3 4 4 Sc he d ule P K s a m pli n g 
3 da y s o n/ 4 d a y s 
off 
Or 
5 da y s o n/ 2 d a y s 
off M 4 3 4 4 (a n d meta b olites) plas ma P K sa m ples will be c ollecte d d uri n g 
t he f oll o wi n g ti mes: 
-C y cle 1 Da y  1: pre d ose at [ADDRESS_208546] d ose at 0. 5 t o 2 h o urs , a n d e n d 
of visit (at least 1 h o urs after t he pre vi o us sa m ple). 
-C y cle 1 D a y  8 : [ADDRESS_208547] 1 h o ur 
a part. 
-C y cle 1 Da y  1 5: [ADDRESS_208548] 1 h o ur 
a part. 
-E ver y  s ec o n d c y cle d uri n g C ycles 2 -8 o n Da y 1: [ADDRESS_208549] 1 h o ur a part. 
-E ver y  f o urt h c y cle fr o m C y cle 1 2 o n war ds o n Da y  1 : [ADDRESS_208550] 1 h o ur a part. 
7 da y s o n/ 7 d a y s
off M 4 3 4 4 (a n d meta b olites) plas ma P K sa m ples will be c ollecte d d uri n g 
t he f oll o wi n g ti mes: 
-C y cle 1 Da y  1: pre d ose at [ADDRESS_208551] d ose at 0. 5 t o 2 h o urs , a n d e n d 
of visit (at least 1 h o urs after t he pre vi o us sa m ple). 
-C y cle 1 Da y  1 5: [ADDRESS_208552] 1 h o ur 
a part. 
-E ver y  s ec o n d c y cle d uri n g C ycles 2 -8 o n Da y 1: [ADDRESS_208553] 1 h o ur a part. 
-E ver y  f o urt h c ycle fr o m C ycle 1 2 o n war ds o n Da y 1 : [ADDRESS_208554] 1 h o ur a part. 
1 4 da y s o n/ [ADDRESS_208555] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 8 / [ADDRESS_208556] u d y .
7. 6. 4 Bi o a n al ysis 
Plas ma sa m ples will be a nal y ze d usi n g a vali date d a nal y tical met h o d i n c o m plia nce wit h S p o ns or 
or desi g nee sta n dar d o perati n g pr oce d ures. A descri pti o n of t he assa y  a n d vali dati o n data will be 
pr o vi de d i n se parate re p orts. Uri ne sa m ples will be a nal yz e d usi n g a q ualifie d assa y . A descri pti o n 
of t he assa y  will be i ncl u de d i n a se parate re p ort. 
If re q uire d, w h ole bl o o d, plas ma, or uri ne sa m ples ma y  b e utilize d f or assa y  v ali dati o n or 
q ualificati o n a n d m a y  b e f urt her a nal yz e d t o d oc u me nt t he prese nce of circ ulati o n meta b olites 
usi n g q ualifie d researc h met h o ds. Sa m ples o btai ne d f or P K a nal ys es m a y  b e use d f or t he f ut ure 
meta b olite i de ntificati o n a n d/ or ot her e x pl orat or y  e val uati o ns. T hese data will be use d f or 
e x pl orat o r y  p ur p oses a n d ma y n ot be i ncl u de d i n t he cli nical st u d y re p ort. I n a d diti o n, P K sa m ples 
ma y  be st ore d f or f ut ure a nal ys es of pr otei n bi n di n g, ot her pr otei n relate d a nal ys es, bi oc he mistr y, 
bi o mar ker, a n d meta b olite pr ofili n g. Sa m ples will be a nal yz e d usi n g a n o nc haracterize d assa y 
( n o n vali date d).  
S u bse q ue nt a nal ys es wit h vali date d met h o ds, w hic h were first de vel o pe d i n 
parallel t o t he c o n d uct of Part A 2, will be re p orte d i n t he cli nical st u d y  re p ort .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI C CI C CI 
C CI 
M [ADDRESS_208557] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 1 9 / [ADDRESS_208558] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 0 / [ADDRESS_208559] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 1 / [ADDRESS_208560] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 2 / 1 5 9 8. 1 Se q ue nce of A n al yses 
P art s C 
A n I n de pe n de nt Data M o nit ori n g C o m mittee (I D M C )will be i m ple me nte d f oc usi n g o n t he re vie w 
of safet y  d ata after Sta ge [ADDRESS_208561] 
1c o nfir me d C R/ P R. I n  c ase n o res p o n ders are re p orte d, e nr ol lme nt will be st o p pe d o nce t he last 
partici pa nt is e nr olle d i n Sta ge 1. 
T he c ut off date of t he i nteri m a nal ys is is defi ne d b y  t he ti me p oi nt at w hic h e ver y  p artici pa nt i n 
Sta ge [ADDRESS_208562] 1 of t he f oll o wi n g criteria: 
Ha ve pr o gresse d acc or di n g t o R E CI S T 1. 1, 
Ha ve s h o w n a n o bjecti ve res p o nse, 
Ha ve st o p pe d pla n ne d o n -st u d y  t u m or assess me nt f or a n y reas o n, 
Starte d treat me nt at least [ADDRESS_208563] a ge 2 
T he (i nteri m) a nal ys is f or eac h st u d y part will be perf or me d after all partici pa nts i n Sta ge [ADDRESS_208564] 4 partici pa nts i n 
Sta ge 1 a n d 2 ha ve s h o w n a c o nfir me d C R/ P R. I n  c ase [ADDRESS_208565] 1 of t he f oll o wi n g criteria: 
Ha ve pr o gresse d acc or di n g t o R E CI S T 1. 1, 
ha ve s h o w n a n o bjecti ve res p o nse, 
St o p pe d pla n ne d o n -st u d y  t u m or assess me nt f or a n y  reas o n, 
Starte d treat me nt at least [ADDRESS_208566] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 3 / [ADDRESS_208567] 1 o f t he 
f oll o wi n g criteria: 
S h o w n a c o nfir me d Best Overall Res p o nse of P R or C R, 
Ha ve pr o gresse d acc or di n g t o R E CI S T 1. 1, 
St o p pe d pla n ne d o n -st u d y  t u m or assess me nt f or a n y  reas o n 
Starte d treat me nt at least [ADDRESS_208568] u d y . Details will be pr o vi de d i n t he 
I A P. 
T he o verall safet y pr ofile of M 4 3 4 4 will be assesse d i n ter ms of t he f oll o wi n g safet y e n d p oi nts: 
I n ci de nce of D L Ts ,
I n ci de nce of T E A Es, i ncl u di n g A Es lea di n g t o d ose m o dificati o ns or disc o nti n uati o ns ,
Cli nical la b orat or y  val ues ,
E C G o utc o mes ,
Vital si g ns .
D oc u me nt N o. 
O bject N o. C CI C CI C CI 
M [ADDRESS_208569] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 4 / [ADDRESS_208570] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 5 / 1 5 9 8. 3 R a n d o miz ati o n 
N ot a p plica ble. 
8. 4 E n d p oi nts 
8. 4 . 1 Pri m ar y E n d p oi nts 
8. 4 . 1. 1 P art A 
Safet y  p ara meters, i ncl u di n g A Es, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d BI W. 
8. 4 . 1. 2 P art sA 2 a n d A 3 
Safet y  p ara meters, i ncl u di n g A E s, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P 2 D of si n gle a ge nt M 4 3 4 4 a d mi nistere d wit h a d ose de nse sc he d ule. 
8. 4 . 1. 3 P art B 1 
Safet y  p ara meters, i ncl u di n g A E s, cli nical la b orat or y  v al ues (ser u m c he mistr y  a n d 
he mat ol o g y ), vital si g ns, a n d E C G assess me nts 
M T D a n d/ or R P 2 D of M 4 3 4 4 a d mi nistere d i n c o m bi nati o n wit h car b o plati n .
8. 4 . 1. 4 P art s C 
Occ urre n ce of :
oT E A Es a n d treat me nt -relate d A E s gra de d acc or di n g t o N CI -C T C A E 
( Versi o n 5) 
oLa b orat or y  a b n or ma lities 
oCli nicall y  si g nifica nt a b n or mal vital si g n 
oCli nicall y  si g nifica nt a b n or mal E C G 
O bjecti ve res p o nse (i.e. c o nfir me d C R or P R) acc or di n g t o R E CI S T 1. [ADDRESS_208571] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 6 / 1 5 9 8. 4 . 2 Sec o n d ar y E n d p oi nts 
8. 4 . 2. 1 P art A 
P K para meter esti mates of si n gle a ge nt M 4 3 4 4 a d mi nistere d BI W, deri ve d fr o m plas ma 
c o nce ntrati o n -ti me data 
O R a n d disease sta bilizati o n as e val uate d b y R E CI S T 1. 1. 
8. 4 . 2. 2 P art sA 2 a n d A 3 
P K para meter esti mates of si n gle a ge nt M 4 3 4 4 (a n d meta b olites as a p pr o priate) 
a d mi nistere d wit h a t wice dail y or o nce d ail y  s c he d ule , deri ve d fr o m plas ma 
c o nce ntrati o n -ti me data 
O R a n d disease sta bilizati o n as e val uate d b y R E CI S T 1. 1 
8. 4 . 2. 3 P art B 1 
P K para meter esti mates of M 4 3 4 4 a d mi nistere d i n c o m bi nati o n wit h car b o plati n 
deri ve d fr o m plas ma c o nce ntrati o n -ti me data 
O R as e val uate d b y Res p o nse Criteria E val uati o n R E CI S T 1. 1. 
8. 4 . 2. 4 P art s C 
C o nfir me d Best O verall Res p o nse (res p o nse assess me nt acc or di n g t o R E CI S T 1. 1 as 
assesse d b y t he In vesti gat or will be use d) 
D urati o n of res p o nse assesse d fr o m C R or P R u ntil pr o gressi o n of disease ( P D), deat h, 
or last t u m or assess me nt 
Pr o gressi o n -free s ur vi val 
O verall s ur vi val 
P K para mete r esti mates of M 4 3 4 4 (a n d meta b olites as a p pr o priate) i n i n di vi d ual 
partici pa nts wit h l oss - of- f u ncti o n m utati o ns .
D oc u me nt N o. 
O bject N o. C CI 
C CI 
C CI 
M [ADDRESS_208572] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 7 / [ADDRESS_208573] u g. T he safet y a nal ys is 
set will be use d f or safet y  a n al y ses. 
T he D L T E val ua ble Set 
Defi ne d as all partici pa nt s e nr olle d i n Parts A or B w h o eit her: 
E x perie nce d a D L T bef ore t he e n d of C y cle [ADDRESS_208574] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 8 / 1 5 9 Recei ve d all sc he d ule d assess me nts t hr o u g h t he e n d of C y cle 1 (i ncl u di n g D a y 1 of 
C y cle 2) a n d recei ve d d oses of M 4 3 4 4 a n d/ or car b o plati n, as s pecifie d i n Secti o n 5. 2. [ADDRESS_208575] u d y pr o hi bite d me dici ne a n d dietar y  restricti o ns (Ta ble 1 3 ).
T he F ull A nal ys is Set 
F or Parts A a n d B, t he f ull a nal y sis s et is defi ne d as all e nr olle d partici pa nt s w h o recei ve d at least 
1d ose of st u d y  dr u g, ha ve a baseli ne sca n a n d ha ve at least 1 disease assess me nt o n treat me nt. 
P art C 
T he a nal ys is p o p ulati o ns are s pecifie d bel o w. T he fi nal decisi o n t o e xcl u de partici pa nts fr o m a n y 
a nal ys is p o p ulati o n will be ma de d uri n g t he data re vie w meeti n g pri or t o data base l oc k. 
A n al y s i s S et D e s cri pti o n 
E nr oll e d All p arti ci p a nt s, w h o si g n e d i nf or m e d c o n s e nt 
F ull A n al y si s S et ( F A S) All p arti ci p a nt s, w h o r e c ei v e d at l e a st o n e d o s e of M [ADDRESS_208576] u d y . Met h o d ol o gical details (e . g., missi n g data ha n dli n g) will be pr o vi de d i n the IA P f or t his 
st u d y , w hic h will be fi nalize d bef ore cli nical data base l oc k. 
8. 5. 1 Part C
All efficac y  a nal y ses will be perf or me d o n t he f ull a nal ys is set ( F A S ). 
A nal y sis o n baseli ne c haracteristics a n d de m o gra p hics as well as t he safet y  a nal ys is will be 
perf or me d o n t he safet y  a nal y ses set ( S A F ). 
T he statistical a nal y sis of P K, a n d  data will be perf or me d o n t he res pecti ve 
a nal ys is set s. 
8. 5. 1. [ADDRESS_208577] w he n all partici pa nts are e nr olle d (f or details see Secti o n  8. 1 ), 
w hereas t he fi nal F U -a nal y sis is pla n ne d w he n all partici pa nt s ha ve c o m plete d t he st u d y .
8. 5. 1. [ADDRESS_208578] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 2 9 / 1 5 9 8. 5. 1. 3 Si g nific a nce le vel 
A n o mi nal si g nifica nce le vel of 5 % will be use d. N o a dj ust me nt f or m ulti plicit y  will be ma de. 
8. 5. 1. [ADDRESS_208579] atistics a n d c o nfi de nce i nter v als 
C o nti n u o us varia bles will be s u m marize d usi n g descri pti ve statistics, i.e. , n u m ber of partici pa nt s 
( N), mea n, me dia n, sta n dar d de viati o n, 2- si de d 9 5 % CI sw here a p pr o priate, [ADDRESS_208580] Cl o p per -Pears o n 9 5 % CI s. U nless ot her wise state d, t he calc ulati o n of pr o p orti o ns will be 
base d o n t he sa m ple size of t he a nal y sis set of i nterest. C o u nts of missi n g o bser vati o ns will be 
i n cl u de d i n t he de n o mi nat or a n d prese nte d as a se parate cate g or y .
8. 5. 1. [ADDRESS_208581] or 
ce nter will n ot be c o nsi dere d i n statistica l m o dels or f or s u b gr o u p a nal ys es beca use of t he hi g h 
n u m ber of partici pati n g ce nters a n d t he a ntici pate d s mall n u m ber of partici pa nt s e nr olle d at eac h 
ce nter. 
N o f urt her a nal ys es are pla n ne d. 
8. 5. 2 Ge ner al C o nsi der ati o ns 
F or all parts, c o nti n u o us data wil l be s u m marize d b y  d ose a n d visit usi n g t he f oll o wi n g descri pti ve 
s u m mar y  s tatistics: t he n u m ber of o bser vati o ns ( n), mea n, S D, sta n dar d err or ( S E), me dia n, 
mi ni m u m val ue, a n d ma xi m u m val ue. Cate g orical data will be s u m marize d usi n g c o u nts a n d 
perce nta ges. All partici pa nt data, i ncl u di n g t h ose deri ve d, will be prese nte d i n t he partici pa nt data 
listi n gs; listi n gs will dis pla y  a ll partici pa nt s w h o were e nr olle d, re gar dless of w het her or n ot t he y  
recei ve d t he st u d y dr u g. 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208582] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 0 / 1 5 9 8. 5. 3 B ac k gr o u n d C h ar acteristics 
8. 5. 3. 1 P artici p a nt Dis p ositi o n 
T he n u m ber a n d perce nta ge of partici pa nt s i n eac h dis p ositi o n cate g or y  ( e. g., ra n d o mize d, 
i ncl u de d i n safet y a nal ys is set, D L T Eval ua ble Set, f ull a nal ys is set, c o m pleti n g treat me nt peri o d, 
c o m pleti n g t he [ADDRESS_208583] u d y  [ wit h a brea k d o w n of t he 
reas o ns f or disc o nti n uati o n]) will be s u m marize d b y  d ose gr o u p. 
8. 5. 3. [ADDRESS_208584] u g Dicti o nar y 
( W H O -D D E) f or t he f ull a nal ys is set fre q ue nc y  ta bles i n 2 parts :
Pri or me dicati o n: m e dicati o n t hat starte d bef ore t he first d ose of st u d y  dr u g, re gar dless 
of w he n d osi n g of t he me dicati o n e n de d 
C o nc o mita nt me dicati o n: me dicati o n recei ve d at or after t he first d ose of st u d y dr u g, or 
me dicati o n t hat was recei ve d bef ore i nitial d osi n g a n d c o nti n ue d after i nitial d osi n g of 
st u d y  dr u g, or wit h missi n g st o p date. 
Me dicati o n t hat starte d bef ore t he first d ose of st u d y  d r u g a n d c o nti n ue d after t he first d ose of 
st u d y  d r u g will be s u m marize d as pri or me dicati o n a n d se paratel y as c o nc o mita nt me dicati o n. 
Me dicati o ns wit h a missi n g start date will be c o nsi dere d t o ha ve a start date bef ore t he first d ose 
of st u d y  dr u g. 
8. 5. 3. [ADDRESS_208585] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 1 / [ADDRESS_208586] u d y  p art. F or eac h pr o p orti o n, a 9 0 % c o nfi de nce i nter val will be pr o vi de d 
usi n g t he e xact met h o d. 
O bjecti ve res p o nse b y visit: C R or P R de m o nstrate d b y  visit 
Disease c o ntr ol rate b y visit: C R , or P R , or sta ble disease de m o nstrate d b y visit 
Best o verall res p o nse: C R or P R de m o nstrate d at a n y ti me after i nitiati o n of treat me nt. 
T u m or re s p o nse will als o be de pi[INVESTIGATOR_21043] d via waterfall pl ots. Ti me t o e ve nt e n d p oi nts s uc h as 
pr o gressi o n -free s ur vi val (P F S )a n d res p o nse d urati o n will be esti mate d usi n g t he Ka pla n -Meier 
met h o d if t he n u m ber of e ve nts is a de q uate. 
8. 5. [ADDRESS_208587] u d y  t reat me nt t o P D or deat h 
(i n case P D is n ot o bser ve d pri or t o deat h). Deat h is o nl y ta ke n i nt o acc o u nt, if o bser ve d wit hi n 
2c o nsec uti ve misse d pla n ne d t u m or assess me nts. after t he last t u m or assess me nt s h o wi n g C R, P R, 
or S D. 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208588] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 2 / [ADDRESS_208589] ati sti c al A n al y si s M et h o d s 
Pri m ar y: 
O bj e cti v e 
r e s p o n s e O bj e cti v e r e s p o n s e r at e, i n cl. 9 5 % 2- si d e d Cl o p p er -P e ar s o n 
C o nfi d e n c e i nt er v al 
S e c o n d ar y 
B O R C o u nt a n d p er c e nt a g e p er B O R c at e g or y 
D o R 
P F S 
O v er all 
s ur vi v al K a pl a n -M ei er pl ot 
K a pl a n -M ei er e sti m at e s a n d c orr e s p o n di n g st ati sti c s 
N o a dj ust me nt f or m ulti plicit y  will be ma de. 
Selecte d s u b gr o u p a nal ys es will be perf or me d per i n dicati o n wit h eac h st u d y  part. 
Sec o n dar y  efficac y  e n d p oi nts will be a nal y ze d descri pti vel y  o nl y. 
Details of all a nal ys is will be pr o vi de d i n t he I A P .
8. 5. [ADDRESS_208590] u d y  p arts 
(a n d/ or a d diti o nal f ut ure st u dies) i n a p o p ulati o n P K a nal y sis t o de vel o p a p o p ulati o n P K m o del 
f or M [ADDRESS_208591] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 3 / 1 5 9 F urt her details of t he P K a nal y ses f or M 4 3 4 4 i n Parts A, A 2, A 3, B 1, a n d Cwill be pr o vi de d i n 
t he I A P .
8. 5. 6. 3 E x p os ure -Q Tc A n al yses 
Ti me matc he d P K a n d E C G sa m ples fr o m Parts A, A 2, A 3, a n d C will be use d t o assess t he 
relati o ns hi p bet wee n c o nce ntrati o n of M 4 3 4 4 (a n d meta b olites, if a p plica ble) a n d Q T/ Q Tc 
i nter val. T he relati o ns hi p(s) will be e x pl ore d gra p hicall y i nitiall y  a n d m a y  b e f urt her e x pl ore d 
mat he maticall y . F urt her details will be pr o vi de d i n t he I A P. 
8. 5. 7 A n al ysis of S afet y a n d Ot her E n d p oi nts 
8. 5. 7. 1 S afet y i n P art sA a n d B 1
T he o verall safet y pr ofile of M 4 3 4 4 will be assesse d i n ter ms of t he f oll o wi n g pri mar y  ( safet y ) 
e n d p oi nts: 
I n ci de nce of treat me nt -e mer ge nt A Es (i ncl u di n g A Es lea di n g t o d ose m o dificati o ns or 
disc o nti n uati o ns) 
I n ci de nce of D L Ts ( Parts A, B 1) 
Cli nical la b orat or y  v al ues (i ncl u di n g ser u m c he mistr y , he mat ol o g y , a n d c oa g ulati o n 
st u dies) 
E C G o utc o mes 
Vital si g ns 
Safet y  data will b e s u m marize d b y  treat me nt gr o u p a n d st u d y  part, a n d o verall. 
I n  ge neral, safet y a nal ys es will be base d o n t he safet y  a nal ys is set. T he s u m mar y  of D L Ts will be 
base d o n t he D L T e val ua ble set. 
D oc u me nt N o. 
O bject N o. C CI 
C CI C CI C CI 
M [ADDRESS_208592] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 4 / 1 5 9 All safet y data will be prese nte d i n i n di vi d ual partici pa nt data listi n gs. 
A d verse e ve nts will be c o de d acc or di n g t o Me dical Dicti o nar y  f or Re g ulat or y  A cti vities 
(Me d D R A ). T he n u m ber a n d perce nta ge of partici pa nt s e x perie nci n g a n A E will be s u m marize d 
b y  t he Me d D R A S y ste m Or ga n Class a n d Preferre d Ter m, as well as b y  d ose gr o u p, c o nc urre nt 
re gi me n a n d st u d y p art, a n d o verall. A Es will be classifie d as pretreat me nt or treat me nt -e mer ge nt. 
Pretre at me nt A Es are defi ne d as A Es t hat were re p orte d or w orse ne d after si g ni n g t he I C Fu p t o 
start of st u d y  dr u g d osi n g. 
Tre at me nt -e me r ge nt a d verse e ve nts ( T E A Es) are defi ne d as A Es t hat were re p orte d or w orse ne d 
o n or after start of st u d y dr u g d osi n g t hr o u g h t he Safet y  F oll o w -u p Visit. 
O nl y  T E A Es will be s u m marize d i n ta bles. All s u m maries of T E A Es will be prese nte d b y  t he 
se verit y of the A E a n d relati o ns hi p t o t he st u d y  d r u g. S o me r ules t hat will a p pl y t o t he 
s u m marizati o n of A Es are ( 1) a partici pa nt wit h m ulti ple occ urre nces of t he sa me A E or c o nti n ui n g 
A Es will o nl y  b e c o u nte d o nce; ( 2) o nl y  t he ma xi m u m se verit y  l e vel will be prese nt e d i n t he 
se verit y s u m mar y ; a n d ( 3) o nl y  t he w orst relati o ns hi p le vel will be prese nte d i n t he relati o ns hi p 
s u m mar y . Treat me nt e mer ge nt a d verse e ve nts lea di n g t o st u d y  d r u g d ose m o dificati o n or 
per ma ne nt disc o nti n uati o n will be s u m marize d. 
A Es lea di n g t o deat h, S A Es, d ose i nterr u pti o n of st u d y  d r u g, or per ma ne nt disc o nti n uati o n of st u d y  
dr u g, a n d S A Es will be liste d se paratel y. Pretreat me nt A Es a n d T E A Es will be liste d i n i n di vi d ual 
partici pa nt data listi n gs. U nres ol ve d, o n g oi n g A Es re p orte d t hr o u g h t he 1 4- D a y Safet y  F oll o w -u p 
will be liste d se paratel y i n a n i n di vi d ual partici pa nt data listi n g. 
8. 5. 7. 2 S afet y i n P art sA 2 a n d A 3 
A nal y ses t o deci de o n d ose escalati o n will be base d o n safet y a n d preli mi nar y  P K/ P d data as 
a vaila ble. 
F or t he l o west d ose le vel , t he st o p pi n g criteria are base d o n t he p osteri or pr o ba bilit y  t hat t he tr ue 
M T D is greater t ha n t he tar get pr o ba bilit y . If t his p osteri or pr o ba bilit y  i s 9 0 % or hi g her f or t he 
l o west d ose le vel t he d ose escalati o n will be st o p pe d. 
I n  c ase t he p osteri or pr o ba bilit y t hat t he tr ue M T D is greater t ha n t he tar get pr o ba bilit y f or t he 
c urre nt d ose le vel is at least 9 5 %, the c urre nt d ose le vel a n d all hi g her d oses will be eli mi nate d 
fr o m t he set of pla n ne d d ose le vels , i.e. t hese d ose le vels ca n n ot be c h ose n f or a n y  f urt her c o h ort .
D oc u me nt N o. 
O bject N o. C CI C CI C CI 
M [ADDRESS_208593] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 5 / 1 5 9 After t he c o m pleti o n of t he d ose escalati o n, t he M T D will be deter mi ne d base d o n is ot o nic 
re gressi o n (Li u a n d Y ua n, 2 0 1 5 ).
A nal y ses f or t he B OI N m o del will be perf or me d o n t he D L T E val ua ble Set . 
8. 5. 7. [ADDRESS_208594] a vaila ble versi o n of t he Me d D R A. Se verit y 
of A Es will be gra de d b y  t he I n vesti gat or usi n g t he N CI -C T C A E ( Versi o n 5) t o xicit y  g ra des. 
A d verse e ve nts relate d t o trial me dicati o n will be defi ne d as a n y A E c o nsi dere d as relate d t o 
M [ADDRESS_208595] u d y i nter ve nti o n will be c o nsi dere d relate d t o t he trial 
treat me nt. 
A n y  treat me nt - e mer ge nt A Es will be s u m marize d, i .e. t h ose e ve nts t hat :
are e mer ge nt d uri n g o n- treat me nt peri o d ha vi n g bee n a bse nt pretreat me nt or 
w orse n relati ve t o t he pretreat me nt state a n d wit h o nset dates occ urri n g i n t h e o n- 
treat me nt peri o d .
F or la b orat or y  v al ues, vital si g ns a n d ot her safet y  p ara meter o nl y t he baseli ne val ue a n d val ues 
d uri n g t he o n -treat me nt peri o d will be s u m marize d. 
L a b or a t or y v ari a bles 
La b orat or y  res ults will be classifie d b y  gra de acc or di n g t o N CI -C T C A E v 5. 0. 
Res ults f or varia bles t hat are n ot part of N CI- C T C A E will be prese nte d as bel o w, wit hi n, or 
a b o ve n or mal li mits. 
E n d p oi nt St ati sti c al A n al y si s M et h o d s 
T E A Es 
S A E 
Relate d T E A Es 
Relate d S A Es 
T E A E of Gra de ≥ 3 
Relate d T E A E of Gra de ≥ 3 
T E A Es lea di n g t o treat me nt 
i nterr u pti o ns or m o dificati o ns I n ci de nce of T E A E o verall a n d b y  S O C a n d 
P T 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208596] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 6 / 1 5 9 T E A Es lea di n g t o per ma ne nt 
treat me nt disc o nti n uati o n 
T E A Es lea di n g t o deat hs 
A E SI s. 
Deat h C o u nt a n d perce nta ge of deat hs o verall a n d 
b y  pri mar y  reas o n of deat h 
Deat hs after start of treat me nt 
Deat hs wit hi n [ADDRESS_208597] d ose 
of trial i nter ve nti o n 
Deat hs wit hi n [ADDRESS_208598] 
d ose of trial i nter ve nti o n 
La b orat or y  varia bles Para meter wit h C T C gra di n g: S u m mar y 
statistics 
W orst o n -treat me nt gra de 
S hifts fr o m baseli ne t o w orst o n- 
treat me nt 
B o x -pl ot ( L a b orat or y  val ues o ver ti me) 
Vital si g ns S u m mar y  statistics 
Hi g hest i ncrease fr o m baseli ne 
Hi g hest decrease fr o m baseli ne 
S hifts fr o m baseli ne t o hi g hest i ncrease 
o n- treat me nt 
S hifts fr o m baseli ne t o hi g hest decrease 
o n- treat me nt 
8. [ADDRESS_208599] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 7 / [ADDRESS_208600] u d y  part f or 
eac h sc he d ule d visit will be pr o vi de d f or t he f oll o wi n g E C G para meters: P R, Q T, Q R S, a n d Q Tc 
i nter vals, a n d heart rate. I n  a d diti o n, t he n u m ber a n d perce nta ge of partici pa nt s b y  m a xi m u m 
o n- treat me nt val ue of Q T/ Q Tc i nter vals, cate g orize d as ≤4 5 0 msec, > 4 5 0 msec a n d ≤ 4 8 0 msec, 
> 4 8 0 msec a n d ≤ 5 0 0 msec, a n d > 5 0 0 msec, as well as ma xi m u m o n- treat me nt c ha n ge fr o m 
baseli ne val ue of Q T/ Q Tc i nter vals, cate g orize d as ≤3 0 msec, > 3 0 msec a n d ≤ 6 0 msec, a n d 
> [ADDRESS_208601] u d y  p art, a n d 
o verall f or eac h sc he d ule d visit will be pr o vi de d f or t he f oll o wi n g vital si g n para meters: s y st olic 
a n d diast olic bl o o d press ure ( m m H g), b o d y  t e m perat ure, p ulse ra te ( b p m), a n d res pi[INVESTIGATOR_1305] y  r ate 
( breat hs per mi n ute). Cli nicall y  s i g nifica nt a b n or mal fi n di n gs i n vital si g ns will be re p orte d as 
A Es. 
8. [ADDRESS_208602] u d y .
Acc or di n g t o U nite d States C o de of Fe deral Re g ulati o ns Part 5 4. 2 (e), f or st u die s c o n d ucte d i n a n y 
c o u ntr y  t hat c o ul d res ult i n a pr o d uct s u b missi o n t o t he U nite d States F o o d a n d Dr u g 
A d mi nistrati o n f or mar keti n g a p pr o val a n d c o ul d c o ntri b ute si g nifica ntl y  t o t he de m o nstrati o n of 
efficac y  a n d safet y  of a st u d y  dr u g ( w hic h are c o nsi dere d “c o vere d cli nical st u die s” b y  t he F D A), 
t he I n vesti gat or a n d all s u b -I n vesti gat ors are o bli ge d t o discl ose a n y fi na ncial i nterest w hic h t he y, 
t heir s p o uses or t heir de pe n de nt c hil dre n ma y  ha ve i n t he S p o ns or or t he S p o ns or’s pr o d uct u n der 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208603] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 8 / [ADDRESS_208604] t heref ore be gi ve n t o t he partici pa nt b y  t he I n vesti gat or or a n 
a p pr o priate desi g nee (if l ocal re g ulati o ns per mit) bef ore i nf or me d c o nse nt is o btai ne d. 
A partici pa nt i nf or mati o n s heet m ust be pre pare d i n t he l ocal la n g ua ge i n acc or da nce wit h I C H
G C P a n d will be pr o vi de d b y  t he S p o ns or f or t he p ur p ose of o btai ni n g i nf or me d c o nse nt. I n  
a d diti o n t o pr o vi di n g t his writte n i nf or mati o n t o a p ote ntial partici pa nt , t he I n vesti gat or or a 
desi g nate will i nf or m t he partici pa nt ver ball y of all perti ne nt as pects of t he st u d y , usi n g la n g ua ge 
c h ose n s o t hat t he i nf or mati o n ca n be f ull y  a n d rea dil y  u n derst o o d b y  l a y pers o ns. T he partici pa nt 
will be gi ve n s ufficie nt ti me t o rea d t he i nf or mati o n a n d t he o p p ort u nit y  t o as k q uesti o ns a n d t o 
re q uest a d diti o nal i nf or mati o n a n d clarificati o n. 
If per mitte d b y  n ati o nal re g ulati o ns, a pers o n ot her t ha n t he I n vesti gat or ma y i nf or m t he partici pa nt 
a b o ut t he st u d y a n d si g n t he I C F, as a b o ve. 
After t he i nf or mati o n is pr o vi de d b y  t he I n vesti gat or , t he I nf or me d C o nse nt F or m m ust be si g ne d 
a n d date d b y t he partici pa nt a n d t he I n vesti gat or . 
T he si g ne d a n d date d declarati o n of i nf or me d c o nse nt will re mai n at t he I n vesti gat or ’s site, a n d 
m ust be safel y arc hi ve d s o t hat t he f or ms ca n be retrie ve d at a n y t i me f or m o nit ori n g, a u diti n g a n d 
i ns pecti o n p ur p oses. A c o p y  o f t he si g ne d a n d date d i nf or mati o n a n d I C F s h o ul d be pr o vi de d t o 
t he partici pa nt pri or t o partici pati o n. 
W he ne ver i m p orta nt ne w i nf or mati o n bec o mes a vaila ble t hat ma y  b e rele va nt t o i nf or me d c o nse nt, 
t he I n vesti gat or will re vise t he partici pa nt i nf or mati o n s heet a n d a n y  o t her writte n i nf or mati o n t o 
be pr o vi de d t o t he partici pa nt s a n d s u b mit t he m t o t he I R B f or re vie w a n d o pi [INVESTIGATOR_9384] o n. Usi n g t he 
a p pr o ve d re vise d partici pa nt i nf or mati o n s heet a n d ot her writte n i nf or mati o n, T he I n vesti gat or will 
e x plai n t he c ha n ges t o t he pre vi o us versi o n t o eac h st u d y partici pa nt a n d o btai n ne w writte n 
c o nse nt f or c o nti n ue d partici pati o n i n t he st u d y . T he partici pa nt will be gi ve n s ufficie nt ti me t o 
rea d t he i nf or mati o n a n d t he o p p ort u nit y  t o as k q uesti o ns a n d t o re q uest a d diti o nal i nf or mati o n 
a n d clarificati o n a b o ut t he c ha n ges. 
9. 3 P artici p a nt I de ntific ati o n a n d Pri v ac y 
A u ni q ue n u m ber will be assi g ne d t o eac h partici pa nt , i m me diatel y  a fter i nf or me d c o nse nt has 
bee n o btai ne d. T his n u m ber will ser ve as t he partici pa nt ’s i de ntifier i n t he st u d y as well as i n t he 
cli nical st u d y data base. If a partici pa nt is scree n fail ure a n d is re -scree ne d or c o nse nts f or 
partici pati o n i n a differe nt part of t he st u d y , t hat partici pa nt will be assi g ne d a ne w u ni q ue n u m ber. 
Al lpartici pa nt data c ollecte d i n t he st u d y will be st ore d u n der t h e a p pr o priate partici pa nt n u m ber. 
O nl y  t he I n vesti gat or will be a ble t o li n k st u d y data t o a n i n di vi d ual partici pa nt via a n i de ntificati o n 
list ke pt at t he site. F or eac h partici pa nt , ori gi na l me dical data will be accessi ble f or t he p ur p oses 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208605] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 3 9 / [ADDRESS_208606] u d y c o m pleti o n. D uri n g t his ti me, t he sa m ples ma y be rea nal yz e d f or ne wl y  i de ntifie d  
or wit h ne w or i m pr o ve d tec h n ol o g y. After 1 0 ye ars, t he sa m ples wil l be destr o ye d or f ull y 
a n o n y mize d or a ne w I E C/I R B a p pr o val a n d i nf or me d c o nse nt will be re q ueste d t o kee p t he 
sa m ples f or a n a d diti o nal peri o d. If t u m or tiss ue re mai ns, t he site will be n otifie d, a n d t he t u m or 
tiss ue will be ret ur ne d t o t he site u p o n re q uest. If t he site d oes n ot re q uest t he ret ur n of t he t u m or 
tiss ue, it will be destr o y e d. 
9. [ADDRESS_208607] u d y a n d t o gi ve healt h care pr o vi ders access 
t o a n y i nf or mati o n a b o ut t his partici pati o n t hat ma y  be nee de d t o deter mi ne t he c o u rse of me dical 
treat me nt f or t he partici pa nt .T he i nf or mati o n pr o vi de d o n t he E mer ge nc y Me dical S u p p ort car d 
ma y  i ncl u de t he p r ocess f or e mer ge nc y  u n bli n di n g (if a p plica ble) .
T he first p oi nt of c o ntact f or all e mer ge ncies will be t he cli nical st u d y I n vesti gat or cari n g f or t he 
affecte d partici pa nt . T he I n vesti gat or a grees t o pr o vi de his or her e mer ge nc y  c o ntact i nf or mati o n 
o n t he car d f or t his p ur p ose. If t he I n vesti gat or is a vaila ble w he n a n e ve nt occ urs, t he y will a ns wer 
a n y  q uesti o ns. A n y  s u bse q ue nt acti o n (f or e xa m ple, u n bli n di n g) will f oll o w t he sta n dar d pr ocess 
esta blis he d f or I n vesti gat or s. 
I n  c ases w here t he I n vesti gat or is n ot a vaila ble, t he P hase I facilit y will pr o vi de t he a p pr o priate 
mea ns t o c o ntact a p h y sicia n. T his i ncl u des t he pr o visi o n of a [ADDRESS_208608] u d y pr ot oc ol will be s u b mitte d 
t o get her wit h its ass ociate d d oc u me nts (pr ot oc ol, I n vesti gat or 's  B r oc h ure, sa m ple I C F, 
a d vertise me nts [if a p plica ble], writte n i nf or mati o n gi ve n t o t he partici pa nt s [i ncl u di n g diar y  c ar ds], 
safet y u p dates, a n n ual pr o gress re p orts, a n d a n y re visi o ns t o t hese d oc u me nts )t o t he res p o nsi ble 
D oc u me nt N o. 
O bject N o. C CI 
C CI C CI C CI 
C CI 
M [ADDRESS_208609] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 0 / 1 5 9 I n de pe n de nt Et hics C o m mittee (I E C) or I nstit uti o nal Re vie w B oar d (I R B )f or its fa v ora ble o pi [INVESTIGATOR_9384] o n 
or a p pr o val , w hic h will be file d i n t he I n vesti gat or Site File . A c o p y will be file d i n t he S p o ns or 
Trial Master File at t he S p o ns or. 
T he I E C or I R B will be as ke d t o d oc u me nt t he date of t he meeti n g at w hic h t he fa v ora ble o pi [INVESTIGATOR_9384] o n 
or a p pr o val was gi ve n a n d t he me m bers a n d v oti n g me m bers prese nt. Writte n e vi de nce of 
fa v ora ble o pi [INVESTIGATOR_9384] o n or a p pr o val t hat clearl y i de ntifies t he st u d y , t h e cli nical st u d y pr ot oc ol versi o n 
a n d t he Partici pa nt I nf or mati o n a n d I C Fversi o n re vie we d s h o ul d be pr o vi de d. W here p ossi ble, 
c o pi[INVESTIGATOR_1309] t he meeti n g mi n utes s h o ul d be o btai ne d. 
A me n d me nts t o t h is cli nical st u d y pr ot oc ol will als o be s u b mitte d t o t he c o ncer ne d I E C or I R B, 
bef ore i m ple me ntati o n of s u bsta ntial c ha n ges (see Secti o n 1 0. 5 ). Rele va nt safet y i nf or mati o n will 
be s u b mitte d t o t he I E Cor I R B d uri n g t he c o urse of t he st u d y i n acc or da nce wit h nati o nal 
re g ulati o ns a n d re q uire me nts. 
9. [ADDRESS_208610] u d y pr ot oc ol a n d a n y a p p lica ble d oc u me ntati o n (f or e xa m ple, I n vesti gati o nal 
Me dici nal Pr o d uct D ossier, Partici pa nt I n f or mati o n a n d I C F) will be s u b mitte d or n otifie d t o t he 
Healt h A ut h orities i n acc or da nce wit h all l ocal a n d nati o nal re g ulati o ns f or eac h site .
[ADDRESS_208611] e ns ure t hat t he e C R Fs a n d a n y ot her ass ociate d d oc u me nts 
f or war de d t o S p o ns or or its desi g nate d or ga nizat i o n c o ntai n n o me nti o n of a n y partici pa nt na mes. 
T he data will be e ntere d i nt o a vali date d data base. T he Sp o ns or or its desi g nee will be res p o nsi ble 
f or data pr ocessi n g, i n acc or da nce wit h t he S p o ns or’s data ma na ge me nt pr oce d ures. Data base l oc k 
will occ ur o nce q ualit y c o ntr ol a n d q ualit y  a ss ura nce pr oce d ures ha ve bee n c o m plete d. P D F files 
of t he e C R Fs will be pr o vi de d t o t he I n vesti gat or s at t he c o m pleti o n of t he st u d y .
[ADDRESS_208612] kee p a file ( me dical file, ori gi nal me dical rec or ds) o n pa per or electr o nicall y 
f or e ver y  partici pa nt i n t he st u d y . It m ust be p ossi ble t o i de ntif y  e ac h partici pa nt b y  u si n g t his 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
M [ADDRESS_208613] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 1 / 1 5 9 partici pa nt file. T his file will c o ntai n t he de m o gra p hic a n d me dical i nf or mati o n f or t he partici pa nt 
lis te d bel o w a n d s h o ul d be as c o m plete as p ossi ble. 
Partici pa nt ’s f ull na me, date of birt h, se x, hei g ht , w ei g ht 
Me dical hist or y  a n d c o nc o mita nt diseases 
Pri or a n d c o nc o mita nt t hera pi[INVESTIGATOR_014] (i ncl u di n g c ha n ges d uri n g t he st u d y )
St u d y  i de ntificati o n , t hat is, t he S p o ns or st u d y n u m ber f or t his cli nical st u d y ,a n d 
partici pa nt n u m ber 
Date sf or e ntr y i nt o t he st u d y (i nf or me d c o nse nt) a n d visits t o t he site 
A n y  m e dical e xa mi nati o ns a n d cli nical fi n di n gs pre defi ne d i n t his cli nical st u d y 
pr ot oc ol 
All A E s
Date t hat t he partici pa nt left t he st u d y i ncl u di n g a n y reas o n f or earl y wit h dra wal fr o m 
t he st u d y or st u d y  dr u g (if a p plica ble ). 
All d oc u me nts c o ntai ni n g s o urce data m ust be file d , i n cl u di n g , b ut n ot li mite d t o C T or M RI  sca n 
i ma ges, E C G rec or di n gs, a n d la b orat or y  r es ults. S uc h d oc u me nts m ust bear t he partici pa nt n u m ber 
a n d t he date of t he pr oce d ure. If p ossi ble, t his inf or mati o n s h o ul d be pri nte d b y  t he i nstr u me nt 
use d t o perf or m t he assess me nt or meas ure me nt. As necessar y , m e dical e val uati o n of s uc h rec or ds 
s h o ul d be perf or me d; all e val uati o ns s h o ul d be d oc u me nte d ,si g ne d ,a n d date d b y  t he I n vesti gat or .
Electr o nic partici pa nt files will be pri nte d w he ne ver t he M o nit or perf or ms s o urce data verificati o n. 
Pri nt o uts m ust be si g ne d a n d date d b y  t he I n vesti gat or , c o u ntersi g ne d b y  t he M o nit or a n d ke pt i n 
a safe place at t he site. Pri nti n g t he files will n ot be necessar y if t he m o nit or is per mitte d t o access 
a n d re vie w electr o nic partici pa nt files or ot her electr o nic st u d y  r ec or ds at In vesti gat or sites, 
pr o vi de d t hat t he y  are gi ve n t heir o w n u ni q ue access a n d is “ Rea d O nl y. ”
[ADDRESS_208614] 1 5 ye ars ( or l o n ger, per l ocal re q uire me nts or as ot her wise n otifie d b y  t he S p o ns or) 
after t he e n d of t he st u d y . T he d oc u me nts t o be arc hi ve d i ncl u de t he Partici pa nt I d e ntificati o n L ist 
a n d t he si g ne d partici pa nt I C Fs . If arc hi vi n g of t he I n vesti gat or Site File is n o l o n g er p ossi ble at 
t he site, t he I n vesti gat or m ust n otif y  t he S p o ns or / d esi g nee .
All ori gi nal partici pa nt files ( me dical rec or ds) m ust be st ore d at t he site ( h os pi[INVESTIGATOR_307], researc h i nstit ute, 
or practice) f or t he l o n gest p ossi ble ti me per mitte d b y  t he a p plica ble r e g ulati o ns, a n d/ or as per I C H 
G C P g ui deli nes, w hic he ver is l o n ger. I n a n y case, t he I n vesti gat or s h o ul d e ns ure t hat n o 
destr ucti o n of me dical rec or ds is perf or me d wit h o ut t he writte n a p pr o val of t he S p o ns or. 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208615] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 2 / [ADDRESS_208616] u d y pr ot oc ol will be d oc u me nte d i n writi n g . S u bsta n ti ve a me n d me nts 
will us uall y  r e q uire s u b missi o n t o t he Healt h A ut h orities a n d t o t he rele va nt I E C/I R B f or a p pr o val 
or fa v ora ble o pi [INVESTIGATOR_9384] o n. I n s uc h cases, t he a me n d me nt will be i m ple me nte d o nl y  a fter a p pr o val or 
fa v ora ble o pi [INVESTIGATOR_9384] o n has bee n o btai ne d. 
Mi n or ( n o ns u bsta ntial) pr ot oc ol a me n d me nts, i ncl u di n g a d mi nistrati ve c ha n ges, will be file d b y  
t he S p o ns or a n d at t he site. T he y  w ill be s u b mitte d t o t he rele va nt I E C/I R B or t o Healt h A ut h orities 
o nl y  w here re q ueste d b y  perti ne nt re g ulati o ns. A n y  a me n d me nt t hat c o ul d affect t he partici pa nt ’s 
a gree me nt t o partici pate i n t he st u d y re q uires a d diti o nal i nf or me d c o nse nt pri or t o i m ple me ntati o n 
f oll o wi n g t he pr ocess as descri be d i n Secti o n 9. [ADDRESS_208617] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 3 / [ADDRESS_208618] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 4 / 1 5 9 1 1 Refere nces Cite d i n t he Te xt 
A merica n Ca ncer S ociet y. Ca ncer facts a n d fi g ures 2 0 1 2. Atla nta: A merica n ca ncer s ociet y; [ADDRESS_208619] 
t u m o urs. Nat ure. 2 0 1 2; 4 9 0: [ADDRESS_208620] C haracteristics [I nter n et]. 
Ci m pric h K A, C ortez D. A T R: a n esse ntial re g ulat or of ge n o me i nte grit y. Nat ure Re vie ws 
M olec ular Cell Bi ol o g y . 2 0 0 8; 9: [ADDRESS_208621] C haracteristics [I nter net]. 
Creas y D M, F oster P M D ( 2 0 0 2). Male Re pr o d ucti ve S y ste m. I n W M Hasc he k, C G R o ussea u x, 
M A Walli g ( E ds.), Ha n d b o o k of T o xic ol o gic Pat h ol o g y ( p p. 7 8 5). Sa n Die g o, Calif or nia: Else vier 
Scie nce. 
Di n g L, Getz G, W heeler D A, et al. S o matic m utati o ns affect ke y  p at h wa y s i n l u n g 
a de n ocarci n o ma. Nat ure. 2 0 0 8; 4 5 5: 1 0 6 9- 7 5. 
Eise n ha uer E A, T herasse P, B o gaerts J, et al. Ne w res p o nse criteria i n s oli d t u m o urs: Re vise d 
R E CI S T g ui deli ne ( versi o n 1. 1). E ur o pea n J o ur nal of Ca ncer. 2 0 0 9; 4 5: 2 2 8 - 4 7. 
Ferla y  J, S hi n H R, Bra y  F, et al. Esti mates of w orl d wi de b ur de n of ca ncer i n 2 0 0 8: G L O B O C A N 
2 0 0 8. I n t J Ca ncer. 2 0 1 0; 1 2 7: 2 8 9 3 - 2 9 1 7. 
Fl y n n R L , C o x K E, Jeita n y  M , et al. Alter nati ve le n gt he ni n g of tel o meres re n ders ca ncer cells 
h y perse nsiti ve t o A T R i n hi bit ors. Scie nce. 2 0 1 5; 3 4 7( 6 2 1 9): 2 7 3- 7. 
F urt her a nal ys is of t he data i n t he Cr o w n Bi o re p ort e ntitle d “ E val uati o n of efficac y  a n d safet y  of 
Verte x’s test c o m p o u n d V Xc - [ADDRESS_208622] ca ncer xe n o graft m o del”. Re p ort K [ADDRESS_208623] C haracteristics [I nter net]. 
Gila d O, Na bet B Y, Ra gla n d R L , et al. C o m bi ni n g A T R s u p pressi o n wit h o nc o ge nic Ras 
s y ner gisticall y  i ncreases ge n o mic i nsta bilit y , ca usi n g s y nt hetic let halit y or t u m ori ge nesis i n a 
d osa ge -de pe n de nt ma n ner. Ca ncer Researc h. 2 0 1 0; 7 0: 9 6 9 3 - 7 0 2. 
Gree n ma n C, Ste p he ns P, S mit h R, et al. Patter ns of s o matic m utati o n i n h u ma n ca ncer ge n o mes. 
Nat ure. 2 0 0 7; 4 4 6: 1 5 3 - 5 8. 
Ha m m o n d E M, D orie MJ, Giaccia AJ. I n hi biti o n of A T R lea ds t o i ncrease d se nsiti vit y  t o 
h y p o xia/re o x y ge nati o n. Ca ncer Researc h. 2 0 0 4; 6 4: [ADDRESS_208624] o ma. Ne w E n gla n d J o ur nal of Me dici ne. 2 0 0 5; 3 5 2: 9 9 7- 1 0 0 3. 
H o wla der N, N o o ne A M, Kra pc h o M, et al (e ds). S E E R Ca ncer Statistics Re vie w , 1 9 7 5- 2 0 1 1, 
Nati o nal Ca ncer I nstit ute. Bet hes da, M D, htt p://seer.ca ncer. g o v/csr/ 1 9 7 5 _ 2 0 1 1/, base d o n 
N o ve m ber [ADDRESS_208625] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 5 / 1 5 9 I T R La b orat ories. V R T -1 2 2 8 6 9 2: A [ADDRESS_208626] u d y  n u m ber: V R T - [ADDRESS_208627] u d y  n u m ber: 7 2 1 7 1. 
Re p ort date: 1 5 N o ve m ber 2 0 1 3. 
I T R La b orat ories. V R T -1 2 2 8 6 9 2: A [ADDRESS_208628] u d y n u m ber: V R T -[ADDRESS_208629] u d y  n u m ber: 6 1 3 8 8. Re p ort 
date: 1 8 N o ve m ber 2 0 1 3. 
I v a n o va A. Escalati o n, gr o u p a n d A + B desi g ns f or d ose -fi n di n g trials. Statist Me d. 2 0 0 6; 2 5: 3 6 6 8 -
7 8. 
Jia n g H, Rei n har dt H C, Bart k o va J, et al. T he c o m bi ne d stat us of A T M a n d p 5 3 li n k t u m or 
de vel o p me nt wit h t hera pe utic res p o nse. Ge nes & De vel o p me nt. 2 0 0 9; 2 3: 1 8 9 5 - 9 0 9. 
Kasta n M B ,Barte k J. Cell -c y cle c hec k p oi nts a n d ca ncer. Nat ure. 2 0 0 4; 4 3 2: 3 1 6 - 2 3. 
Li J, Z h a o, T, Z ha n g Y, et al. Perf or ma nce e val uati o n of pat h o ge nicit y- c o m p uta ti o n met h o ds f or 
misse nse varia nts . N ucleic Aci ds Res. 2 0 1 8; 4 6( 1 5): 7 7 9 3 - 8 0 4. 
Mi n A, I m  S A, Ja n g H, et al. A Z D 6 7 3 8, A N o vel Oral I n hi bit or of A T R, I n d uces S y nt hetic 
Let halit y  wit h A T M Deficie nc y  i n Gastric Ca ncer Cells. M ol Ca ncer T her. 2 0 1 7; 1 6( 4): 5 6 6 - 5 7 7. 
M PI  R esearc h. V R T -1 2 2 8 6 9 2: A 2 8- d a y  o ral ( ga va ge) t o xicit y  a n d t o xic o ki netic st u d y  i n rats wit h 
a [ADDRESS_208630] u d y n u m ber: V R T -1 2 2 8 6 9 2- T X -0 0 4. M PI  s t u d y  n u m ber: 8 6 3 -
1 6 5. Re p ort date: [ADDRESS_208631] 2 0 1 4. 
M PI  R esearc h. V R T -1 2 2 8 6 9 2: A 2 8- d a y  o ral ( ga va ge) t o xicit y  a n d t o xic o ki netic st u d y  i n d o gs 
wit h a [ADDRESS_208632] u d y n u m ber: V R T -[ADDRESS_208633] u d y  n u m ber: 
8 6 3- 1 6 6. Re p ort date: [ADDRESS_208634] 2 0 1 4. 
M ur ga M, B u nti n g S, M o nta na M F, et al. A m o use m o del of A T R -Sec kel s h o ws em br y o nic 
re plicati ve stress a n d accelerate d a gi n g. Nat ure Ge netics. 2 0 0 9; 4 1: [ADDRESS_208635] ural & M olec ular Bi ol o g y 
2 0 1 1; 1 8: 1 3 3 1 - 5. 
N C C N Cli nical Practice G ui deli nes i n O nc ol o g y f or N o n -S mall Cell L u n g Ca ncer. Versi o n 2. 
2 0 1 3. A vaila ble fr o m: htt p:// w w w. ncc n. or g/ pr ofessi o nals/ p h y sicia n _ gls/f _ g ui deli nes.as p 
Li u S, Y ua n, Y. Ba yesia n O pti mal I n ter val Desi g ns f or P h ase I Cli nical Trials. J o ur nal of t he R o y al 
Statistical S ociet y : Series C, 6 4, 5 0 7 - 2 3. 
N g hie m P, Par k P K, Ki m Y, et al. A T R i n hi biti o n selecti vel y  s e nsitizes G 1 c hec k p oi nt -deficie nt 
cells t o let hal pre mat ure c hr o mati n c o n de nsati o n. Pr ocee di n gs of t he Nati o nal Aca de m y  o f 
Scie nces of t he U nite d States of A merica. 2 0 0 1; 9 8: 9 0 9 2 - 7. 
N g hie m P, Par k P K, Ki m Ys, et al. A T R is n ot re q uire d f or p 5 3 acti vati o n b ut s y ner gizes wit h p 5 3 
i n t he re plicati o n c hec k p oi nt. J o ur nal of Bi ol o gical C he mistr y . 2 0 0 2; 2 7 7: [ADDRESS_208636] ori n g B R C A 1/ [ADDRESS_208637] 
c he m ot hera p y resista nce i n here ditar y o varia n carci n o mas. J o ur nal of Cli nical O nc ol o g y . 
2 0 1 1; 2 9: [ADDRESS_208638] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 6 / 1 5 9 Ola usse n K A, D u na nt A, F o uret P, et al. D N A re pair b y  E R C C 1 i n n o n- s mall -cell l u n g ca ncer a n d 
cis plati n -base d a dj u va nt c he m ot hera p y. Ne w E n gla n d J o ur nal of Me dici ne. 2 0 0 6; 3 5 5: 9 8 3 - 9 1. 
Pi[INVESTIGATOR_6054] I M, Olci na M M, A n bala ga n S, et al. Tar geti n g ra diati o n -resista nt h y p o xic t u m o ur cells 
t hr o u g h A T R i n hi biti o n. Britis h J o ur nal of Ca ncer. 2 0 1 2; 1 0 7: 2 9 1 - 9. 
Rea per P M, Griffit hs M R, L o n g J M, et al. Selecti ve killi n g of A T M -or p 5 3 -deficie nt ca ncer cells 
t hr o u g h i n hi biti o n of A T R. Nat ure C he mical Bi ol o g y . 2 0 1 1; 7: 4 2 8 - 3 0. 
R usti n GJ, Q ui n n M, T hi g pe n T, et al. Re: Ne w g ui deli nes t o e val uate t he res p o nse t o treat me nt i n 
s oli d t u m ors ( o varia n ca ncer). J o ur nal of t he Nati o nal Ca ncer I nstit ute. 2 0 0 4; 9 6: 4 8 7 - 8. 
R uza n ki na Y, Pi [INVESTIGATOR_177590] o n -G uz ma n C, Asare A, et al. Deleti o n of t he de vel o p me ntall y  e sse ntial ge ne 
A T R i n a d ult mice lea ds t o a ge -relate d p he n ot ypes a n d ste m cell l oss. Cell Ste m Cell. 2 0 0 7; 1: 1 1 3 -
2 6. 
Sa n gster - G uit y N, C o nra d B H, Pa pa d o p o ul os N, et al. A T R me diates cis plati n resista nce i n a p 5 3 
ge n ot y p e-s pecific ma n ner. O nc o ge ne. 2 0 1 1; 3 0: 2 5 2 6- 3 3. 
Sc her HI , Hala bi S, Ta n n oc k I,  e t al: Desi g n a n d e n d p oi nts of cli nical trials f or patie nts wit h 
pr o gressi ve pr ostate ca ncer a n d castrate le vels of test oster o ne: Rec o m me n dati o ns of t he Pr ostate 
Ca ncer Cli nical Trials W or ki n g Gr o u p. J o ur nal of Cli nical O nc ol o g y . 2 0 0 8; 2 6: 1 1 4 8 - 5 9. 
Sc h o p p y  D W, Ra gla n d R L , Gila d O, et al. O nc o ge nic stress se nsitizes m uri ne ca ncers t o 
h y p o m or p hic s u p pressi o n of A T R. T he J o ur nal of Cli nical I n vesti gati o n 2 0 1 2; 1 2 2: [ADDRESS_208639] ural & M olec ular Bi ol o g y . 
2 0 1 1; 1 8: 7 2 1 - 7. 
Willia ms o n C T, Miller R, Pe m bert o n H N, et al. A T R i n hi bit ors as a s y nt hetic let hal t hera p y  f or 
t u m o urs deficie nt i n A RI D 1 A. Nat C o m m u n. 2 0 1 6; 7: [ADDRESS_208640] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 7 / [ADDRESS_208641] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 4 8 / 1 5 9 A p pe n di x I: Si g n at ure P a ges a n d Res p o nsi ble Pers o ns f or t he St u d y 
D oc u me nt N o. 
O bject N o. C CI 
C CI 
P P D 
P P D P P D P P D P P D P P D 
P P D C CI 
C CI 
C CI 
C CI 
C CI P P D 
P P D P P D C CI 
M [ADDRESS_208642] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 1 / 1 5 9 Si g n at ure P a ge –Pri nci p al I n vesti g at or 
St u d y Title A n O pe n -La bel St u d y  o f t he Safet y , T olera bilit y , a n d 
P har mac o ki netic/ P har mac o d y na mic Pr ofile of M 4 3 4 4 
(f or merl y V X -8 0 3) as a Si n gle A ge nt a n d i n 
C o m bi nati o n wit h C y t ot o xic C he m ot hera p y i n 
Partici pa nt s wit h A d va nce d S oli d T u m ors 
I N D N u m ber 
E u dr a C T N u m ber [ADDRESS_208643] u d y Pr ot oc ol D ate / 
Versi o n 2 9 Ja n uar y  2 0 2 0 / Versi o n 8. [ADDRESS_208644] u d y pr ot oc ol, a n y  a p pr o ve d 
pr ot oc ol a me n d me nts, I n ter nati o nal C o u ncil f or Har m o nisati o n (I C H) g o o d La b orat or y Practice 
(G C P )( T o pic E 6) a n d all a p plica ble Healt h A ut h orit y  re q uire me nts a n d nati o nal la ws. 
I als o affir m t hat I  u n dersta n d t hat Healt h A ut h orities ma y  re q uire t he S p o ns ors of cli nical st u die s 
t o o btai n a n d s u p pl y deta ils a b o ut o w ners hi p i nterests i n t he S p o ns or or I n vesti gati o nal Me dici nal 
Pr o d uct a n d a n y  ot her fi na ncial ties wit h t he S p o ns or. T he S p o ns or will use a n y  s uc h i nf or mati o n 
s olel y  f or t he p ur p ose of c o m pl y i n g wit h t he re g ulat or y  r e q uire me nts. I t heref ore a gr ee t o s u p pl y 
t he S p o ns or wit h a n y necessar y  i nf or mati o n re gar di n g o w ners hi p i nterest a n d fi na ncial ties 
i ncl u di n g t h ose of m y s p o use a n d de pe n de nt c hil dre n, a n d t o pr o vi de u p dates as necessar y t o meet 
Healt h A ut h orit y  re q uire me nts. 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Si g nat ure Date of Si g nat ure 
Na me, aca de mic de gree: 
F u ncti o n / Title: 
I nstit uti o n: 
A d dress: 
Tele p h o ne n u m ber: 
Fa x n u m ber: 
E-mail a d dress: 
D oc u me nt N o. 
O bject N o. C CI 
C CI C CI 
M [ADDRESS_208645] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 2 / 1 5 9 A p pe n di x II: Pr ot oc ol A me n d me nt Hist or y 
T he i nf or mati o n f or t he c urre nt a me n d me nt is o n t he title pa ge. 
Pr ot oc ol Hist or y 
Versi o n a n d D ate of Pr ot oc ol C o m me nts 
Versi o n 7. 0, [ADDRESS_208646] u d y Desi g n a n d Pla n 
T he de vel o p me nt of M 4 3 4 4 i n c o m bi nati o n wit h c yt ot o xic a ge nts li ke 
car b o plati n, ge mcita bi ne, a n d cis plati n was de pri oritize d, a n d 
c o nse q ue ntl y t he i nitiall y pla n ne d Parts B 2, B 3, a n d C w er e r e m o ve d. 
[ADDRESS_208647] u d y pa rts ( Parts C 1, C 2, a n d C 3) w ere a d de d t o i n vesti gate t he 
p ote ntial a ntit u m or efficac y i n partici pa nts w h ose t u m ors ha ve certai n 
bi o mar kers t hat ha ve bee n i de ntifie d t o se nsitize t o A T R i n hi biti o n i n 
precli nical m o dels a n d f or w h o m n o sta n dar d treat me nt o pt i o ns are 
a vaila ble. T he rec o m me n de d P hase II d ose ( R P 2 D) deter mi ne d i n Part 
A or A 2 will be use d i n Parts C 1, C 2, a n d C 3. 
Part A 2: O nce Pr ot oc ol Versi o n 7. 0 ( 2 8 A pril 2 0 1 9) has bee n a p pr o ve d 
a n d i m ple me nte d at all partici pati n g ce nters, aB a y esia n o pti mal 
i nter val desi g n will re place t he 3 + 3 desi g n if a n y c ha n ge i n t he 
sc he d ule of M 4 3 4 4 a d mi nistrati o n occ urs (e. g., t o a o nce dail y 
a d mi nistrati o n, or a dr u g h oli da y sc he d ule ). 
Te xt w as m o difie d t o all o w  partici pa nts w h o re q uire c o nc o mita nt 
treat me nt wit h pr ot o n p u m p i n hi bit ors ( P PI) t o c o nti n ue treat me nt i n 
t he trial. 
T he rati o nale f or i ntr o d ucti o n of BI D d osi n g i n Part A 2 (i n t he 
pre vi o us a me n d me nt) w as i m pr o ve d f or clarit y. 
C ha n ge i n N u m ber a n d L ocati o n of Sites E x pecte d t o Partici pate 
T he n u m ber of sites a n d c o u ntries partici pati n g i n t he st u d y was 
u p date d t o reflect c urre nt e x pectati o ns. 
Cha n ge i n P har mac o d y na mic/ Bi o mar ker te xt 
A d de d assess me nt of treat me nt -relate d c ha n ges i n p har mac o d y na mic 
mar kers i n P B M C i n Part A [ADDRESS_208648] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 3 / 1 5 9 U p date t o C o ntrace pti o n Met h o ds 
Details a n d defi niti o ns f or a p pr o priate a n d acce pta ble met h o ds of 
c o ntrace pti o n were u p date d. 
E dit orial C ha n ges 
F urt her m ore , t his a me n d me nt i nc or p orate dclarificati o ns a n d c ha n ges 
t o all o w  i n vesti gati ve sites a d diti o nal ease i n e nr olli n g a n d a d heri n g t o 
t he pr ot oc ol. 
Date of last partici pa nt o ut was c ha n ge d fr o m [ADDRESS_208649] u d y Desi g n a n d Pla n 
Ge nerall y, Ata xia tela n giectasia m u tate d a n d Ra d 3 -relate d pr otei n 
(A T R) si g nali n g is re q uire d t o e na ble ca ncer cells t o pr o gress t hr o u g h 
t o S/ G 2 -p hase, a n d i n hi biti o n of A T R let hall y c o m pr o mises t his 
pr ocess. Re peate d or pr ol o n ge d A T R i n hi biti o n is e x pecte d t o res ult i n 
i ncrease d a ntit u m or efficac y ( V X -9 7 0 I n vesti gat or Br oc h ure 2 0 1 7 ). 
F or M [ADDRESS_208650] u dies of 
M4 3 4 4 i n alter nati ve le n gt he ni n g of tel o meres (A L T + )m o dels 
de m o nstrate t hat i ncrease d fre q ue nc y of d osi n g is ass ociate d w it h, a n d 
p ossi bl y re q uire d, f or o pti mal a ntit u m or acti vit y i n t he m o n ot hera p y 
setti n g ( Verte x Re p ort E 0 4 5 3 -U 1 6 0 7 2 0 1 6 ) w hile mai ntai ni n g 
t olera bilit y base d o n b o d y wei g ht a n d m ortalit y. T hese data s u g gest 
t hat pr ol o n ge d or re peate d i n hi biti o n of A T R n ot o nl y p ote ntiates t he 
c y t ot o xic effects of de o x yri b ose n ucleic aci d ( D N A )d a m a ge, b ut it 
ma y als o be efficaci o us as m o n ot hera p y i n ca ncers w hic h are relia nt o n 
A T R si g nali n g ( Fl y n n 2 0 1 5 ). Of n ote, si milar a ntit u m or acti vit y was 
o bser ve d f or t he sa me t otal wee kl y d ose w he n a d mi nistere d o nce dail y 
or t w ice dail y i n t he precli nical st u d y ( Verte x Re p ort E 0 4 5 3 -U 1 6 0 7 
2 0 1 6 ). T heref ore, t w ice dail y (BI D ), dail y d osi n g was selecte d as t he 
i nitial sc he d ule f or Part A 2 t o s ustai n A T R i n hi biti o n a n d mi ni mize 
p ote ntial f or ma xi m u m c o nce ntrati o n ( Cma x )relate d a d verse e ve nts. 
A 1 0 0 -m g si n gle d ose a d mi nistere d BI D ( 2 0 0 m g dail y) was selecte d 
as starti n g d o se f or Part A 2. 
T his starti n g d ose is base d o n t he a vaila ble cli nical e x perie nce i n 3 6 
partici pa nts treate d w it h u p t o t he 1 2 0 0 m g t wice wee kl y d osi n g 
sc he d ule i n Part A. As of D e c e m ber 2 0 1 7, i n t otal 1 0 partici pa nts ha ve 
c o m plete d t he d ose li miti n g t o xicit y ( D L T )peri o d at t he [ADDRESS_208651] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 4 / 1 5 9 le vel. O ne D L T of Gra de 3 fe ver w as o bser ve d a n d t he criteria f or 
M T D w ere n ot yet f ulfille d. T he 1 2 0 0 m g t wice wee kl y sc he d ule 
res ults i n a t otal wee kl y d ose of 2 4 0 0 m g. A 1 0 0 -m g d ose a d mi nistere d 
t w ice dail y res u lts i n a t otal wee kl y d ose of 1 4 0 0 m g a n d is t heref ore 
e x pecte d t o be a t olera ble starti n g d ose. 
T he tar get d ose f or o pti mal acti vit y as m o n ot hera p y i n h u ma ns is 
a p pr o xi matel y [ADDRESS_208652] u g 
acc u m ulati o n is e x pecte d w it h t he t wice dail y or o nce dail y sc he d ules. 
W he n M 4 3 4 4 is a d mi nistere d t wice dail y, t he sec o n d dail y d ose is 
h y p ot hesize d t o be o pti mall y a d mi nistere d at 1 2 -h o ur i nter vals t o 
pr o vi de s ustai ne d A T R i n hi biti o n. H o w e ver, a 4 -h o ur w i n d o w ( 8 t o 1 6 
h o urs) is per mitte d f or partici pa nt c o n ve nie nce. 
Clarificati o n of P har mac o d y na mic/ Bi o mar ker te xt 
S o m e c ha n ges i n p har mac o d y na mic / bi o m ar ker e x pl orat or y o bjecti ves 
a n d e n d p oi nts, t he Part B a n d Part C sc he d ule of assess me nts, a n d 
ot her bi o mar ker te xt were m a de i n or der t o pr o vi de clarit y a n d 
c orrect ness of c o nce pts a n d re d uce re d u n da ncies. 
E dit orial C ha n ges 
Mi n or e dit orial c ha n ges (i ncl u di n g t he c ha n ge fr o m “s u bject” or 
“ patie nt” t o “ partici pa nt”, w here a p plica ble) w ere m a de f or rea da bilit y, 
clarit y, a n d fl o w,  a n d, al o n g wit h ne wrefere nces, are n ot i ncl u de d i n 
t he f oll o wi n g c o m paris o n ta ble. 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208653] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 5 / [ADDRESS_208654] 2 0 1 7 C ha n ge of S p o ns or 
T he st u d y will tra nsiti o n fr o m Verte x P har mace uticals I nc or p orate d, t o 
Merc k K Ga A, Fra n kf urter Strasse 2 5 0, 6 4 2 9 3 Dar msta dt, Ger ma n y f or 
sites i n t he U K a n d T he Net herla n ds, a n d t o E M D Ser o n o Researc h & 
De vel o p me nt I nstit ute, I nc., [ADDRESS_208655] u g na me 
T he dr u g na me V X -[ADDRESS_208656] u d y desi g n were ma de t hat affecte d 
m ulti ple secti o ns i n t he pr ot oc ol: 
D ue t o s p o ns or decisi o n t o f oc us o n s oli d t u m ors, s u bjects wit h 
l y m p h o mas will n o l o n ger be i ncl u de d i n t he st u d y. 
I n or der t o e val uate t he safet y a n d t olera bilit y of V X -8 0 3 i n 
c o m bi nati o n wit h ge mcita bi ne a n d w it h cis plati n, d ose escalati o n of 
V X -8 0 3 i n c o m bi nati o n wit h ge mcita bi ne ( Part B 2) a n d i n 
c o m bi nati o n wit h cis plati n ( Part B 3) w ere a d de d. Parts B [ADDRESS_208657] ore d i n Part B 1 a n d s p o ns or 
decisi o n. 
O n -treat me nt t u m or bi o ps y s u bst u d y was a d de d t o Part B i n a n eff ort 
t o de m o nstrate A T R i n hi biti o n i n res p o nse t o V X -8 0 3 i n c o m bi nati o n 
wit h car b o plati n ( Part B 1), ge mcita bi ne ( Part B 2), a n d cis plati n ( Part 
B 3). 
S u bject n u m bers i n Parts A a n d B w ere u p date d t o reflect c ha n ges i n 
t he st u d y desi g n. 
Part C w as u p date d t o i ncl u de t he o pti o n of d osi n g V X -[ADDRESS_208658] u d y was delete d fr o m Part C as it was deter mi ne d fr o m 
m o deli n g t hat d osi n g i n t he fe d state is u nli kel y t o i m pr o ve t he s yste mic 
e x p os ure of V X -8 0 3. 
T o f urt her e val uate t he p har mac o ki netic ( P K )of V X -[ADDRESS_208659] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 6 / 1 5 9 I n or der t o f oll o w  s u bjects after t he [ADDRESS_208660] 
6 c ycles of treat me nt a n d disc o nti n ue treat me nt f or reas o ns ot her t ha n 
disease pr o gressi o n. 
Fl u or ot h y mi di ne p ositr o n e missi o n t o m o gra p h y [1 8 F] -F L T -P E T sca ns 
were delete d fr o m Part B a n d circ ulati n g t u m or cells ( C T Cs )we re 
delete d fr o m Parts B a n d C. [ 1 8 F] -F L T -P E T sca ns w ere re m o ve d 
beca use sites i n dicate d t hat [ADDRESS_208661] u d y, 
we ha ve de m o nstrate d t hat t he n u m bers of tra diti o nal C T Cs/ m L of 
bl o o d are e xtre mel y l o w (a p pr o xi matel y 1 -5 C T Cs/ m L) , ma ki n g 
assess me nt of g H 2 A X le vels i n C T Cs c halle n gi n g as a tar get 
e n ga ge me nt rea d o ut. 
I ntras u bject d ose escala ti o n was a d de d t o Part A a n d is per mitte d o nl y 
if V X -[ADDRESS_208662] w h o is c o nti n ui n g d osi n g, res p o n di n g t o treat me nt, a n d has n o 
si g nifica nt t o xicit y. 
Base d o n re vie w  of t he a vaila ble cli nical a n d n o ncli nical data a n d 
o utsi de e x pert o pi [INVESTIGATOR_9384] o n, t he f oll o w i n g c ha n ges were ma de t o t he D L T 
defi niti o n: 
oE xcl u de tra nsie nt ele vati o ns i n li ver f u ncti o n tests. 
E xcl u de Gra de 3 or 4 i ncrease i n bilir u bi n, if t he i ncrease is assesse d 
as arisi n g fr o m i n hi biti o n of bilir u bi n gl uc ur o ni dati o n. If t he i ncrease 
i n bilir u bi n is assesse d as arisi n g fr o m i n hi biti o n of bilir u bi n 
gl uc ur o ni dati o n, t he n o nl y bilir u bi n le vels a b o ve 1 5 m g/ d L 
( 2 5 7 µ m ol/ L) will be c o nsi dere d D L Ts. 
I ncl usi o n criteri o n 6f was u p date d t o i ncl u d e m i ni m u m  ser u m al b u mi n 
val ue nee de d at Scree ni n g. 
E xcl usi o n criteri o n [ADDRESS_208663] u dies, de pleti o n of ata xia 
tela n giectasia m utate d (A T M) or p [ADDRESS_208664] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 7 / 1 5 9 Clarificati o n was a d de d i n Parts B a n d C t hat ma g netic res o na nce 
i m a gi n g ( M RI )ma y be use d as a n alter nati ve t o c o m p ute d t o m o gra p h y 
(C T )sca ns f or disease asses s me nt ,b ut eac h s u bject s h o ul d be f oll o w e d 
usi n g t he sa me sca n tec h ni q ue f or assessi n g res p o nse t hr o u g h o ut t he 
st u d y if p ossi ble. 
D ose m o dificati o n secti o n was u p date d t o pr o vi de m ore details f or 
d ose escalati o ns f or t he differe nt c he m ot hera pe utic a ge nts. 
T he defi niti o n of F ull A nal ysis Set was u p date d. 
Pr ot oc ol s y n o psis was u p date d t o ali g n wit h c ha n ges ma de t hr o u g h o ut 
t he pr ot oc ol. 
Versi o n 3. 0, [ADDRESS_208665] 2 0 1 5 Part A wa s re vise d t o all o w  e nr oll me nt of u p t o 2 a d diti o nal s u bjects ( 3 
per c o h ort) at t he discreti o n of t he In vesti gat ors a n d Sp o ns or, i n t he 
si n gle s u bject c o h ort at a n y d ose le vel, irres pecti ve of t he t o xicit y, t o 
f urt her e x pl ore safet y a n d/ or P K. 
Clarificati o n was a d de d t hat V X -8 0 3 d oses w ill be escalate d b y u p t o 
5 0 % d uri n g d ose esc alati o n i n Parts A a n d B. 
T he Safet y F oll o w -u p Visit wi n d o w  f or all Parts wa s e xte n de d fr o m 
3da ys t o [ADDRESS_208666] c ycle of treat me nt 
t o all o w s u bjects a d diti o na l fle xi bilit y. 
W h ole bl o o d (all Parts ) a n d peri p heral bl o o d m o n o n uclear cell 
( P B M C) c ollecti o n ( Parts B a n d C) f or p ote ntial e x pl orat or y e val uati o n 
of c orrelati o ns bet w ee n bi o mar kers a n d P K, p har mac o d y na mic ( P D) 
were delete d beca use of tec h nical diffic ulti es wit h t he pla n ne d assa ys. 
I n res p o nse t o re g ulat or y fee d bac k, a heari n g assess me nt at t he 
Scree ni n g Visit, o n Da y 1 of eac h treat me nt c ycle, a n d at t he Safet y 
F oll o w -u p Visit was a d de d as part of t he p h ysical e xa mi nati o n i n 
Parts B a n d C. 
I n res p o nse t o re g ulat or y fee d bac k, E xcl usi o n Criteri o n [ADDRESS_208667] u d y, 
will be e xcl u de d i n Parts B a n d C. 
Versi o n 2. 0, 1 4 N o ve m ber 2 0 1 4 A d de d f o ot n ote t o t he Sc he d ule of Assess me nts f or Parts A, B, a n d C 
t o pr o vi de g ui da nce o n misse d assess me nts 
Clarifie d eli gi bilit y criteria relate d t o t he disease stat us of s u bjects i n 
Parts A a n d B 
D oc u me nt N o. 
O bject N o. C CI C CI 
M [ADDRESS_208668] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 8 / 1 5 9 Re vise d te xt relate d t o C o m m o n Ter mi n ol o g y Criteria f or A d verse 
E ve nts ( C T C A E) Gra de [ADDRESS_208669] u g. 
Clarifie d d ose escalati o n of V X -[ADDRESS_208670] u g -relate d a n d d oes n ot q ualif y as a 
d ose -li miti n g t o xicit y ( D L T). 
Decrease d t he n u m ber of a d diti o nal s u bjects e val uate d i n t he i nitial 
e x pa nsi o n c o h ort w he n a si n gle D L T occ urs fr o m 5 s u bjects t o 
2s u bjects. A n a d diti o nal 3 s u bjects w o ul d be i ncl u de d at t he sa me d ose 
o nl y if n o D L Ts occ ur i n t he 2 a d diti o nal s u bjects. 
U p date d d urat i o n of l o n g -ter m f oll o w -u p f or s u bjects i n Part C wit h o ut 
d oc u me nte d disease pr o gressi o n at last st u d y visit t o e ver y 3 m o nt hs t o 
ma ke c o nsiste nt wit h Secti o n 3a n d Secti o n 8. 1. 1 0 .
M o difie d t he defi niti o n of a D L T t o n o l o n ger e xcl u de Gra des 3 or 4 
m uc ositis i n s u bjects w h o ha ve n ot recei ve d o pti mal t hera p y; Gra des 3 
or 4 m uc ositis w o ul d n o w be c o nsi dere d a D L T. 
Clarifie d t hat i n a d diti o n t o all safet y data, re vie w of a vaila ble 
p har mac o ki netic ( P K) data w o ul d be c o n d ucte d d uri n g d ose escalati o n 
i n Pa rt A. 
I ncl usi o n criteria were ma de m ore s pecific: 
1. S u bjects wit h k n o w n or s us pecte d Gil bert’s s y n dr o me are 
e xe m pt e d fr o m ser u m bilir u bi n e xcl usi o n 
2. Al kali ne p h os p hatase m ust be of li ver ori gi n 
U p date d he m o gl o bi n a n d esti mate d gl o mer ular filtrati o n rate val ues 
re q uire d f or a d mi nistrati o n of V X -8 0 3 or c he m ot hera p y o n Da y 1 of 
C y cle 1 i n Ta ble 1 0 - 1 f or c o nsiste nc y wit h i ncl usi o n criteria s pecifie d 
i n Secti o n 9. 1 . I n res p o nse t o i n vesti gat or fee d bac k, esti mate d 
gl o mer ular filtrati o n rate val ues re q uire d f or a d mi nistrati o n of V X -8 0 3 
or c he m ot hera p y o n Da y 1 of all c ycles be y o n d C ycle 1 i n Ta ble 1 0 - 1 
wa s c ha n ge d fr o m " ≥2 0 m L/ mi n" t o " D oes n ot meet D L T criteria." 
M o difie d E xcl usi o n Criteri o n [ADDRESS_208671] u d y 
M S 2 0 1 9 2 2- 0 0 0 1 
C O N F I D E N T I A L 
I N F O R M A T I O N 1 5 9 / 1 5 9 Clarifie d t hat i nterr u pti o n of treat me nt is re q uire d, a n d was n ot at t he 
discreti o n of t he i n vesti gat or, f or Gra de 3 or greater t o xicit y be y o n d 
C y cle 1. 
Clarifie d details re gar di n g st u d y dr u g s u p pl y a n d ha n dli n g. 
Clarifie d t he defi niti o n of a n a d verse e ve nt. 
Clarifie d t he seri o us a d verse e ve nt criteria relate d t o h os pi[INVESTIGATOR_1314] o ns 
a n d m o ve d t his te xt fr o m Secti o n [ADDRESS_208672] N o. C CI 
C CI 